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 Schizophrenia is a neuropsychological disorder in which the neural systems 
which regulate attention allocation, primarily the dorsolateral prefrontal cortex, are 
dysfunctional, resulting in deficient gating of attention to irrelevant inputs from the 
environment. This sensory processing dysfunction hinders goal-directed behaviour to 
the extent that the subsequent cognitive deficits of schizophrenia prevent many chronic 
patients from leading normal lives. It is the onus of neuroscience to understand the 
nature of deficits induced by the disorder, thus providing target mechanisms for 
remediation of those deficits in patients. To accomplish this, manipulations in rats with 
relevance to schizophrenia are examined in assays with translation to human 
neurobiology and behaviour. In this thesis, three manipulations with relevance to 
schizophrenia, were examined for attentional regulation in the attentional set-shifting 
task, and similar assays, to determine how different forms of schizophrenia-related 
pathology influence attentional regulation and behavioural flexibility. 
 The foremost findings of the experiments herein were that manipulations 
inducing schizophrenia-related neurobiology, resulted in impaired performance in 
extradimensional set-shifting and reversal learning. These deficits were found following: 
acute inhibition of the mPFC in adult rats, in adult rats who had been exposed to a 
glutamate receptor antagonist during the neonatal period of development, and/or in 
adult rats who had gestational disruption of neuron proliferation. Across all three 
manipulations, a clear behavioural pattern of deficient sensory gating, evidenced by 
responding to irrelevant stimuli during the set-shifting task was found.  
 These findings suggest that at the core of the cognitive deficits in schizophrenia 
is the ‘loosening of associations’ such that patients suffer the inability to regulate 
attention, and limit sensory processing to relevant information. The subsequent 
aberrant learning about irrelevant information then impairs performance during  goal-
directed behaviours.  
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Chapter 1. Introduction to Attentional Regulation 
and Schizophrenia 
Attentional regulation is a key process in navigating changing environments. 
Under most conditions it is best to limit attention (i.e. sensory processing) to 
certain features of the environment. However, there are certain conditions, 
when not having biased attentional processing, may lead to gathering more 
beneficial information about the environment. Unfortunately, the latter appears 
to be the default state of persons suffering from schizophrenia, such that they 
experience ‘aberrant salience’ which subsequently impairs their cognition. The 
neural substrates for attentional regulation are known to coalesce at the 
dorsolateral prefrontal cortex, whereby a process known as ‘working memory’ 
maintains task relevant information and biases attention. In this chapter I review 
how the pathology of schizophrenia, affects the brain and causes deficits in tasks 
dependent on the functioning of the dorsolateral prefrontal cortex (primarily 
attentional set-shifting). The findings in humans are then explored in rats with 
the aim of developing translational tools with potential for exploring and treating 
the cognitive symptoms of schizophrenia.   




 I was recently required to complete the matriculation process to begin the 
4th year of my PhD. As an international student, an in-person visa check was 
mandated, requiring me to navigate the busy Gateway building. As it was the 
beginning of a new semester, the building was filled with undergraduates (also 
matriculating), whom I tried to ignore as much as possible, lest I truly felt old and 
out of place. The process took roughly 30 mins of navigating ill-placed A4-sized 
signs directing me to the correct queue, however, by selectively attending to the 
relevant environmental cues, I was successful in completing the process. Indeed, 
although I was vaguely aware of the teenagers chatting to each other, the details 
of those conversations eluded me as my focus of attention was on reaching the 
next queue and help desk. However, as I was leaving the Gateway building, this 
time fully focused on following the exit signs, I heard my name called. I turned to 
see some fellow doctoral students who were working some tables off to the side, 
at which point we then had a brief chat. 
The brief narrative above actually depicts two key phenomena within 
attentional process. Specifically, the process by which I selectively attended to 
visual stimuli (the directions from the A4 signs), and used those cues to achieve 
my goal, while ignoring the auditory stimuli (chatter of the undergrads) which 
provided no information as to which queue I should be in, is the basis for 
‘attentional set’ (Sutherland and Mackintosh, 1971;  but see: Brown and Tait, 
2016). That is to say, while the stimuli were changing, new relevant signs on each 
floor, as well as new irrelevant background stimuli, my ability to complete the 
matriculation process was enhanced by ignoring the irrelevant stimuli within the 
environment. Attentional set then, is a goal-directed process, wherein 
endogenous attentional regulation guides sensory processing. On the other hand, 
my colleague calling my name elicited the stimulus-driven (exogenous) attention 
process known known as the ‘cocktail party effect’ (Cherry, 1953; but see: Conway 
et al., 2001). The high importance of recognising my name being called, despite 
my attention being focused on visual stimuli, suggests that sensory systems are 
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tuned such that the salience of certain stimuli remains high under many 
circumstances. Indeed, shifting my sensory processing bias (attention) from gating 
auditory stimuli initially, to selectively attending to the conversation with my peers 
(while still gating irrelevant chatter in the background), is also an endogenous 
goal-directed process, known as ‘attentional set-shifting’ (Berg, 1948; but see: 
Roberts et al., 1988). These attentional processes depend on the functional 
integrity of several neural circuits, many of which are found to be dysfunctional in 
neuropsychiatric disorders. One disorder in which both processes are 
dysfunctional is schizophrenia. As described within this thesis introduction and 
empirical chapters, patients with schizophrenia, and animals with manipulations 
with relevance to schizophrenia, suffer from deficits in both exogenous attention 
(in the form of ‘aberrant salience’), as well as endogenous allocation of attention 
in goal-directed behavioural task. To further understand the psychological and 
neurobiological mechanisms underlying this pathology, this thesis focuses on 
impaired attentional regulation within the context of ‘schizophrenia-related’ 
manipulations in rats.  
1.2 Schizophrenia genetics and neurochemistry 
Schizophrenia is a complex neurodevelopmental disorder characterised by 
positive symptoms (e.g., hallucinations and delusions), negative symptoms (e.g., 
flat affect and social withdrawal), and cognitive symptoms (e.g., impairments in 
working memory, and attention; National Institute of Mental Health). Recent 
reviews of schizophrenia genetics have found that, although the genetic 
heritability of the disorder has been well evidenced (Owen et al., 2004), the 
disease has polygenetic risk factors (Sun et al., 2010; Farrell et al., 2015), and highly 
influenced by gene-environment interactions (Tsuang, 2000). Specifically, a review 
of the published genetic association studies through 2008 implicated over 10 
genes including: DRD1, COMT, GRIN2B, and GABRB2 (Allen et al., 2008). However, 
while mutations in these genes increased the risk for development of 
schizophrenia, no single mutation determines whether a person will eventually 
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develop schizophrenia. Further studies have revealed that in combination with 
genetic risk factors for developing schizophrenia, environmental stressors during 
sensitive periods such as gestation (Hultman et al., 1999; Van et al., 2016), and 
throughout the lifespan (Howes et al., 2017), as well as the epigenetic 
modifications of genes (Zhang et al., 2010) can greatly exacerbate the risk.  
The heterogeneity of the aetiology of schizophrenia has necessitated a 
focus on the common schizophrenia phenotypes resultant from any number of 
aetiologies. Of these common phenotypes, the positive symptoms can be 
considered the most severe of the core symptoms, and are of utmost importance 
for immediate treatment. Fortunately, early antipsychotic treatments targeting 
the dopaminergic system have proven efficacious for remediation of the positive 
symptoms (Seeman et al., 1975; for review see: Howes and Kapur, 2009). 
However, research into treatment of the negative and cognitive symptoms is 
ongoing, as the current antipsychotics to do not remediate those for many 
patients (Lieberman et al., 2005a; Walters and Agius, 2014). Although many 
neurotransmitter systems show abnormal signalling in schizophrenia, in this 
section I review the most prominent (dopamine, glutamate, and gamma-
aminobutyric acid; GABA), in the context of disease pathology and potential for 
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symptom alleviation. Figure 1.1 presents a representative diagram of the 
neurochemical findings discussed.  
1.2.1 Dopamine  
 Currently, antipsychotic treatments for schizophrenia mainly target the 
dysfunctional dopaminergic neurotransmission. Dopaminergic neurotransmission 
can occur through several subtypes of dopamine receptors; D1-like receptors 
(D1Rs; D1 and D5) and D2-like receptors (D2Rs; D2, D3, and D5). Within these two 
major subdivisions, it was found that early efficacious antipsychotics targeted the 
D2Rs (Seeman et al., 1975). Activation of D2Rs typically initiates inhibitory 
intracellular signalling cascades. These early antagonists of D2Rs likely inhibited 
this function of dopaminergic neurotransmission, resulting in enhanced 
stimulatory (D1R-mediated) signalling in cortical areas, while reducing 
hyperdopaminergic signalling in subcortical areas. While this approach has been 
largely effective at treating the positive symptoms associated with schizophrenia, 
the cognitive symptoms are not rescued by the currently available D2R 
pharmacotherapies (reviewed in: Conn et al., 2009). 
 
 
Figure 1.1) Diagram of relevant findings for the role of dopamine, glutamate, and 
GABA in schizophrenia, from genetic and pharmacological studies. 
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 In a recent review of the ‘classical’ dopamine hypothesis of schizophrenia, 
Howes and Kapur (2009) described how the dopamine hypothesis has undergone 
several revisions. In version I, the efficacy of D2R antagonists for treating the 
disorder led clinicians and researchers (in the 1970s and ‘80s) to consider the 
dopamine receptor dysfunctions as the aetiological beginning of the disorder. This 
‘dopamine receptor hypothesis’ quickly came under criticism as new data 
indicated differential expression and functions of dopamine receptors based on 
neuroanatomical localisation, in addition to brain region-specific alterations in 
dopaminergic signalling. Version II, was based largely on the review published by 
Davis et al. (1991) which identified hypodopaminergic signalling in the prefrontal 
cortex (PFC) as a large contributing factor to the negative (and potentially the 
cognitive) schizophrenia symptoms, in addition to the hyperdopaminergic 
signalling in subcortical brain regions as the main cause the positive symptoms. 
Yet still, the second version was limited. Howes and Kapur postulate Version III, 
which incorporates disparate genetic findings by including a ‘multiple hits’, gene x 
environment, interaction into the aetiology of the disorder, as opposed to looking 
at D2Rs alone. Version III includes the well characterised presynaptic dopamine 
dysregulation, i.e. the driving hypo- or hyperdopaminergic neurotransmission in 
each brain region. Also, since D2R antagonists do not alleviate the negative or the 
cognitive symptoms, in Version III, dopamine dysregulation is limited to the 
aetiology of the positive symptoms. Indeed, Howes and Kapur, surmise that 
dopamine dysregulation alters the “appraisal of stimuli perhaps through a process 
of aberrant salience”. This refinement was a step in the right direction, however it 
was still limited to dopaminergic neurotransmission. Many studies had also found 
that healthy patients treated with glutamate receptor antagonists had symptoms 
akin to those seen in schizophrenia patients (reviewed by: Javitt and Zukin, 1991). 
These and other findings from post-mortem, preclinical, and experimental studies, 
suggest that there is more to the neurochemical dysfunction than just dopamine. 
Furthermore, D2R antagonism also has unavoidable side effects which further 
motivated the discovery of new targets for treatment of symptoms (Marder, 
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1999). The next sections focus on the disruptions to, and the role of, glutamatergic 
and GABAergic signalling in schizophrenia. Since D2R antagonists have proven 
largely successful at alleviating the positive symptoms associated with the 
disorder, glutamatergic and GABAergic manipulations are examined primarily in 
the context of the negative and cognitive symptoms.  
1.2.3 Glutamate 
Key mediators of learning and memory, N-methyl-D-aspartate receptors 
(NMDARs) are highly implicated in the glutamatergic pathology of schizophrenia. 
Activation of NMDARs is multi-fold, requiring both voltage-dependent removal of 
the Mg2+ block, and binding of glutamate and a co-agonist (glycine or d-serine) to 
their respective sites on the receptor (Dingledine et al., 1999). Although they are 
only one of many types of glutamate receptors, antagonism of solely NMDARs is 
known to generate and exacerbate schizophrenia symptoms in both healthy 
controls and patients with schizophrenia respectively (Javitt and Zukin, 1991; 
Umbricht et al., 2000; Aalto et al., 2005; Krystal et al., 2005; Stone et al., 2007; 
Heekeren et al., 2008; Moore et al., 2011; Moghaddam and Javitt, 2012). The 
positive symptoms induced by NMDAR antagonists are likely due to increases in 
striatal dopaminergic signalling (Miller and O'Callaghan, 1995; Yan et al., 1997; 
Kegeles et al., 2000). Combined with alterations of genes, and proteins, associated 
with glutamatergic neurotransmission in schizophrenia patients (Akbarian et al., 
1996; Mueller and Meador-Woodruff, 2004; Woo et al., 2004), these lines of 
evidence led to the ‘NMDAR hypofunction’ theory of schizophrenia. In 1994 and 
1996, clinical trials with the NMDAR co-agonist glycine revealed that the addition 
of glycine, adjunctive to a patient’s antipsychotic treatment, provided significant 
reduction in negative symptoms associated with the disorder (Javitt et al., 1994; 
Leiderman et al., 1996). Following this research, the same group found that 
pharmaceutically targeting the glycine binding site with the NMDAR agonist D-
cycloserine also reduced negative symptoms in patients with schizophrenia 
(Heresco-Levy et al., 1998). Such early findings opened the door to treatment of 
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the previously untouchable negative symptoms associated with the disorder. 
Since glycine circulates above saturating levels in the brain (Ferraro and Hare, 
1985), clinical trials researching the glutamatergic-mediated pathology shifted 
from targeting a receptor site which was likely already optimally functional, to 
enhancing NMDAR neurotransmission (or reducing presynaptic glutamate 
release) via other receptors or an NMDAR allosteric binding site.  
Metabotropic glutamate receptors (mGluRs), like NMDARs, are activated 
by glutamate. However, unlike the ionotropic NMDARs, mGluRs are G-protein 
coupled receptors, meaning they signal through intracellular biochemical cascades 
(e.g., second messenger systems; Conn and Pin, 1997). Although there are a total 
of eight mGluR subtypes divided across three groups (Nakanishi, 1992), of interest 
to regulation of NMDAR signalling are mGluRs 2 & 3 (group II) and mGluR 5 (group 
I). Located presynaptically, mGluR 2/3 activity reduces glutamate release 
(Battaglia et al., 1997). Krystal et al. (2005), reported that administration of mGluR 
2/3 agonist, LY354740, reduced ketamine-induced schizophrenia-related working 
memory deficits (as measured by the Hopkins Verbal Learning Test) in healthy 
human participants. A later generation mGluR 2/3 agonist (LY404039) reduced 
both positive and negative symptoms in human patients with schizophrenia (Patil 
et al., 2007). Unfortunately, these mGluR 2/3 agonists target the receptor’s 
glutamate binding site, thus downregulation of the receptors, and desensitisation, 
may occur over time, limiting the efficacy of these drugs (Conn et al., 2009; 
Moghaddam and Javitt, 2012). On the postsynaptic terminal, activation of mGluR 
5 enhances NMDAR neurotransmission via a stimulatory G-protein signalling 
cascade (Conn et al., 2009). Albeit positive thus far, studies with mGluR 5 have not 
however, progressed past preclinical findings in rodents (for review see: Matosin 
and Newell, 2013).  
Until this point I have neglected to discuss NMDARs located on GABAergic 
interneurons. It is possible that the hyperactive hippocampus in patients with 
schizophrenia (described further in Chapter 1.3 Schizophrenia Neuroanatomy) is 
due specifically to NMDAR hypofunction on the GABAergic interneurons, which 
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are known to be more sensitive to NMDAR antagonists (Grunze et al., 1996), and 
have reduced expression in post-mortem brain samples from schizophrenia 
patients (Lewis et al., 2004; Lewis, 2013). Indeed, all of the NMDAR-directed 
pharmacotherapies discussed above could be efficacious through enhancement of 
GABAergic inhibition in the hippocampus. In the next section I briefly discuss 
GABAergic neurotransmission in relation to schizophrenia. 
1.2.4 GABA 
Findings in patients with schizophrenia of altered hippocampal anatomy 
(Weiss et al., 2005; Jaaro-Peled et al., 2010; Ledoux et al., 2014), and hyperactive 
hippocampus-related theta oscillations (Siekmeier and Stufflebeam, 2010; 
Kirihara et al., 2012), make it possible that altered hippocampal activity drives the 
dopaminergic dysfunctions evidenced in schizophrenia patients. In addition, the 
fact that several of the glutamatergic system alterations are densely localised to 
GABAergic interneurons (for review see: Nakazawa et al., 2012), suggests that 
perhaps hypofunction of hippocampal inhibitory interneurons may play a critical 
role in the overall dysregulation of the system.  
GABA receptors come in two classes: ionotropic GABA-A receptors 
(GABAAR), and metabotropic GABA-B receptors (Tao et al., 2013). The fast 
inhibitory actions of GABA act through GABAAR-mediated Cl- influx (Fritschy and 
Panzanelli, 2014), making it the ideal target for enhancement of GABAergic 
neurotransmission. GABAARs are unusually diverse, as their subunits can be 
composed from over 19 genes. Of these options, α5-subunit-containing GABAARs 
are known to be upregulated in patients with schizophrenia (Guidotti et al., 2005). 
It is also known that upregulation of GABAARs is inverse to levels of GABA. That is 
to say that the increased expression of GABAARs in schizophrenia may be a 
compensatory mechanism by the system to normalise GABAergic 
neurotransmission which is reduced due to deficits in GABA synthesis (Guidotti et 
al.). Therefore, a method to increasing GABA levels is to increase the activity of 
existing GABAARs. This has proven of potential benefit in patients with 
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schizophrenia as the GABAAR positive allosteric modulator (PAM) diazepam has 
been found to reduce positive and negative symptom progression (Carpenter et 
al., 1999). However, these compounds have yet to be shown as procognitive in 
preclinical or clinical trials. Further studies have examined the potential for 
enhancing GABAAR activity through partial agonism of the α2/α3 subunit, and 
have provided positive, albeit limited, results for enhancing cognition in clinical 
trials (Lewis et al., 2008; Buchanan et al., 2011).  
1.3 Schizophrenia neuroanatomy 
The pathology of schizophrenia severely affects select brain regions. One 
of the most robust neuroanatomical markers obtained from human imaging 
studies is the enlargement of the lateral and third ventricles in schizophrenia 
patients compared to healthy controls (for review see: Jaaro-Peled et al., 2010). It 
is hypothesised that ventricular enlargement is progressive, as it is evident in first 
episode schizophrenia patients (Steen et al., 2006), and may continue to increase 
for several decades following the onset of symptoms (Jaaro-Peled et al.). This 
increase in ventricle size is likely related to the MRI findings of reductions in grey 
matter which are is also widely reported (Wright et al., 2000; Ellison-Wright et al., 
2008; Jaaro-Peled et al.), and is also purported as being progressive with time from 
the first episode (Borgwardt et al., 2008; Jaaro-Peled et al.). While whole brain 
volume is believed to be reduced (Wright et al., 2000), specific regions of reduction 
include: the temporal lobe (hippocampus), amygdala, thalamus, caudate 
putamen, and frontal cortex (Chakirova et al., 2010; Jaaro-Peled et al.; Takayanagi 
et al., 2010). Animal studies have revealed regulation of striatal dopamine activity 
by the hippocampus (for review see: Grace, 2012), and findings in schizophrenia 
patients of altered hippocampal anatomy (Weiss et al., 2005; Jaaro-Peled et al.; 
Ledoux et al., 2014), hyperactive hippocampus-related electroencephalography, 
and magnetoencephalographic measured oscillatory activity (Siekmeier and 
Stufflebeam, 2010; Kirihara et al., 2012), which are often positively correlated with 
positive symptom severity (Siekmeier and Stufflebeam, 2010), make it possible 
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that disrupted hippocampal activity drives the dopaminergic dysfunctions 
evidenced in schizophrenia patients (Grace). Thus, the altered dopaminergic 
dysfunctions are likely secondary to a hippocampal pathology. Furthermore, the 
hippocampal dysregulation is also linked to, and possibly caused by, the 
dysfunction of the PFC (Meyer-Lindenberg et al., 2005; Grace, 2012). Indeed, the 
brain region of origin for the pathology remains under considerable debate. One 
hypothesis focuses on the frontal lobe (frontal cortex) dysfunction, positing that a 
disruption of cognitive abilities renders the rest of the brain susceptible to further 
insult, whereas a competing theory posits a pathology arising from disrupted 
temporal lobe (hippocampus) connectivity (reviewed in: Ragland et al., 2007). The 
hippocampus is critical to the pathology of schizophrenia, and thus also 
occasionally revisited throughout the thesis. However, as the frontal cortex is the 
likely mediator of the cognitive deficits explored further within this thesis, the 
focus herein is primarily placed on the frontal lobe dysregulation. 
The grey matter reductions in the frontal lobes (specifically, the 
dorsolateral PFC; dlPFC) are linked with severity of symptoms and chronicity (van 
Haren et al., 2007; Bonilha et al., 2008), and is often the area with the most evident 
reduction (Selemon et al., 1995; Selemon et al., 2003; van Haren et al.). 
Interestingly, although clinically available antipsychotic treatments do not 
effectively treat the cognitive symptoms for all patients, there is evidence that 
treatment with atypical antipsychotics, olanzapine or clozapine, can abate the 
grey matter loss. This is likely through their high affinity for serotonin receptors, 
whereas the high affinity D2R antagonist, haloperidol, does not hinder grey matter 
loss (Lieberman et al., 2005b; van Haren et al.). That cell-receptor level 
interactions can have such a profound effect on gross tissue level phenomena, 
necessitates the examination of cellular neuroanatomy associated with 
schizophrenia. 
Despite the reduction in grey matter, the total number of neurons within 
post-mortem PFC tissue of schizophrenia patients, is not reduced (reviewed by: 
Garey, 2010); thus there is a higher density of neurons within the tissue (Selemon 
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et al., 1995; Rajkowska et al., 1998; Selemon et al., 1998). Further research has 
shown reductions in the number dendritic spines of PFC glutamatergic neurons, 
indicative of reduced information processing power through excitatory cell-cell 
communication (Garey, 2010). However, the neuronal density and dendritic 
arborisation disarray is likely reflective of disrupted neural development related 
to abnormal regulation of proteins involved in neuron localisation (reelin or 
Disrupted-in-Schizophrenia-1; DISC1), and cell-surface functions such as 
neurotransmitter (neuregulin 1) and synaptic (postsynaptic density protein 95; 
PSD95) signalling. Implicated in the PFC-hypofunction pathology, is enhanced 
NRG1 signalling which was has been found to interact with PSD95, resulting in 
reduced NMDAR activity within the PFC (Hahn et al., 2006). Also reported are PFC 
reductions in reelin protein expression in ~50% of patients with schizophrenia 
(Impagnatiello et al., 1998). While reelin is implicated in developmental processes, 
that it is preferentially expressed within GABAergic interneurons of the PFC, 
suggests additional perturbations to the inhibitory neurons within the PFC. 
The protein parvalbumin (PV) is a marker of interneurons which has proved 
useful in studying dysfunction outside of PFC pyramidal cells. While total number 
of PV-expressing neurons is not altered in schizophrenia patients (for review see: 
Lewis, 2013), there is evidence for dlPFC layer III and IV specific reductions in PV-
mRNA (Hashimoto et al., 2003), as well as reduced mRNA expression of PV-
expressing neuron potassium channel Kv9.3, which is involved in activation of PV-
expressing interneurons. Furthermore, a subset of PV-expressing neurons also 
express GABA synthesising enzyme glutamate decarboxylase (isoform 67; GAD67). 
As consistent reductions in GAD67 mRNA are reported in post-mortem brains from 
schizophrenia patients (Lewis et al., 2005), the loss of inhibitory function of these 
PV-expressing neurons may contribute critically to the dysfunction of the PFC. 
Indeed, expression of GABA transporter subtypes (1 & 3) within the dlPFC is 
abnormal in tissue from schizophrenia patients, further suggestive of dysregulated 
GABA signalling (Schleimer et al., 2004).  
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While this brief review cannot nearly begin to highlight all the 
neurochemical (Figure 1.1) and anatomical pathology (Figure 1.2) induced by 
schizophrenia, it provides a basic framework for understanding many of the 
significant impacts of the disease on PFC circuitry. Thus, the following review of 
the behavioural consequences of these neurobiological pathologies can be 
understood in context. Furthermore, within the empirical chapters following the 
introduction, many of these neurobiological pathologies are re-explored in 
relation to observed (or un-observed) behavioural phenotypes, with a primary 
focus on deficits in behavioural flexibility and attentional regulation.  
1.4 Schizophrenia behavioural flexibility and attentional 
regulation 
 When exposed to a weak auditory prestimulus, healthy persons have 
reduced blinking (startle reflex) in response to a subsequent (~120-150 ms later) 
additional pulse (Graham, 1975). Due to the biological abnormalities described in 
the previous section, patients with schizophrenia do not exhibit this effect to the 
same degree as controls (Braff et al., 1978). While the initial measurements have 
 
 
Figure 1.2) Diagram of schizophrenia-related anatomical alterations to the 
dlPFC, striatum, and hippocampus.  
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technologically advanced to examine the amplitude of cortical 
electroencephalogram (EEG) detected potentials (e.g. the P50) in response to the 
auditory cue, the prepulse inhibition (PPI) paradigm has proven useful as a reliable 
index of deficient sensory gating in schizophrenia, and a window into the 
pathology of delusions and hallucinations (Javitt and Freedman, 2015). 
Interestingly, experiments have implicated the PFC in PPI response in both healthy 
controls and patients with schizophrenia (Tregellas et al., 2007; Mayer et al., 
2013). Indeed, studies from lesion patients further evidence the role of the dlPFC 
in sensory gating (Knight et al., 1989; Yamaguchi and Knight, 1990; Knight et al., 
1999). Critically, these sensorimotor gating deficits in schizophrenia, in addition to 
the hyperactive dopaminergic system are crucial to the higher-order, dlPFC-
dependent, behavioural flexibility and attentional regulation deficits associated 
with the disorder. Indeed, deficits in sensory gating are evidenced not only during 
non-goal directed EEG recordings, but also during tasks which require attentional 
regulation such as dichotic listening (Rosburg et al., 2008). In the next sections, I 
focus on paradigms which test these functions during goal-directed behaviour.  
1.4.1 Schizophrenia and the Wisconsin Card Sorting Test 
While patients with schizophrenia are challenged with real world effects of 
deficits in attentional regulation, clinically measuring those deficits requires 
operationalising of the dysfunctions in conjunction with identifying the relevant 
neural substrates for the individual cognitive processes. An early tool for 
measuring attentional regulation is the Wisconsin Card Sorting Test (WCST; Berg, 
1948). The task (Figure 1.3), as described by Berg, originally used a deck of 60 
response cards. Each card contained information from each of three perceptual 
dimensions; colour (red, yellow, blue, green), shape (stars, crosses, triangles, 
circles), and number of stimuli on a card (ranging from one to four stimuli per 
card). The experimenter would present four ‘stimulus cards’ (such that each of the 
four stimuli within each of the three categories were presented once across all 
four cards) and inform the subject to sort the response cards based on which 
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stimulus card they thought it corresponded to. Following each placement, the 
experimenter would provide feedback on whether the subject’s choice was 
correct or incorrect. This continued until the subject had sorted five cards 
consecutively using the correct category (e.g. number of stimuli), then the 
category changed to sorting based on a different perceptual dimension (e.g. colour 
or shape). This process continued for nine category shifts. Berg found that 
participants could be divided into three groups, A) those who were “successfully” 
aware of the category shifts, B) those who were “vaguely” aware of the shifts, and 
C) those who remained unaware of the shifts.  
While group A showed an increase in errors for the first two category shifts, 
they performed near floor (sorting in five cards) for the remainder of the nine 
categories. Group B had a pattern of more errors through the entirety of the task 
than group A, and group C showed drastically worse performance than both A and 
B. Task performance critically reflects the ability to not only maintain, and respond 
based on, the relevant category (i.e. short-term and working memory 
 
 
Figure 1.3) Diagrams of the Wisconsin Card Sorting Test (left), and the CANTAB 
ID/ED ASST (right; both images from Brown and Tait, 2016).  
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mechanisms), but to do so in the presence of distractors (i.e. attentional 
mechanisms). Thus, participants who reported the ability to ascertain and attend 
to the relevant sorting category had the best performance in the task. As described 
in the neuroanatomy section, patients with schizophrenia often exhibit a 
combination of neurochemical and neuroanatomical abnormalities within the 
PFC. Predictably, as tasks which involve attentional regulation rely on the integrity 
of the PFC for optimal performance, patients with schizophrenia exhibit deficits in 
the WCST. Indeed, WCST performance in schizophrenia patients is positively 
correlated with their PFC integrity and subsequent hypofunction (Berman et al., 
1986; Weinberger et al., 1986; Deicken et al., 1995; Bonilha et al., 2008), thus the 
task is very popular as a measure of PFC function in schizophrenia patients. 
A meta-analysis in 2004 reported over 300 studies in the PubMed library 
using the WCST in patients with schizophrenia (Li, 2004). The majority of these 
studies focus/report on a single metric derived from performance in the WCST: 
the number of perseverative errors (errors where the participant has used the 
same category for their choice as the previous choice, in spite of negative 
feedback). This type of error generally occurs following the completion of a 
category, when the subject is unware a shift is required. Control subjects typically 
only make one error per switch, whereas schizophrenia patients are consistently 
reported to make significantly more perseverative errors (Li, 2004). Patients with 
frontal lobe lesions also make more perseverative errors in the WCST (Milner, 
1963; Goldstein et al., 2004), thus researchers hypothesised that the perseverative 
errors made by schizophrenia patients were induced by PFC-hypofunction 
(reduced glutamatergic signalling), as opposed to the other neurochemical and 
neuroanatomical pathologies associated with the disorder. Albeit a step forward, 
the classification of errors as ‘perseverative’ does not indicate which of two 
possible mechanisms underlie the errors. The first possible mechanism for 
elevated preservative errors is an inability to reallocate attention from the 
previously relevant rule/dimension. The second would be enhanced ‘learned 
irrelevance’ regarding the irrelevant dimension stimuli, thus impairment based on 
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reduced allocation of attention to the irrelevant dimension beyond the levels in 
controls. However, the nature of the WCST prevents analysis of these 
mechanisms. 
Since the WCST uses card stimuli in which the exemplars within all 
dimensions are partially reinforced across the sorting categories (i.e. specific 
exemplars are repeated across stages, but require sorting into a different 
category), it is described as a ‘partial change’ design, which can confound 
processes such as reversal learning and set-shifting (Slamecka, 1968). A 
modification of the WCST, therefore, involves using novel stimuli, and ‘stages’ that 
don’t require a category shift. This modification has been termed a ‘total change’ 
design and, with two-choice discriminations, allows for parsing the processes of 
stimulus-response contingencies (allowing for reversals within stimuli of the same 
perceptual dimension), as well as evidence of ‘attentional set-formation’, the 
phenomena by which attending to stimuli within one perceptual dimension 
enhances learning for stimuli within that dimension (within compound 
discriminations). For example, learning to attend to shape, across multiple stages, 
would speed discrimination of the correct stimulus, despite each stage presenting 
with novel shape, colour, and number exemplars. An early example of this total 
change attentional set-shifting task, for primates is the 
intradimensional/extradimensional (ID/ED) attentional set-shifting task (ASST) 
developed by Roberts et al. (1988). 
1.4.2 Schizophrenia and the Attentional Set-Shifting Task 
Generally, ASSTs measure reversal learning, and attentional set-shifting, 
additionally, set-formation can be inferred through the latter. In the commonly 
used touchscreen CANTAB ID/ED ASST for humans (Figure 1.3), shapes, lines, and 
solidity are the three perceptual dimensions used, with two unique, not readily 
verbally categorised, exemplars within each dimension (Sahakian and Owen, 
1992). In a two-choice discrimination, the participant must select the appropriate 
stimulus to a criterion of beyond chance selection (normally six consecutive 
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correct responses). Upon completion of each discrimination between novel 
stimuli, the stimulus-reinforcement contingency is reversed (REV; i.e. the 
previously incorrect stimulus becomes the correct stimulus). The task begins with 
a simple discrimination (SD; e.g. between two differing line stimuli), then an SD 
reversal. Next the task progresses to compound discriminations in which the 
relevant exemplars (both correct and incorrect) presented in compound with 
novel exemplars in an irrelevant dimension (e.g. shape). In the first compound 
discrimination, the stimuli are presented side by side (C_D). Once participants 
perform that stage to criterion they advance to a CD in which the stimuli are 
presented overlapping. Participant must also complete that stage to criterion, and 
afterwards all stimuli are present as overlapping compounds. The next stage is a 
CD reversal (CDR), following which, a ‘total change’ is implemented for the ID 
acquisition. In the ID, the previously relevant dimension (shape or line) remains 
relevant, however new exemplars are used across all dimensions (i.e. new line and 
shape exemplars). In the final stage novel exemplars are again presented in both 
dimensions, however the correct exemplar is now from within the previously 
irrelevant dimension. This is an ED shift acquisition, and should induce a shift-cost 
(greater trials to criterion or errors to criterion) relative to the ID if an attentional 
set was formed (Eimas, 1966). Due to this structuring of stages researchers can 
parse trials to criterion (TTC) or errors to criterion for individual learning and 
attentional processes. Specifically, aside from the reversal stages, where reversing 
stimulus-reward contingencies is intended, the use of novel stimuli eliminates 
possible interference from stimulus-reward contingencies from previous stages, 
and the ED stage can be manipulated to examine perseveration to the previously 
relevant dimension compared to learned irrelevance of the previously irrelevant 
dimension (Owen et al., 1993).  
While control participants are typically able to reach criterion for each 
stage within 50 trials (the cut-off for progression to the next stage), initial findings 
revealed that only ~50 - 60% of schizophrenia patients could complete the task 
(reaching criterion for each stage within 50 trials; Elliott et al., 1995), similar to 
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findings of reduced number of total shifts completed for schizophrenia patients in 
the WCST (Everett et al., 2001). Those patients who completed the task committed 
significantly more errors at the SD reversal and the CD. Additionally, the 
researchers used a manipulation at the ED to examine perseveration versus 
learned irrelevance. In the perseveration condition, the previously relevant 
dimension (e.g. line) became the irrelevant dimension, and the previously 
irrelevant dimension (e.g. shape) was replaced with a novel dimension (e.g. 
solidity) which the correct exemplar was derived from: thus, the participant was 
only be required to shift attention away from the previously relevant dimension. 
In the learned irrelevance condition, the previously relevant dimension (e.g. line) 
was replaced by a novel and irrelevant dimension (e.g. solidity), and novel 
exemplars were presented in the previously irrelevant dimension (e.g. shape), 
which became relevant: thus, the participant could only be require to shift to the 
previously irrelevant dimension. While schizophrenia patients showed no deficit 
at the ID or the learned irrelevance ED, they performed worse than controls during 
the perseveration ED, suggestive of an impairment in reallocating attention away 
from the previously relevant dimension. However, a subsequent study by the 
same research group found a different pattern of results (Pantelis et al., 1999), 
and is reviewed further in the next section.  
Pantelis et al. (1999) tested schizophrenia patients in the ID/ED ASST, this 
time using a standard ED stage (where the relevant dimension became irrelevant, 
and vice versa). Critically, this differs from the modified task (Elliott et al., 1995), 
as the shift to the previously irrelevant dimension, could be still be due to learned 
irrelevance or perseveration, as a novel dimension was not introduced at the ED. 
This difference notwithstanding, they still found an impairment at the ED (similar 
to Elliot et al.). However, unexpectedly the researchers also found a significant 
impairment at the ID, in addition to the ID reversal. This apparently contradictory 
finding was very informative, as further examination of patient populations 
revealed that differences in the age of patients, and length of hospitalisation, may 
account for the discrepant findings. The patients in the Pantelis et al. experiment 
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were ~10 years older, and hospitalised for an average of 18 years, whereas the 
majority of the schizophrenia patients in the Elliot et al study were outpatients. 
Thus, the behavioural manifestation and nature of deficits can possibly change 
and/or exacerbate over the duration of the illness, with chronicity impairing set-
formation (ID acquisition).  
The possibility that the disease causes progressive deterioration, with time 
from onset correlating with impairments in attentional regulation, is actually 
supported by many additional behavioural studies. Using the same ID/ED ASST, 
(Hutton et al. (1998)) found that patients classified as first experiencing 
schizophrenia symptoms (first-episode), while failing to reach criterion at the ED, 
exhibited no other significant deficits at any other stages. Further, the percent of 
first-episode schizophrenia patients failing to reach criterion was less than as 
reported previously for chronic patients (Pantelis et al., 1999 1995). This finding 
was later replicated in a direct comparison of first-episode schizophrenia patients 
and chronic schizophrenia patients (Pantelis et al., 2009). Additional studies 
comparing amongst patients past the first-episode lend more support to the 
argument that the duration of illness influences the impairments (Pantelis et al., 
2004; Hilti et al., 2010). However, a longitudinal study examining patients from 
their first-episode through follow up testing after 1, 3, and 6 years found no 
significant reduction in performance, as patients exhibited consistent significant 
reversal and ED shifting impairments, that did not differ by length of disease onset 
(Leeson et al., 2009). It possible that differences in patient selection methods can 
again explain these discordant results, as the Pantelis et al. (2009) study was a 
between-subjects design (no repeat ID/ED testing), whereas the Leeson et al., 
study was a within-subjects design with participants completing the task a total of 
four times. As patients in both studies were taking neuroleptic medication, these 
effects cannot be considered a consequence of reduced treatment. Overall, the 
progressive cortical atrophy (primarily PFC) reported in neuroanatomical findings 
would support the findings of the deficits in the ASST also being progressive. 
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As described in the neurochemistry section, the positive symptoms of the 
disorder are commonly tractable to treatment with D2R antagonists, while the 
cognitive symptoms are resistant to dopaminergic treatment (Conn et al., 2009). 
This is critical, as the degree of cognitive dysfunction is a strong indicator of long-
term outcome in patients (Ventura et al., 2009; Meyer et al., 2014; Torgalsboen et 
al., 2014). Therefore, there is a desperate need for therapies which can enhance 
cognition in patients with schizophrenia. To this end, a large movement in 
preclinical rodent experiments has focused on developing: 1) rodent 
manipulations with relevance to schizophrenia, 2) tasks with translational validity 
in which to assay cognition in rats, 3) putative pharmacotherapies which can 
enhance cognition of the rats performing those tasks, following the schizophrenia 
related manipulation. While many of the visual discrimination based tasks (e.g. the 
CANTAB ID/ED) developed for human use are readily performed by non-human 
primates (Dias et al., 1996a, b), the lengthy developmental maturation period, and 
expense of performing tests with non-human primates, prevents high throughput 
testing. Thus, many preclinical researchers focus on experiments with 
manipulations in rats which eliminates many of those concerns, while providing 
access to many of the evolutionarily conserved neural structures and functions 
which are being targeted for investigation. In the next section I introduce some of 
the behavioural flexibility tasks that have been developed within this framework.  
1.5 Tasks used to measure behavioural flexibility in rodents 
 One of the earliest perceptual set-shifting tasks in rats attempted to use 
visual stimuli (shapes and stripes) in a two-choice discrimination paradigm (Shepp 
and Eimas, 1964). Training required several days for rats to reach criterion with 
the discriminations (simple then compound), however once attained the following 
day the rats were tested in either an ID (e.g. continue responding to shape), or an 
ED (e.g. respond to stripe). This was the first instance of a total change design (i.e., 
the stimuli were novel) to assess set-shifting (in any mammal), and as expected 
the rats tested in the ID condition committed fewer errors than the rats tested in 
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the ED condition. Testing of behavioural flexibility in rats continued with this stage 
progression (acquisition phases followed by either ID, ED, or REV) for several 
decades, however (Birrell and Brown, 2000) reported on an improved perceptual 
set-shifting task for rodents, the rodent ASST (Figure 1.4).  
Based on the ID/ED ASST developed for primates (marmoset monkeys and 
humans) by T.W. Robbins (Roberts et al., 1988; Sahakian and Owen, 1992), the 
rodent ASST relies on digging bowls containing olfactory and somatosensory 
stimuli, as opposed to visual discriminations which rats do not readily perform 
(Bussey et al., 1997). Indeed, by taking advantage of rodents’ innate foraging 
behaviour, and discrimination based on odours and media, the training phase for 
the task can typically be done in the course of an hour, with complete testing 
proceeding the following day. Following closely to the CANTAB ID/ED ASST, the 
rodent ASST contains 7 stages (SD, CD, REV 1, ID, REV 2, ED, and REV 3). As a 
measure of construct and concurrent validity, the Birrell and Brown (2000) study 
examined if rats with medial PFC (mPFC) lesions exhibited similar performance as 
human patients with frontal lobe damage and monkeys with lateral PFC (lPFC) 
lesions. The rodent ASST was validated by this standard, as ibotenic acid-induced 
mPFC-lesioned rats had a deficit at the ED, consistent with the findings in human 
and non-human primates (Owen et al., 1991; Owen et al., 1993; Dias et al., 1996b). 
This task is the most widely used perceptual ID/ED set-shifting task, although other 
tasks also exist which measure ‘switching’ behavioural flexibility. These tasks are, 
however, typically more closely related to the WCST, as the stimuli remain 
constant throughout testing phases/stages. 
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 In 1999, Ragozzino et al., tested mPFC-inhibited rats in a plus maze task 
(Thompson et al., 1980), in which either allocentric spatial location (each arm 
corresponding to north, south, east, or west), or an egocentric cue (always turn 
right regardless of starting location), served as rules to guide the animal to the 
baited arm. Rats were initially tested in the allocentric or egocentric discrimination 
conditions and then required to switch to responding to the opposite cue during 
the next phase. Rats with inactivation of the mPFC (pre- and infralimbic cortex) 
were impaired at the “cross-modal shifts” (e.g. switching from allocentric to 
egocentric responding), but not acquisition of either response strategy or “intra-
modal” reversal of either strategy. The researchers concluded that mPFC is 
important for these cross-modal shifts. 
Floresco et al. (2008) reported the use of a new automated procedure to 
measure behavioural flexibility in rats. In an operant chamber with a lever to the 
right and left of the reward pellet dispenser, and a light-emitting diode above each 
lever, rats were trained to respond either based on the lever location or the light 
location. Following simple discrimination learning, where either only the light cues 
or the lever cues were presented, there followed compound discrimination, 
wherein light and lever cues were presented in compound. During this stage the 
rat had to continue to respond to the cue from the SD (either the light cue or the 
egocentric lever cue). The ‘compound’ nature of the light/lever stimuli was 
considered an advancement over the plus maze rule-switching test, and removed 
the need for allocentric-based responding (Ragozzino et al., 1999). Inactivation of 
the mPFC in this task impaired the strategy-shift either from visual cue to 
egocentric response cue or vice versa (Floresco et al.). However, this task was not 
with limitations, which along with those of the plus maze task (Ragozzino et al.) 
are discussed in the next section. 
In the operant chamber task (Floresco et al., 2008), clear differences in the 
difficulty of acquisition of, and shifting to, the egocentric lever cue strategy were 
evident in both mPFC-inactivated and control rats. Furthermore both tasks, plus 
maze and operant chamber, require days to weeks of habituation and training 
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prior to testing. The subsequent testing phase can also require days prior to 
acquisition by experimental and control groups. While these tasks are similar to 
the WCST in that they require a rule switch or strategy-shift, they cannot address 
questions of attentional set as the ID/ED tasks do, as they lack discriminations 
based on multiple stimuli within a perceptual dimension. The only possible 
manipulations within the tasks (Ragozzino et al., 1999; Floresco et al.) are location 
based, whereas the ID/ED ASST with multiple stimuli based within a dimension 
(odour or medium) can present those stimuli, in compound, in any spatial location, 
without confounding. Additionally, whereas the light stimulus is either on or off 
(Floresco et al.), ID/ED ASST dimensional stimuli can change while maintaining the 
higher order ‘response rule’, for example respond to an odour regardless of 
medium. Thus, the ‘total change’ nature of the perceptual rodent ID/ED ASST 
developed by Birrell and Brown (2000) provides the same advantages over the 
spatial-based behavioural flexibility tasks, as the ID/ED ASST over the WCST. Given 
the advantages of the Birrell and Brown ASST, all studies within this thesis adhere 
to that protocol, or are slightly modified from that protocol to address different 
learning and attentional processes.   
1.6 Thesis rationale 
The primary aim of using the ID/ED ASST in the following experiments is to 
study schizophrenia-related learning and attentional processes. To this end, three 
targeted manipulations in rats with relevance to schizophrenia were examined. 
The manipulations induce different schizophrenia-related phenotypes (both 
behavioural and biological), targeted at three different developmental time points 
corresponding to adulthood, juvenile, and gestational periods in humans. In 
Chapter 3, the manipulation examined is based on acute inhibition of mPFC 
glutamatergic neuronal signalling in adult rats. In Chapter 4, the effects of 
transient blockade of NMDARs during the neonatal period on adult behaviours is 
tested. Finally, in Chapter 5, another developmental manipulation is examined, as 
I report experiments in adult rats following inhibition of DNA translation within 
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neurons during critical period in gestation for cortical development. Figure 1.5 
presents how each manipulation targets a known sensitive period for 
development of schizophrenia. The focus of these studies to test the hypotheses 
that: 1) schizophrenia-like ASST behaviour in rats can arise from targeted 
manipulation of the brain at several timepoints; 2) these targeted manipulations 




Figure 1.5) Diagram of sensitive period targeted by each manipulation.  
Chapter 4: Neonatal-PCP treatment
• Late gestational/early childhood 
disruption of cortical glutamatergic 
signalling
Chapter 3: Inhibition of mPFC
glutamatergic signalling
• Adult PFC hypofunction induced by 
NMDAR antagonism or 
acute/chronic stress 
Chapter 5:Gestational MAM-treatment
• Early gestational genetic disruption 
which alters cortical layering and 
neuronal density
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Chapter 2. General Methods 
 
All experiments in this thesis were conducted in accordance with the regulations 
laid down in the United Kingdom Animals (Scientific Procedures) Act 1986, and 
performed with the authority of a Project License (PPL 60  / 4459) approved by the 
UK Home Office and the University of St Andrews Animal Welfare and Ethics 
Committee(personal licence number: IEB1CF8FE). Animals were kept under 
standard housing conditions (two-three per cage, 0700–1900 hr light phase, 
controlled temperature and humidity, ad libitum water). 
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2.1 ASST protocol 
2.1.1 Apparatus 
Training and testing took place in a modified plastic housing-cage (69.5 x 
40.5 x 18.5 cm). The testing arena has two individually dividable chambers in which 
ceramic bowls containing digging stimuli and reward are placed.  
2.1.2 Training 
At least 12 hrs prior to training, each rat was given a bowl filled with home-
cage sawdust and six pieces of food reward (half a Honey Loop cereal piece; 
Kellogg, UK) in the home-cage. Following exposure to the reward, rats were 
trained to dig in bowls filled with sawdust to obtain a food reward within the 
testing arena. To shape this response, the reward was placed on top of the 
sawdust on the initial trial. After the rat completed the trial by retrieving the 
reward, it was placed slightly deeper on the subsequent trial. This continued until 
the reward was completely buried at the bottom of the bowl and the rat was 
reliably retrieving it on each trial. Both chambers were baited and the rat was 
required to retrieve the reward from each side to prevent formation of a side bias. 
This ‘digging’ training regimen was typically completed in six trials. Next, two-
choice simple discrimination training was performed. All rats were trained on the 
same exemplars for both odour (mint and oregano) and medium (shredded paper 
and polystyrene) discriminations. These exemplars were not used again.  For the 
first four trials of a discrimination, rats were permitted to obtain the food reward 
from the correct bowl after an incorrect dig; however, after these four trials, an 
incorrect dig led to access to the correct bowl being blocked. Completion of a stage 
required rats to reach a criterion performance of consecutive correct responses 
which was greater than that predicted by chance 6-in-a-row (p = 0.016). Correct 
responses within the first four trials were included in this measure. The first test 
commenced the day following training. Subsequent tests were completed without 
the need for simple discrimination training.  
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2.1.3 Standard 7-stage ASST testing 
The seven discrimination stages proceeded as follows: 
1) a simple discrimination (SD) in which the rat either responds to an 
odour in sawdust, or an unscented digging medium 
2) a compound discrimination (CD) in which the correct stimulus from 
the previous stage is paired with irrelevant stimuli from a different 
dimension  
3) the first reversal (REV 1) in which the previously incorrect stimulus 
from the SD and CD becomes the correct stimulus  
4) an intradimensional discrimination (ID) where new compound 
stimuli are presented however the correct stimulus is still within 
the same dimension as the preceding stages  
5) a second reversal (REV 2) where the incorrect stimulus from the ID 
stage becomes the correct stimulus  
6) an extradimensional shift (ED) in which all new compound stimuli 
pairs are presented and the correct stimulus is now one of the 
stimuli in the previously irrelevant dimension 
7) lastly a third reversal (REV 3) in which the incorrect stimulus from 
the ED (within the same dimension) becomes the correct stimulus) 
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All exemplars used were counterbalanced for presentation order, and 
ED shift direction (i.e. odour to medium, or medium to odour). Table 
2.1 depicts the exemplar pairs used. 
2.2 Histology 
Following behavioural testing rats were anaesthetised with 0.8 ml 
pentobarbital (ip; Pharmasol, Ltd, UK), then intracardially perfused with 4% 
paraformaldehyde in 0.1 M phosphate buffer. Brains were stored in 20% sucrose 
for 24 hours at 4°C, then the brainstem and cerebellum were removed prior to 
weighing. Following weighing, brains were washed in distilled water, dried, placed 
in wells, covered in egg yolk, and placed in a formaldehyde bath for 72 hours. 
Afterwards, brains were sectioned at 50 µm on a freezing stage microtome (Jung 
Histoslide 2000, Reichert-Jung, Cambridge Instruments). Sections were stored in 
glycerol solution at  -20° C. 
For parvalbumin immunoreactivity detection, every 8th section of the 
frontal cortex was collected, and every 8th section of the hippocampus. Sections 
were placed in 9-hole netwells and petri dishes and washed four times for 5 min 
each in phosphate buffered saline (PBS: 158 M NaCl in 50% distilled H2O and 50% 
0.2 M phosphate buffer) on an automated rotator. Next the netwells were placed 
in blocking solution (1:5 normal goat serum, 1:100 10% Triton, in PBS) and rotated 
for an hour at room temperature. Sections were then washed in PBS three times 
 
 
Table 2.1) Exemplars used for standard ASST testing. Exemplars were 
presented in these pairs. Presentation order during testing was 
counterbalanced (e.g. 1 → 2 → 3 or 2 → 3 → 1). 
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for 5 min each. Sections were placed in histology pots before being incubated with 
5 ml of anti-parvalbumin antibodies (mouse anti-parvalbumin 1:8000, Sigma; in 
antibody diluting solution; ADS; 1:100 normal goat serum, 1:100 10% triton, in 
PBS) overnight at room temperature. The following day sections were washed in 
9-hole netwells in PBS three times for 5 min each. Sections were then switched 
back into histology pots and incubated in 5 ml anti-mouse antibodies (goat anti-
mouse, 1:200, Vectastain, in ADS) for one hour at room temperature. After 
incubation, sections were washed three times for 5 min in PBS, then placed in 
histology pots containing 5 ml of the biotinylation solution (Vectastain ABC KIT) 
and incubated for one hour. Sections were than washed three times for 5 min in 
PBS and parvalbumin immunoreactivity was detected by staining with 3,3’-
Diaminobenzidine (DAB; one tablet per 20 ml, Sigma, in distilled H20). The sections 
were determined to be stained when landmark anatomical structures were clearly 
identifiable or until they had been incubated for 20 min. Following DAB staining 
sections were washed three times for 5 min in PBS, and stored in 9-hole netwells 
at 4°C until (up to 72 hours) they were mounted to treated glass slides and 
coverslipped with DPX.  
All sections were imaged on a Zeiss Axio Imager M2 with ZEN software. 
Immunostaining was quantified using ImageJ automated cell counter. Images 
were grayscale transformed so that immunostaining appeared black. For the PFC 
7-10 sections per brain were counted. For the hippocampus 3-4 sections per brain 
were counted. Regions of interest were outlined manually per the Paxinos and 
Watson atlas (1998). The settings for image J automated counting were (width:7; 
minimum distance between cells of 2.5; and opacity threshold of 2.5). Size 
measurements were also gathered from outlined regions of interest, with distance 
defined using the image scale bar for accuracy of measurements. An example of 
the analysis is provided in Figure 4.9 where it is first used. 
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2.3 Statistical analysis 
2.3.1 Frequentist approach: Null hypothesis testing  
Multi-factorial repeated measures ANOVA were performed with the 
relevant variables as the repeated factors (e.g. stage or test). Data were analysed 
in SPSS v21. When the repeated measures ANOVA revealed significant 
interactions, restricted comparisons were performed using corrected F values, 
calculated by dividing the mean square effect from the multivariate ANOVA, by 
the mean square error from the relevant interaction in the omnibus repeated 
measures ANOVA, and using the degrees of freedom associated with the error. 
This method of calculation is known as a corrected-omnibus analysis (Winer, 
1971), which is a better estimate of the population error. To ensure statistical 
robustness, Huynh-Feldt corrected values were used for all F- and error values 
obtained from repeated measures ANOVAs. The Huynh-Feldt correction increases 
the error value to account for violations of sphericity/non-homogeneity of 
variance. For all figures *, indicates significantly different from controls, and #, 
indicates ID significantly different than ED, both p < 0.05. 
2.3.2 Probability approach: Bayesian analysis 
 Issues with frequentist criterion standards for the ASST 
Confirmation of stage completion, within the ASST used for primates and 
rats, uses a frequency criterion level of performance, which is typically 6-correct-
in-a-row (p = 0.016). This approach is a traditional ‘null vs alternative hypothesis’ 
framework, with ‘random-guess’ implied as the null hypothesis. However, there 
are three issues with the standard frequentist approach:  
1. Although the p-value of 6-correct-in-a-row = 0.016, this value is 
only valid for independent instantiations of 6 trials. In a cumulative 
distribution, such as TTC measurements, the probability of 
attaining 6-correct-in-a-row rises as the number of trials rises; 
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2. Frequentist approaches are prone to under- and over-training, as 
they are insensitive to the subject’s behavioural pattern outwith 
the window they measure (e.g. six trials);  
3. There are other possible strategies that a subject may be using 
aside from the responding to the desired stimulus which need to 
be rejected. In the next sections I discuss some limitations of 
frequentist criterion and describe how a Bayesian analysis may 
alleviate these concerns. 
 
 Frequentist criterions are susceptible to false positives with increasing trials 
As mentioned above frequentist criterions are used based on the 
probability of getting k correct-out-of-N trials. The CANTAB version of the ASST 
uses the 6-in-a-row criterion with a limit of 50 trials (Sahakian and Owen, 1992). 
The rat task adopted the human ASST frequentist criterion (Birrell and Brown, 
2000). However, some researchers using the task have a stricter criterion: mice 
typically require more trials and so for mouse ASST an 8-in-a-row criterion has 
been used (Bissonette et al., 2008), although, an automated set-shifting test for 
mice has used a less strict criterion of 8-out-of-10 criterion (Scheggia et al., 2014). 
Marmosets have been tested with even more strict criterion of 90% correct-out-
of-32 trials on two consecutive sessions (Dias et al., 1997), and more recently 90% 
correct-out-of-40 within a single session (Clarke et al., 2005). The first issue with 
many of these frequentist criteria, is that the p-value only remains significant 
within Nk trials. This is evidenced by Monte Carlo simulations (simulations of trial 
by trial random choice behaviour during a two-choice discrimination) to determine 
the familywise error rate (mathematical false positive) for each of the above 
criteria (Figure 2.1). The simulated data represent the mathematical false positive 
rate given random responding in a two-choice discrimination. Specifically, for the 
rodent criteria, after 10 trials, the potential for a mathematical false positive rose 
above p < 0.05, revealing that the risk of a Type I error was no longer statistically 
desirable.  
Chapter 2. General Methods 
34 
 
 Frequentist criterions are susceptible to over- and undertraining subjects 
The second issue is the insensitivity to the entirety of the subject’s 
decisions in the task. All of the frequentist criteria are limited to the k-out-of-N 
trials, however it is possible that ‘learning’ has occurred prior to this, or not 
occurred despite criterion being reached. Undertraining, reflects a circumstance 
where a subject progresses to the next stage after reaching the frequentist 
criterion, however, the subject is not actually making decisions based on the 
correct rule. This could occur by chance as seen in Figure 2.1 for the 6-in-a-row 
criterion. Indeed, the greater the TTC for a stage the higher the probability that a 
percentage of subjects are attaining the 6-in-a-row criterion by chance. This could 
be critical for stages which often require upwards of ten trials such as reversals or 
the ED and even more so in impaired subjects. A control measure for this would 
be raising the criterion standard to reduce the potential for undertraining. 
However, this approach is susceptible to unintended overtraining. The stringent 
criterion of the marmoset ASST, while reducing the occurrence of mathematical 
false positives to null (Figure 2.1), fails to actually detect when the subject has 
attained the learning rule. Thus, some subjects will receive additional trials beyond 
learning of the rule. In the case of the consecutive correct criterions, the 
progression correct resets after errors, thus repeated near attainments (e.g. 5-out-
of-6 correct) are not recognised as a metric of the subjects’ learning. If this pattern 
repeats again the subject could be unintentionally overtrained. This overtraining 
could potentially bias later decision making, such as the phenomenon of the 
overtraining reversal effect (Richman et al., 1972).   
 Frequentist criterions are insensitive 
 If the aim of the criterion is to progress the task when the subject has 
evidenced ‘learning’ and applied the correct ‘strategy’, then all of these criteria 
are insensitive to the ‘strategy’ the subject is using. A Bayesian approach would 
allow for testing amongst a multitude of hypotheses including the intended 
strategy (responding based on the correct perceptual dimension), thus increasing 
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the likelihood of passing the subject to the next stage for the correct reason. 
Furthermore, when the subject is making decisions that reflect an incorrect 
strategy, such as choosing a location repeatedly instead of responding to the 
relevant stimulus dimension, a Bayesian approach can test that hypothesis and 
quantify the probability for that strategy. Recent papers have tried to ‘predict’ an 
animal’s decision process by fitting behavioural data to Bayesian Inference models 
(Costa et al., 2015; Rygula et al., 2015). In the next section, I show how I have 
adapted Bayes’ theorem for a similar purpose. To avoid confusion with the term 
‘strategy-shifting’ used by others (Floresco et al., 2008), and to emphasise that the 
analysis within this thesis does not quantify what the rat is ‘thinking’, the term 
employed henceforth is ‘behavioural pattern’. Thus, a rat’s behavioural pattern 
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may reflect responding using a spatial pattern (e.g. place-match), or to a 
perceptual stimulus (e.g. cinnamon).  
 
 
Figure 2.1) Simulated data for two-choice discriminations over cumulative 
trials. Top. Currently, used rodent criterions remain within the acceptable p-
value range (< 0.05) up until the number of trials required for the stage 
exceeds ~10. Bottom. While Bayesian criterions are also susceptible to 
generating false positives, this is at a greatly reduced rate. 
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 Bayes Theorem Application 
Given a history of prior choices, and a specified number of hypotheses 
(behavioural patterns), Bayes theorem (1763) allows for calculation of the 
probability that each choice supports each of the hypotheses. This can be applied 
to the ASST to ascertain which of the behavioural patterns a rat’s choice on a trial 
is evidencing, essentially a probability of ‘what’ the rat is doing. Mathematically, 
in the ASST the probability that a decision made by a rat on trial(n) matches the 
desired correct response can be estimated given the rat’s current decision and its 
decision on trials (1 through (n-1)). The formula to perform this calculation is in Figure 
2.2. 
From this formula provided by Bayes, it is possible to derive an algorithm 
that updates the probability for defined hypotheses (i.e. behavioural patterns) on 
a trial by trial basis. Thus, I have numerated how many ‘logical’ behavioural 
patterns a rat might provide evidence for during the task. To this end, the lab has 
determined that there are eight probable behavioural patterns. The performance 
data may show a spatial-based behavioural pattern (place-match: choosing the 
same side on consecutive trials; alternation; win-stay; or win-shift), or a 
perceptual-based behavioural pattern (to any one of the four stimuli from the two 
perceptual dimensions), as depicted in Figure 2.2. Behavioural patterns are simply 
what is seen in the data. It is not possible to know that the animal is necessarily 
selecting a response on the basis of that pattern. Nevertheless, the probability of 
each pattern can be tested against each other during each trial using Bayes 
theorem (see formulae in Figure 2.2). While each pattern starts with an equal 
probability (p = 0.125), representing equal evidence amongst them, following the 
rat’s first choice, the probabilities update to increase for those supported by the 
choice and decrease for those patterns not supported. Using these criteria, the 
mathematical false positive rate during a discrimination is greatly reduced (Figure 
2.1), while remaining sensitive to the entirety of the subject’s choice behaviour. 
Aside from the number of behavioural patterns tested, the only free parameter 
within the algorithm is the likelihood of the evidence, that is to say how accurate 
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the choice is actually made based on the pattern(s) it supports. The likelihood 
parameter ‘c’ should ideally be 1. However, the analysis allows for the appearance 
of non-systematic choice behaviour, such as ‘explore-exploit’ (Berry and Fristedt, 




Figure 2.2) Top. Table of possible behavioural patterns. Bottom. Formula for 
Bayesian calculation of the probability for each pattern. 
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probability threshold of 95% to compare to the p-value measure of frequentist 
criterions (Figure 2.1). There is deviation, with the lower value of c = 0.75 reducing 
the rate of mathematical false positives, and c = 0.95 slightly increasing 
mathematical false positive rates. As yet there is no empirical evidence for the 
actual value of ‘c’, which may vary across trials, and across individual rats. The 
value of c = 0.85, used in the analyses here is therefore based purely on 
assumption necessitated by an inability to determine what a rat is ‘thinking’ when 
it makes a decision. As the analysis here is merely used to guide experiments and 
reveal potential differences, additional manipulation of ‘c’ is not needed, however, 
future experiments can determine how varying ‘c’, changes the results presented 
here. 
Due to the differences in TTC for individual rats, the group mean data 
presented here are presented in quartiles. For example, for a rat which completes 
the SD within 12 trials, the probabilities at trials, 3, 6, 9, and 12, were utilised. For 
irregular TTC the corresponding trial number was rounded, such that if criterion 
was reached in 6 trials, the probabilities at trials 2, 3, 5, and 6, were utilised. The 
resultant quartile probabilities were then averaged within a group. Additionally, 
for simplicity of graphs, the maximum evidence for either irrelevant dimension 
stimulus, or any of the four-possible spatial-based patterns is pooled into a single 
metric, irrelevant dimension or spatial, respectively.  
Although the raw mean probabilities for each pattern can be used for 
comparison (with chance performance = 0.125), a more informative measure 
compares the Bayesian-derived posterior probability to chance evidence for the 
pattern. This measure is termed a Bayes factor. When the value yielded by the 
calculation is greater than 3 (reflecting 3 times greater than chance evidence for 
that pattern), the evidence is considered strong, as is consistent with standards 
used to reject the null hypothesis in frequentist measures (Jeffreys, 1939; Dienes, 
2014). Indeed, within this thesis, in which the 6-in-a-row criterion was used for 
data collection, the subsequent behavioural pattern analysis revealed that across 
all stages for control rats the Bayes factor for the correct behavioural pattern was 
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greater than 3 at completion of the stage. The data here are presented as 
heatmaps with colour corresponding to the mean group Bayes factor. Also 
employed are bar graphs and tables for summary analysis.  
For illustration of the method, Figure 2.3 shows an example of the 6-in-a-
row criterion p-value changing trial by trial (a binomial calculation based on N, k, 
q = 0.5), compared to the Bayesian derived posterior probability reflecting 
responding based to the correct stimulus. In this example, the rat’s behavioural 
pattern indicates responding to the correct stimulus 3 trials prior to the frequentist 
criterion. Calculating the Bayes factor reveals that the rat is almost 8 times more 




Figure 2.3) Example table of the posterior probability changing based on the 
rat’s choice compared to the frequentist based p-value. 




Chapter 3. Investigation of Medial Prefrontal 
Cortex (mPFC) Mediated Attentional Set-Shifting 
Deficits 
 
Experiments in this chapter focused on ‘schizophrenia-related’ performance in 
the attentional set-shifting task in rats with acute inhibition of the mPFC 
(mPFCin). The aim was to model the PFC-hypofunction component of 
schizophrenia. The first experiment validated the methodology and replicated 
the finding of an extradimensional set-shifting deficit with mPFCin. Analysis of the 
behavioural patterns implicated dysfunctional sensory gating in the deficit. Two 
further experiments employed modifications of the ASST. In both experiments, 
the hypothesis was that mPFCin rats would learn about the redundant stimulus, 
whereas control rats would not. The experiments confirmed that mPFCin induces 
a deficit in attention regulation wherein redundant information obtains 
associative strength and can guide behaviour. 
 
  




3.1 Introduction to acute manipulations to induce 
‘schizophrenia-related’ behaviour in rodents 
 Schizophrenia is typically characterised as a neurodevelopmental disorder, 
however ‘schizophrenia-related’ symptoms can be acute onset and induced via 
several ‘acute’ mechanisms including NMDAR antagonism (Krystal et al., 2005), 
amphetamine and cannabis abuse (Srisurapanont et al., 2003; Arendt et al., 2005), 
and extreme stress in vulnerable persons (Walker and Diforio, 1997; Walker et al., 
2008). Back translation of these risk factors for acute onset schizophrenia-related 
symptomology has resulted in the development of animal manipulations based 
on: acute and sub-chronic drug treatments, chronic stress, and loss of function in 
select brain regions (i.e. lesion and temporary inactivation manipulations). As a 
measure of validity, sensory gating performance has been found to rely critically 
on the integrity of the mPFC in rats (Koch and Bubser, 1994; Sharpe and Killcross, 
2014), as evidenced for the dlPFC in humans (see Chapter 1: Introduction), 
supporting the PFC-hypofrontality hypothesis of schizophrenia and the potential 
for translation between rodent and human studies. In this chapter, I review the 
literature on the acute manipulations in rodents which generate schizophrenia-
related behavioural flexibility deficits, as well describe my own experiments with 
relevance for schizophrenia induced by acute mPFC-hypofunction in rats.  
3.1.1 Adult sub-chronic/acute NMDA receptor antagonist manipulations  
 Disruption of glutamatergic signalling by NMDAR antagonists induces 
‘schizophrenia-related’ symptomology in healthy volunteers (Umbricht et al., 
2000; Krystal et al., 2005; see Chapter 1: Introduction for review). As a preclinical 
tool, researchers have extensively studied the effects of acute and sub-chronic 
NMDAR antagonists on behaviour and cognition, and the underlying neural 
networks, in adult rats and mice. Early experiments found that sub-chronic 
administration of phencyclidine (PCP; ~1 - 2 mg/kg daily for five days) induced 
metabolic hypofunction and reduction in parvalbumin mRNA and protein 




expression in the PFC of rats (Cochran et al., 2003; Amitai et al., 2012). The 
physiological changes in response to sub-chronic PCP are reportedly severe 
enough to induce deficits in ASST performance, as many researchers have shown 
elevated trials-to-criterion (TTC) and/or errors at reversal stages and the ED stage 
(Rodefer et al., 2008; Broberg et al., 2009; Goetghebeur and Dias, 2009; 
Goetghebeur et al., 2010; Saland and Rodefer, 2011; Dawson et al., 2012; McLean 
et al., 2012). Behavioural flexibility effects are also evident in rats treated sub-
chronically with ketamine (Nikiforuk and Popik, 2012), however, the ketamine 
treatment is only reported to cause a deficit at the ED stage, suggesting a slightly 
different mechanism of action than sub-chronic PCP-treatment.  
 The effects of NMDAR blockade on mPFC physiology are evident following 
a single exposure to a NMDAR antagonist. Reductions in GABAergic interneuron 
markers (PV and GAD67), and the neuronal activity marker, zif 268 mRNA, are 
evident in the thalamic reticular nucleus and mPFC of rats following treatment 
with 2 - 2.5 mg/kg PCP (Egerton et al., 2005; Amitai et al., 2012). Further 
supporting the role of NMDARs in ‘schizophrenia-related’ cognitive 
symptomology, acute blockade of NMDARs in rats also generates ASST deficits. 
First reported by Egerton et al. (2005), acute treatment with PCP (2.5 mg/kg), 24 
hours prior to ASST testing, resulted in elevated TTC at the ED stage. Recently, 
Gastambide et al. (2013) reported that treatment with PCP (2.5 mg/kg) two hours 
prior to ASST induced deficits at the reversal and the ED stage. Treatment with 
ketamine (10 mg/kg) one hour prior to testing also diminished ASST performance 
however more selectively, as the rats only showed a significant deficit at the ED 
stage (Gastambide et al., 2013). 
Ultimately the aim of this line of research is translational utility to 
understanding schizophrenia symptoms in human patients. The sub-chronic 
NMDAR antagonism manipulations (PCP and ketamine) show responsiveness to 
treatment with antipsychotics (particularly sertindole) already in use in human 
patients (Rodefer et al., 2008; Broberg et al., 2009; Goetghebeur and Dias, 2009; 
Nikiforuk and Popik, 2012), and the cognitive ‘enhancing’ drug modafinil 




(Goetghebeur and Dias, 2009; Goetghebeur et al., 2010; Dawson et al., 2012). 
Although there are no known and validated treatments for the cognitive 
symptoms in human patients, the reported efficacy of antipsychotics in sub-
chronic NMDAR antagonism manipulations supports the potential usefulness of 
acute manipulations to mimic schizophrenia symptomology in rats.   
3.1.2 Stress-induced perturbations  
The diathesis stress model of schizophrenia proposes that at-risk 
individuals are ‘tipped over’ the edge via chronic stress exposure (Walker and 
Diforio, 1997). Early research suggests that the ‘tipping’ and subsequent 
manifestation of symptoms was likely due to the impact of stress on the mPFC 
(Weinberger, 1987). Following this hypothesis, researchers began studying how 
stress alters the mPFC resulting in increased susceptibility to cognitive 
dysfunction.  
A well validated method for increasing the stress response hormone 
glucocorticoid in rats is chronic and repeated stress (restraint, tail-pinch, cold-
water swimming, etc.). Rats which undergo this treatment (typically, for 14 - 21 
days) exhibit significantly elevated glucocorticoid levels, similar to the elevations 
in glucocorticoid levels measured in humans who experience chronic psychosocial 
stress such as ‘work overload’ (Kunz-Ebrecht et al., 2004; Schlotz et al., 2004). 
Using this technique to explore stress-induced alterations in the executive 
function network has yielded some interesting results with implications for 
cognitive deficits in schizophrenia.  
Stress-induced alterations in rat mPFC morphology results in significant 
reductions in dendritic arborisation in mPFC, however no significant change in the 
orbitofrontal cortex (OFC; Liston et al., 2006). Consistent with this selective 
disruption of the mPFC, significant set-shifting deficits are found in chronically 
stressed rats, while reversal learning is spared (Liston et al., 2006; Nikiforuk and 
Popik, 2011; Naegeli et al., 2013; Nikiforuk and Popik, 2014). Of note, one paper 
reported deficits at the first reversal stage (REV 1) in chronically stressed rats (Jett 




et al., 2015). The deficit at REV 1 may be due to the slightly different stress-
induction method as the researcher used chronic unpredictable stress protocol 
while all but one (Naegeli et al., 2013) of the early studies utilised restraint stress 
alone. Indeed, it appears that physical stressors affect the OFC more so than the 
‘psychogenic’ restraint stress procedure (Lapiz-Bluhm et al., 2009; Donegan et al., 
2014). Chronic intermittent cold stress induces a select deficit at REV 1, but not at 
any other stages of the ASST (Lapiz-Bluhm et al.; Donegan et al.). This REV 1 deficit 
co-occurs with disruption of serotonin signalling in the OFC, (also known to be 
dysregulated in schizophrenia; Bleich et al., 1988), as well as altering levels of the 
interleukin-6 cytokine, a popular target for immune and inflammatory based 
schizophrenia research (Naudin et al., 1996). These data support the diathesis-
stress model of combining the mPFC stress-induced effects with underlying 
neurochemical disruptions resulting in ‘schizophrenia-related’ cognitive and 
behavioural deficits. However, the basic of how the affected brain regions function 
to facilitate ASST performance remains to be explored fully. While the animal 
manipulations provide some insight, direct manipulation of an individual target 
region also provides beneficial information on underlying mechanisms in both 
typical and dysfunctional brains. 
3.1.3 Lesion experiments 
 As described in the introduction (Chapter 1), several key brain regions are 
known to regulate performance in the ASST in humans (Rogers et al., 2000) and to 
be dysfunctional in patients with schizophrenia. Although schizophrenia affects 
multiple regions, comparison of select dysfunction of a single region grants insight 
into the potential underpinnings of individual symptoms. For example, the ED shift 
deficit in the ASST reported in patients with schizophrenia (Pantelis et al., 1999; 
Turner et al., 2004) may be largely due to dysfunction of the dlPFC in these 
patients. In the early ‘90s two papers highlighted the requirement of a functional 
dlPFC in normal performance of set-shifting (Owen et al., 1991; Owen et al., 1993). 
In a direct comparison between patients with frontal lobe damage and 




schizophrenia patients, both groups exhibited deficits in set-shifting compared to 
controls (Pantelis et al.). It should be noted that this deficit was greater in the 
schizophrenia group, and that the schizophrenia group also had additional deficits 
in reversal learning which were not present in the frontal lobe patients, suggesting 
the additional neurobiological pathologies (e.g. OFC, hippocampal and striatal 
dysfunction) exacerbate the cognitive deficits.  
The previous two sections highlighted how indirect manipulations (drug or 
stress-induced) affect the mPFC. In this section I will briefly, review data from 
direct manipulation (selective lesion) of areas implicated in schizophrenia, and 
how these findings in animal manipulations support findings in humans, and allow 
dissociation of behavioural phenotypes based on localisation, despite lacking 
direct aetiological fidelity to schizophrenia.  
In rats, lesions to the OFC have been found to induce reversal learning 
impairments and loss of attentional set-formation (McAlonan and Brown, 2003; 
Chase et al., 2012), however TTC for the ED shift is spared (although it is 
questionable whether attentional set is formed following OFC-lesions). In mPFC-
lesioned animals however, reversal learning stages are not reliably impaired but 
the ED stage requires more TTC compared to control animals (Birrell and Brown, 
2000; Tait et al., 2009). Similar findings have been reported in mice (Bissonette et 
al., 2008) and marmosets (Dias et al., 1996a ,1997). The findings in lesioned 
animals therefore are consistent not only with the drug and stress manipulations, 
but also with the human findings (Owen et al., 1991; Owen et al., 1993). An 
advantage of animal experiments is that ‘blue skies’ research can be performed. 
For example, Chase et al., were able to replicate the rat OFC reversal learning 
deficit, and then follow up with a 4-ID task to examine the effect of removal of 
reversal stages on set-formation in rats with OFC lesions. In a surprising result, the 
removal of the reversal stages, and addition of three supplementary ID stages, 
revealed that OFC-lesioned rats can form an attentional set when provided ample 
opportunity, and that once an attentional set has been formed, they then manifest 
an ED shift deficit apparently similar to the deficit induced by mPFC lesions.  




Although the direct translational impact of this research is perhaps, less 
clear than the sub-chronic NMDAR antagonist or chronically stressed rats, there is 
an obvious benefit from the challenge the results provide to the role of the OFC in 
‘solely’ reversal learning. The knowledge gained by furthering understanding of 
the basic functionality and psychological mechanisms at work within the OFC may 
eventually provide additional treatment targets for persons suffering from OFC 
dysfunction. In the spirit of ‘blue skies’ research, I sought to examine the 
psychological mechanism underlying the ED deficit in rats with mPFC-disruptions. 
In the next section I briefly review the approach that was used to inhibit the mPFC. 
3.1.4 Inactivation of the mPFC via designer receptors exclusively activated by 
designer drugs (DREADDs) 
The technology available to the neuroscience field has advanced greatly 
since the 20th century. Many of these advancements allow for refinements in 
procedures, reduced animal usage, and replacement of certain procedures 
altogether. Designer receptors exclusively activated by designer drugs (DREADDs), 
is one such technology that provides all the mentioned advancements. DREADDs 
are engineered human muscarinic (hM) receptors which can be packaged into a 
virus and expressed in target cell populations (controlled by manipulation of the 
viral DNA promotor sequence) and specific brain regions (via microinjection 
surgery). Once the desired target is infected, DREADDs can be activated by the 
ligand clozapine N-oxide (CNO). Binding of CNO to the DREADD activates an 
intracellular G-protein signalling cascade, which can be either excitatory or 
inhibitory (Gq- or Gi-subunit coupled DREADDs respectively; Urban and Roth, 
2015). The effectiveness of this approach is evident by numerous publications 
reporting robust physiological and behavioural effects following activation of the 
receptor (for review see: Roth, 2016; Smith et al., 2016). Of particular interest to 
this project is the inhibitory hM4Di-DREADD, which has been used effectively in 
the frontal cortex of monkeys (Eldridge et al., 2016), mice (Perova et al., 2015), 
and rats (Kerstetter et al., 2016). Inhibitory hM4Di receptor signalling can lasts up 
to 5 hours despite CNO only having a predicted half-life of 3 hours in vivo (den 




Hartog et al., 2016). Further supporting the utility of targeted inactivation via 
DREADDs, the effect of temporary inactivation is reportedly similar to that of 
lesions. Ethanol-dependent mice with lesions to the lateral OFC exhibit elevated 
preference for ethanol compared to non-lesioned animals, and this preference is 
recapitulated in mice with inactivation of the lateral OFC via hM4Di-DREADDs 
activation (den Hartog et al., 2016). 
As researchers, it is our duty to develop with the field and improve the 
methods we use to meet the highest standard of animal care and proper usage, 
and in this effort, I sought to utilise temporary DREADD-mediated inactivation of 
the mPFC as opposed to the ibotenic acid lesions which our lab has performed in 
the past (Birrell and Brown, 2000). Four key factors justified this position. The first 
benefit of employing this method was reducing the number of animals by half. 
With repeat testing and an AB design (treatment with CNO or vehicle) each animal 
was its own control thus our studies were within-subjects as opposed to between. 
A second benefit was the reduction of risk to the animal. Unlike with inhibitory 
ligands tetrodotoxin and muscimol, which would require placement of a guide 
cannula increasing risk for infection in the animal, once the DREADD receptor was 
delivered via microsurgery, the animal was no longer subjected to invasive 
procedures, apart from intraperitoneal (i.p.) injections of CNO. Third, the 
fluorescent tag incorporated in the DREADD receptor, allowed for visualisation of 
the extent of viral infection, a benefit not available with most other inactivation 
methods or PCP-administration. Last, the oral bioavailability of CNO (Lin et al., 
1996; Chang et al., 1998), made activation of the DREADDs via a palatable gelatine 
tablet possible, further reducing the need for potentially stress inducing i.p. 
injections.  
3.2 Rationale 
In this chapter, I explore if temporary inactivation of the mPFC (via 
inhibitory DREADDs activation) would replicate the ED deficit induced by mPFC 
lesions (Birrell and Brown, 2000; Tait et al., 2009). Following replication of the ED 




deficit, I sought to reconcile two seemingly opposing symptoms in schizophrenia, 
one being the inability to regulate attention and diminished sensory gating, and 
the other being perseveration and ‘cognitive inflexibility’. The ED stage is prime 
for studying the role of attention to sensory stimuli, as normal rats effectively 
disregard the previously irrelevant dimension stimuli during the initial trials of the 
stage (a consequence of attentional set). This is despite the novelty of the stimuli, 
and results in increased TTC compared to the ID. However, in rats with mPFC-
hypofunction, if they lack the ability to filter irrelevant stimuli and to behave based 
on optimal stimulus-reward contingences is ‘cognitive inflexibility’ in the form of 
reduced ability to shift attentional set actually the cause of the subsequent ED 
deficit?  
3.3 Methods and materials 
3.3.1 Animals 
Adult male (n = 12) Lister Hooded rats (Charles River, UK) were pair-housed 
in standard housing conditions. Seven days prior to surgery rats were placed on 
mild food-control of 15-20 g per day. Water continued to be available ad libitum. 
Prior to surgery, all rats weighed 396 to 426 g. At the completion of all 
experiments, all rats showed evidence of weight gain (end weights 448 – 518 g).  
3.3.2 Pharmacogenetic manipulation 
 After two weeks of acclimation to the new habitat, the rats were 
anaesthetised with a gaseous mix of isoflurane (5% at induction, then reduced to 
1.5 - 2% for maintenance) and oxygen and given 0.05 ml of Carprieve (Carprofen: 
Pfizer, Kent, UK), via subcutaneous injection to reduce any potential surgery-
related pain during recovery. Once the rats were unresponsive, their heads were 
shaved and cleaned with alcohol. Next, they were placed into a stereotaxic frame 
(Kopf, CA, USA), and secured into location with atraumatic ear and tooth bars (set 
and -3.3 mm to achieve level skull). All rats underwent bilateral microinjections of 




1 μl AAV5-CamKII-hM4Di-mCherry. Four injection sites were targeted to 
encompass the entirety of the mPFC. The Paxinos and Watson (Paxinos and 
Watson, 1998) coordinate system was used to calculate the location of all injection 
sites. Anterior/posterior measurements were calculated from Bregma at skull 
surface, while medial/lateral, and dorsal/ventral coordinates were calculated from 
the dura. The following coordinates were used: 1) anterior/posterior + 3.9, 
medial/lateral ± 0.5, dorsal/ventral -3.1; 2) anterior/posterior + 2.9, medial/lateral 
± 0.5, dorsal/ventral -3.1. The skull was removed from the injections site with a 
drill, and a Hamilton syringe with a 30-gauge needle attached was used to deliver 
the virus over a 5-min period, followed by a 5 min post-injection in situ wait period 
for virus diffusion. Once all sites were injected the surgery site was closed with 
alcohol disinfected surgical staples. Following surgery, rats were single housed for 
24 hours, and weighed daily for the next 48 hours to ensure no weight loss due to 
disrupted feeding behaviour. 
For i.p. administration rats were habituated to the injection procedure 
with an i.p. injection of vehicle, for two days prior to test day. On test days, they 
received either CNO (10 mg/mg/ml, suspended in .09% saline) or the 
corresponding volume of vehicle. Following injections rats were isolated into a 
holding cage. For oral administration, 10 mg/kg CNO was suspended in a ‘jelly’ mix 
(60 ml sugar free blackcurrant flavoured Robinsons (Britvic, UK); 6 g, Dr Oetker 
Gelatine Sachet (12 g/sachet); stirred for 15 min). For both administration 
methods testing began 30 mins after the delivery of CNO to allow activation of the 
DREADDs receptors by the ligand. The 10 mg/kg dose was chosen as it was at the 
higher end of the effective range reported in the literature (Roth, 2016) and I 
wanted to ensure successful activation of the receptors for the duration of the 
ASST testing, which can take upwards of three hours (Gilmour et al., 2013). 
3.3.3 Behavioural Testing 
 Two weeks following surgery, all rats underwent the standard 7-stage ASST 
(as described in Chapter 2: General Methods) to familiarise them with stimuli and 




discriminations and ensure they could complete the task within the time course of 
CNO-mediated DREADDs activation (Roth, 2016). Following baseline testing, the 
rats were tested in the 7-stage ASST twice more in an AB design with half of the 
rats receiving 10 mg/kg CNO i.p. and half of the rats receiving saline in each test. 
Next, to validate the effectiveness of oral CNO administration, the rats were tested 
twice more in an AB design. In each test half of the rats received 10 mg/kg CNO 
orally, while the other half received ‘jelly’ alone. 
 4-stage simple task  
Testing took place in the same chamber as the ASST, and followed the 
same procedure for stimuli presentation, counterbalancing, and criterion to stage 
completion (see ASST methods for details; Chapter 2), with few changes to 
account for the ‘simple’ method of stimulus pairing. During the first stage, rats 
were required to perform a simple discrimination (SD) between two stimuli either 
(OA vs OB; or MA vs MB). The second stage introduced a redundant stimulus into 
the irrelevant dimension however, the redundant stimuli were ‘simple’ paired 
with only one of the stimuli from the SD (for example, the rat was always 
presented with OA MA vs OB MB). During the first compound discrimination (CD) 
normal rats should not associate the redundant stimulus with reward as their 
attention to the correct stimulus from the previous stage (the SD), should induce 
the ‘blocking’ phenomenon (Kamin, 1968; Sharpe and Killcross, 2014). After 
acquisition of the CD the rats were required to reverse to the previously incorrect 
stimulus pair (e.g. from OA MA to OB MB). At this reversal stage (REV) the normal 
rats should continue to ignore the redundant stimulus and associate the stimuli 
within the dimension from the SD with the reward. For example, if the rat’s SD 
were between two odours, then the redundant stimuli would be the media paired 
with the odours during the CD and REV stages. This hypothesis is tested at the final 
stage (probe), as the redundant stimulus paired with the REV stage rewarded 
stimulus, is paired with the now correct stimulus, a novel stimulus yet to be 
presented during the task (e.g. OC). Additionally, the redundant stimulus from the 
incorrect REV stimulus is now paired with a novel incorrect stimulus from the other 




dimension (e.g. OD). A representation of this procedure is depicted in Figure 3.1. If 
the rat has been attending to the stimuli within the dimension from the SD (e.g. 
odour) then the pairing of the redundant stimulus from the REV stage with the 
correct stimulus for probe, should not provide any additional information. 
However, if the rat has attended to the redundant stimulus during the REV stage 
then acquisition of probe should occur in fewer trials.  
 6-stage simple-probe ASST 
 Testing took place in the same chamber as the ASST (see ASST methods for 
details). All stages required a 6-in-row-correct criterion to be reached before the 
rat could advance to the next stage. The first four stages (SD, CD, REV, ID) of the 
task followed the same method as the standard 7-stage ASST. After reaching 
criterion at the ID, rats were required to complete a ‘simple probe’. During this 
stage only two bowls were presented, one with the correct stimulus from the ID 
paired with the to-be-correct stimulus for the upcoming ED, one with the incorrect 
stimulus from the ID paired with the to-be-incorrect stimulus from the ED. To 
complete the simple probe rats were required to reach criterion digging in the 
bowl containing the correct stimulus from the ID. This stage was designed to allow 
mPFCin-rats an opportunity to exploit their inability to reduce attention to the 
irrelevant dimension stimuli. The procedure is shown in Figure 3.1. Control rats 
(which have formed an attentional set) should not associate the introduction of a 
‘novel’ redundant stimulus during the ‘simple’ ID with reward, as it should be 
blocked (Kamin, 1968). On the other hand, if mPFCin-rats cannot reduce attention 
to redundant information, they should associate the redundant stimulus with 
reward. This hypothesis is tested in the final stage, a partial change ED (EDPC), 
during which the stimulus paired with the correct stimulus from the ‘simple’ ID is 
rewarded. For control rats, a positive shift-cost should be present, suggesting set-
formation, set-shifting, and successful blocking during the simple probe. However, 
mPFCin-rats should require fewer trials than controls to complete the EDPC, 
evidence of performance enhancement reflective of their inability to reduce 
attention to the redundant irrelevant stimulus during the simple probe.   






















































































































































 Order of Testing 
Two weeks following surgery, all rats underwent the standard 7-stage 
ASST to familiarise them with stimuli and discriminations and ensure they could 
complete the task within the time course of CNO-mediated DREADDs activation 
(Roth, 2016). For all following testing, the rats were tested in an AB design with 
half of the rats receiving 10 mg/kg CNO and half of the rats receiving saline in 
each test. First, the rats were tested in the 7-stage ASST following i.p. injection of 
10 mg/kg CNO. Two weeks later the rats were retested in the 7-stage ASST 
however this time following oral administration of 10 mg/kg CNO suspended in a 
jelly or jelly alone. After validation of oral administration for the effect of 
interest, all following testing was done with oral administration of CNO. The 4-
stage partial reinforcement task occurred two weeks following the last 7-stage 




3.4.1 mPFCin-rats have set-shifting deficits in the standard 7-stage ASST 
 The first experiment tested the effect of mPFCin on performance in the 
standard ASST by administering 10 mg/kg CNO, or vehicle, first by i.p. injection and 
then orally. The mean TTC across all stages was overall slightly higher in the first 
tests, with i.p. injections, compared to the second tests, with oral administration 




(17.14, ± 1.5 versus 15.72, ± 1.33; main effect of Route: F(1, 11)  16.7, p < 0.05). All 
interactions with Route were not significant and, in particular, Route x CNO x Stage: 
F(6,66) < 1). Irrespective of route of administration, CNO-treated rats required more 
trials to complete the ED stage than when they were vehicle-treated (TTC ED: 
mPFCin = 26.04, ± 1.26; control = 15.21, ± 0.66). There was also a small increase in 
TTC when the rats were CNO-treated in the REV 1 stage (TTC REV 1: mPFCin = 23.0, 
± 1.11; control = 19.71, ± 1.48). These effects were confirmed by a significant CNO 
x Stage interaction (F(1, 6) = 7.87, p < 0.05; Figure 3.2) and subsequent restricted 
comparisons (ED: F(1, 11) = 49.39, p < 0.05; REV 1: F(1, 11) = 5.25, p < 0.05).  
 
Figure 3.2) Mean trials to criterion data (+ SEM) on the standard 7-stage task 
following i.p. and oral administration. mPFCin-rats required significantly more 
trials to complete the ED-stage than controls, but do not significantly differ 
from controls at any other stages (#, ID significantly different than ED, both 
controls and mPFCin-rats; *, REV 1 & ED significantly different than controls).  




3.4.2 Behavioural pattern analysis reveals increased irrelevant dimension 
responding in mPFCin-rats  
To further examine the ID/ED deficit mPFCin-rats, an analysis of the rats 
behavioural patterns during the ASST was performed (Figure 3.3; see Chapter 2: 
General Methods section for the Bayesian method description). Analysis of the 
pattern of bowl choices suggested that mPFCin-rats were more likely to respond 
based on irrelevant dimension stimuli during reversal stages as evidenced by more 
quartiles with a Bayes factor of 3 or higher for the irrelevant dimension 
behavioural pattern (mPFCin = 6, controls = 1). Responding to irrelevant dimension 
stimuli was also evidenced at the ED in mPFCin-rats (mPFCin = 2, controls = 0). 
Analysis of behavioural patterns further suggested that while both group of rats 
displayed spatial patterns (e.g. place match or win-stay), mPFCin-rats did so less 
than controls (mPFCin = 6, controls = 11; Figure 3.3), and instead chose bowls based 
on the irrelevant dimension stimuli (mPFCin = 8, controls = 2; Figure 3.3). These 
data suggested rather than solely being cognitively inflexible resulting in impaired 
set-shifting, mPFCin-rats were actually shifting responding across stimulus 
dimensions (relevant/irrelevant) through ASST stages which did not require 
dimensional-shifts. Of final note, the analysis found only one instance of 
perseveration. This occurred during the first quartile of REV 3 for mPFCin-rats 
(Figure 3.3). Given the findings of a behavioural pattern suggesting increased 
irrelevant dimension responding during the ASST, the next experiments sought to 
directly test if indeed mPFCin-rats were still attending to irrelevant dimension 













Figure 3.3.Top. Heatmap of evidence for behavioural patterns during the 
standard ASST (oral and i.p. CNO administration). Bottom left. Table of sum 
quartiles per stage of irrelevant dimension responding. Across all stages 
mPFCin-rats had more evidence for increased responding to irrelevant 
dimension. Bottom right. Bar graph showing total spatial and irrelevant 
dimension quartiles by group across all stages. mPFCin-rats showed less 
evidence of spatial pattern use compared to controls. 
 




3.4.3 mPFCin-rats attend to stimuli in the irrelevant dimension  
 The next set of experiments tested the hypothesis that mPFCin-rats were 
impaired at the ED stage due to an inability to reduce attention to the irrelevant 
dimension stimuli. To examine this, I designed two tasks which would enhance 
performance at the probe stage if the subject were attending to irrelevant 
dimension stimuli during previous stage. In the first task (simple 4-stage ASST; top 
diagram of Figure 3.1), a significant CNO x Stage interaction was found (F(1,6) = 3.86, 
p < 0.05; Figure 3.4) as compared to control rats (TTC probe: 11, ± 1), mPFCin-rats 
performed significantly better at the probe (TTC probe: 7, ± 0). This difference was 
confirmed by ANOVA restricted to the probe stage (F(1, 33) = 14.42, p < 0.05) No 
other significant effects were found across any other stages (Fs < 1). Following 
these results the next experiment sought to further support the findings of mPFCin-
rats attending to irrelevant dimension stimuli by testing them in a ‘true’ ID/ED test 
where only one stage was ‘simple’.  
 
Figure 3.4. Mean trials to criterion (+ SEM) for the 4-stage simple task. mPFCin-
rats are faster to acquire a probe when the to-be-correct stimulus for the 
probe is paired with the correct stimulus from the ID. 




In the 6-stage, simple probe version of the ASST (bottom diagram Figure 
3.1), regardless of CNO-treatment, the rats did not appear to notice when the 
stimuli in the irrelevant dimension changed during the simple-probe stage and 
they continued to respond to the previously-rewarded stimulus. When vehicle was 
administered, the rats showed an ED shift-cost, taking more trials to complete the 
ED stage than to complete the ID stage. However, when CNO-treated, there was 
no difference between ID and ED stages: the rats appeared to have benefitted 
from what should have been unattended-to information. This was confirmed by 
an interaction of CNO x Stage (F(1, 5) = 3.08, p < 0.05; Figure 3.5) and verified by 
restricted comparison (ED: F(1, 55) = 12.54, p < 0.05; all other stages Fs <1). 
 
 
Figure 3.5) Mean trials to criterion data (+ SEM) on the 6-stage simple-probe 
task. mPFCin-rats were faster to acquire an ED when the to-be-correct stimulus 
for the ED was paired with the correct stimulus from the ID (#, ID significantly 
different than ED; * ED significantly different than controls. 




Bayesian analysis of the 6-stage simple-probe revealed a slight change in 
the pattern of behaviour for CNO-treated rats (Figure 3.6). Rather than evidence 
of irrelevant dimension responding during the REV, this pattern was evidenced 





Figure 3.6) Top. Heatmap of evidence for behavioural patterns during the 
standard ASST. Bottom left. Table of sum quartiles per stage of irrelevant 
dimension responding. There was strong evidence for mPFCin-rats responding 
to the irrelevant dimension during the CD as opposed to during the ED as 
controls did. Bottom right. Bar graph showing total spatial and irrelevant 
dimension quartiles by group across all stages.  




whereas control rats showed responding to the previously relevant dimension 
during the EDPC, mPFCin-rats did not have substantial evidence for any incorrect 
behavioural patterns.  
To further illustrate the effect of mPFCin on performance, Figure 3.7 shows 
the difference in TTC shift-cost (ED minus ID) for both the 7-stage (both i.p. and 
oral CNO administration data) and the 6-stage simple probe tasks. In the standard 
7-stage task, control and mPFCin-rats formed and shifted an attentional set as 
indicated by a positive shift-cost in both conditions, however, mPFCin-rats showed 
a greater cost than controls (t(10) = -4.84, p < 0.05), reflecting their impaired ED 
performance. Control rats also show a shift-cost in the 6-stage ‘simple’-probe task, 
but mPFCin-rats do not (t(10) = 2.65, p < 0.05), reflecting enhanced performance at 
the ED stage arising because mPFCin-rats attended the to-be-correct-stimulus 
during the simple-probe stage, while it was irrelevant to control rats. Collectively, 
these data suggest that although mPFCin-rats can form and shift an attentional set, 
they simultaneously attend to irrelevant/redundant stimuli. 
 
 
Figure 3.7) Mean trials to criterion data (+ SEM) on the 6-stage simple-probe 
task. mPFCin-rats were faster to acquire an ED when the to-be-correct stimulus 
for the ED was paired with the correct stimulus from the ID (*, ED significantly 
different than controls). 




3.5 Discussion  
The first finding of the experiments within this chapter is that DREADDs-
mediated inhibition of the mPFC induces a deficit at the ED stage of the standard 
ASST. This finding is consistent with the previous reports described in the 
introduction showing ED deficits following disruption of the mPFC by ibotenic acid, 
acute and sub-chronic NMDAR antagonism, and chronic stress. There was also 
evidence of a REV 1 deficit in CNO-treated rats, however, this increase in TTC was 
small (3 trials), only present at one of the three reversal stages, and not present in 
the later tests (4- or 6-stage modified tasks). However, that is not to say it is not a 
potential result of the manipulation as previous studies in the lab with ibotenic 
acid mPFC-lesioned rats have also sometimes seen a small but significant increase 
at REV 1 (David Tait personal communication).  
Furthermore, in a modification of the ASST, a partial change ED (EDPC) stage 
is performed in fewer TTC than when the rats were CNO-treated. Critically, this 
modification provided information on learning of irrelevant dimension stimuli in 
mPFCin rats and controls. During the simple-probe, through attentional regulation 
mechanisms (blocking/attentional set), vehicle-treated rats did not learn about 
the reward contingency of the redundant stimuli within the irrelevant dimension. 
This was evidenced by a robust shift-cost at the subsequent EDPC relative to the ID. 
However, when the rats were administered CNO, the addition of the simple-probe 
enhanced performance at the EDPC as they showed no shift-cost (ID/ EDPC shift-
cost = 0, ± 2) – evidence that CNO-treated rats had learned the predictive nature 
of the redundant stimulus. That is to say, the redundancy of the irrelevant 
dimension stimulus during the probe facilitated performance at the EDPC following 
CNO-treatment.  
3.5.1 Irrelevant dimension responding during set-shifting inducing enhanced 
learned irrelevance. 
 The analysis of the behavioural patterns of mPFCin-rats during the standard 
ASST suggested increased irrelevant dimension responding during reversal stages. 




Essentially, early in the reversal stage, once responding to the previously correct 
stimulus began to be inhibited (reinforced by the exploratory trials), whereas 
control rats utilised a spatial pattern until they determined the correct stimulus 
and began responding optimally, mPFCin-rats were more likely to respond based 
on stimuli within the irrelevant dimension. The detection of this anomalous 
behaviour via the behavioural pattern analysis highlights the utility of the 
approach for assessing actions which are undetectable by standard TTC and errors 
analysis. The analysis further suggested that while control rats were behaving 
optimally and responding to the correct stimulus by the completion of each stage, 
there was not strong evidence of mPFCin-rats responding based on the correct 
stimulus during REV 1 and REV 3.  
Based on the behavioural pattern analysis, an explanation for the 
behaviour of mPFCin-rats during the standard ASST is as follows: although 
acquisition stages do not appear different from controls, if indeed mPFCin induces 
a deficit in sensory gating (failure to block), than CNO-treated rats ‘learn’ that the 
reward contingency rate of the irrelevant dimension stimuli is 50%, however, their 
behaviour is guided by the 100% reward-contingent correct stimulus. It follows, 
that during REV 1 mPFCin-rats attempt to obtain the reward based on one of the 
irrelevant dimension stimuli, which they learned are partially contingent on 
reward. This choice behaviour would then reward them 50% of the time when 
they chose the irrelevant stimulus that was paired with the now correct stimulus. 
Thus the behaviour of mPFCin-rats is guided by the irrelevant dimension stimuli 
until they learn that the previously incorrect stimulus in now contingent with 
reward. This is in contrast to their behaviour when vehicle-treated, where they 
instead show spatial based responding (also 50% chance of reward), until they 
learn the new reward contingency. By the end of REV 1 under both conditions 
(vehicle or CNO-treated) the rats are able to reach criterion (6-in-a-row; although 
the Bayes factor for the CNO-treated rats suggests they are undertrained). 
However, compared to control rats, CNO-treated rats may have received 
‘enhanced learned irrelevance’ (Baker and Mackintosh, 1977), due to their 




attempt to obtain reward based on irrelevant dimension stimuli. During REV 2, the 
irrelevant dimension responding is again present but less so as mPFCin-rats learn 
that the stimuli in the irrelevant dimension are not 100% predictive of reward 
(likely coincident with set-formation), and complete the stage with strong 
evidence they are responding to the correct stimulus.  
Under these conditions mPFCin-rats would have enhanced learned 
irrelevance of the irrelevant dimension compared to control rats, as for two stages 
(REV 1 and REV 2) they attempted to obtain reward based on the irrelevant 
dimension stimuli. Analysis of the ED suggests that this is in fact the case, as the 
mPFCin-rats attempt to obtain reward based on stimuli from the previously 
relevant dimension. Eventually, mPFCin-rats complete the shift, indicated by the 
strong evidence for the correct stimulus at the end of the ED. Finally, at REV 3 they 
are challenged again and perhaps due to a combination of enhanced learned 
irrelevance and reversal cost, they perseverate on the previously correct stimulus 
before responding to the previously relevant dimension (from the initial 5 stages: 
SD - REV 2) again and although reaching criterion (6-in-a-row-correct), fail to show 
strong Bayesian evidence for responding to the correct stimulus.  
This explanation based on the behavioural pattern analysis is consistent 
with a deficit in sensory gating arising for mPFC-hypofunction as previously 
reported (Koch and Bubser, 1994; Sharpe and Killcross, 2014). In the next section 
I explore the neural mechanisms associated with mPFC-hypofunction which 
generate this abnormal performance the ASST. 
3.5.2 Model of neural mechanisms of the mPFC-inhibition on ASST performance.  
There is evidence for the involvement of dopamine, in the form of reward 
prediction errors, signalling which stimuli within the environment are most 
predictive of reward during operant conditioning (Schultz, 1997). In rats, a 
majority of dopaminergic neurons within the ventral tegmental area (VTA), exhibit 
phasic responses indicative of prediction errors signals and these VTA neurons 
project heavily to the mPFC through the mesocortical pathway (Thierry et al., 1973; 




Hoover and Vertes, 2007). Stimulation of VTA neurons (at a burst firing rate similar 
to prediction error phasic responses) induces a prolonged ‘up state’ during which 
the membrane potential of mPFC neurons are closer to action potential threshold 
(Lewis and O'Donnell, 2000). An early finding in macaques revealed that depletion 
of dlPFC dopamine impaired working memory performance (Brozoski et al., 1979). 
Additional accumulated evidence has supported theorising that the role of 
dopaminergic synapses within dlPFC/mPFC is to stabilise working memory 
representation of reward-relevant stimuli through VTA burst firing (for review see: 
Seamans and Yang, 2004).  
However, dopamine is only one of two neuromodulatory signals known to 
affect ED performance. In rats, lesions of the dorsal noradrenergic bundle, or de-
afferentation of mPFC noradrenergic fibres also induces a deficit at the ED (Tait et 
al., 2007; McGaughy et al., 2008). Indeed the locus coeruleus also exhibits phasic 
responses to reward cues however, this is considered to be derived from PFC 
inputs (Hoover and Vertes, 2007). Thus, the manipulation herein where the mPFC 
was inhibited, might induce the ED deficit through loss of signalling from either 
dopamine or noradrenaline. Importantly, these neuromodulatory systems are 
known to interact during normal mPFC functioning. For example noradrenaline 
levels are known to regulate dopamine levels within the mPFC, such that 
antagonism of noradrenergic α2 receptors increases extracellular noradrenaline 
and dopamine, with the converse being true for agonism of noradrenergic α2 
receptors (Gresch et al., 1995). For sake of simplicity, the focus here remains on 
dopamine as dopamine neuron responses occur earlier in response to reward than 
noradrenergic neuron responses which are more associated with effort to perform 
the action once the decision has been made (Varazzani et al., 2015). 
Dopamine signalling within the mPFC of rats is critically involved in 
sensorimotor gating such as prepulse inhibition (Koch and Bubser, 1994; Arime et 
al., 2012). Similarly, dlPFC dopamine signalling has also been found to mediate 
prepulse inhibition in humans (Giakoumaki et al., 2008). Predictably, lesions of 
either the mPFC or dlPFC also produces impairments in prepulse inhibition (Knight 




et al., 1989; Lacroix et al., 2000). The origin of such deficits are likely multi-fold due 
to several interconnected functions of the mPFC/dlPFC. 
The first relates to the working memory function of mPFC/dlPFC. In task 
with delays (of seconds to minutes), the recurrent (intra-cell layer III) activity of 
glutamatergic cells within dlPFC/mPFC functions to maintain the task relevant 
information (for review see: Arnsten et al., 2012). In support of this function, 
dopamine projections from the VTA signalling reward-relevant information 
supports the activity of the neurons maintaining the reward-relevant information 
in working memory (Brozoski et al., 1979; Arnsten et al., 2012). Current models 
suggest that the activity of dopamine projections to dlPFC/mPFC increase the 
signal to noise for the relevant dlPFC/mPFC network processing (Miller and Cohen, 
2001; van Schouwenburg et al., 2010). By biasing dlPFC/mPFC network activity, a 
second function, the tonic inhibition of dlPFC/mPFC on sensory processing, is also 
biased to gate irrelevant information, and enhance processing of relevant 
information. Indeed, the deficits in sensory gating are likely due to loss of 
dlPFC/mPFC tonic inhibition of sensory processing through excitatory synapses on 
inhibitory neurons within sensory cortices, as well as projections to inhibitory 
thalamic reticular nucleus (Barbas and Zikopoulos, 2007; but for review see: 
Zikopoulos and Barbas, 2007). Critically, the network is filled with feedback loops. 
For example, the mPFC projects directly to the VTA and can modulate the activity 
of dopamine neurons (Lodge, 2011), as well as additional feedback from the 
dlPFC/mPFC biasing of cortical and thalamic sensory processing which may 
modulate the VTA through a network of glutamatergic afferents to the VTA still 
under investigation (Geisler et al., 2007; but for review see: Zellner and Ranaldi, 
2010). Lastly, the dlPFC/mPFC is also involved in reciprocal connectivity with the 
dorsal and ventral striatum, which may act as an intermediary between the 
dlPFC/mPFC and the VTA. Activity in the ventral striatum (nucleus accumbens), has 
been shown to also increase working memory activity within the dlPFC (Fallon and 
Cools, 2014; perhaps through thalamic feedback projections), while mPFC 
glutamatergic afferents to ventral striatum inhibit dopamine-induced increases in 




activity (Ferenczi et al., 2016): dopamine signals which the dorsal striatum also 
uses to perform goal-directed behaviour such as in the ‘strategy-switching’ task 
(Goto and Grace, 2005). Also, mPFC projections to the dorsal striatum provide 
goal-directed information, such that lesions of the dorsomedial striatum, can 
induce similar impairments in attention as mPFC lesions (Rogers et al., 2001). This 
neural network model of attention is diagrammed in Figure 3.8. 
Within the framework of this model, I theorise that the mPFC, dopamine-
dependent, biasing of sensory processing is disrupted such that CNO-treated rats 
learned equally about reward contingency of the stimuli within the relevant and 
irrelevant dimensions. However, control rats effectively lessened attention to the 
irrelevant dimension stimuli, therefore not learning about their reward-
contingencies, such as occurs during blocking. In CNO-treated rats this ‘aberrant 
salience’-induced learning resulted in an increase in TTC at the ED, where novel 
stimuli are presented, and thus the higher order dimension-based discrimination 
guideds behaviour. Conceptually, this is enhanced learned irrelevance resulting in 
perseverative-like responding to the previously relevant dimension. However, this 
attentional regulation deficit is beneficial when, learning about a redundant 
stimulus within the irrelevant dimension can be transferred to a subsequent 
partial change ED. Indeed a similar phenomenon has recently been reported in 
Parkinson’s patients who exhibited both perseveration to the previously irrelevant 
dimension, as well enhanced learned irrelevance (Fallon et al., 2016). Thus the 
origin of the set-shifting deficit here is likely a disruption of neuromodulatory 
signals within mPFC (i.e. reward prediction error signals), resulting in abnormal 
attentional biasing (sensory gating), and stimulus-reward contingency learning 
within the ASST.  




As a caveat for generalisation to other manipulations inducing mPFC-
disruption, it should be stated that the exact mechanisms underlying the ED deficit 
following acute inactivation may differ from the other causes of mPFC-






Figure 3.8) Top. When the mPFC is functioning normally, its sustained 
representation of the task relevant information in working memory, results in 
biasing of sensory processing, i.e. attention, and prediction error signalling. 
Bottom. When the mPFC is not functioning properly, the downstream biasing 
of sensory processing and prediction errors. In this scenario non-selective 
predictive errors drive behaviour through dopamine signalling within the 
striatum.  




hyperactive subcortical dopamine system (Jo et al., 2013), whereas mPFC-ibotenic 
acid lesions induce hypoactive dopamine signalling (Shim et al., 1996).  
Does this model and its focus on dopamine hold up empirically, within the 
context of set-shifting? While there is a clear role for dopamine in the dlPFC/mPFC 
for set-shifting, results are mixed, with some researchers reporting no ID/ED shift-
cost (and thus no evidence of set-formation), and others reporting an ED deficit 
(Table 3.1). Dopamine depletion (6-OHDA lesions) within the dlPFC of marmosets 
(Roberts et al., 1994) resulted in fewer errors to criterion at the ED stage compared 
to controls such that there was no difference between the ED and the previous ID 
stage (i.e. no shift-cost). In the same study, the 6-OHDA-lesioned animals also had 
poorer working memory performance, consistent with a previous report (Brozoski 
et al., 1979). However, results in rodents have found an ED deficit following 
manipulations which reduce mPFC dopamine signalling. In transgenic mice, 
reducing mPFC dopamine signalling via enhanced catechol-o-methyltransferase 
(COMT; a catecholamine degrading enzyme) activity selectively impaired the ED 
shift and working memory (Papaleo et al., 2008). Furthermore, amphetamine 
sensitisation in rats (which induces mPFC-hypofunction; Homayoun and 
Moghaddam, 2006) also impaired set-shifting by increasing TTC at the ED, a deficit 
which was ameliorated by D1R agonism (Fletcher et al., 2005). In contrast, 
increasing mPFC dopamine signalling via inhibition of COMT resulted in no ID/ED 
shift-cost (Tunbridge et al., 2004), a similar finding as the 6-OHDA-lesioned 
marmosets (Roberts et al.). As a positive shift-cost is the only index of set-
formation (Eimas, 1966; Durlach and Mackintosh, 1986), it is not possible to 
ascertain whether the data from 6-OHDA-lesioned marmosets (Roberts et al.) and 
COMT-inhibited rats (Tunbridge et al.), indicates enhanced set-shifting or an 
inability to form an attentional set. 
Given that the marmoset task is substantially different from the rodent 
task in regards to training, feedback (no exploratory trials), and mechanisms of 
stimulus selection (energy intensive digging vs touchscreen), if the focus is placed 
on results from the rodent tasks, then the conclusion for the role of dopamine in 




set-shifting is that mPFC hypo-dopaminergic impairs set-shifting. This 
conceptualisation for reduced mPFC dopamine easily fits with the model (Figure 
3.8). The increased dopamine signalling is more complicated to explain. Further 
examination of the data from Tunbridge et al. (2004) reveals that a substantial 
increase in TTC for all ASST stages was clear for all animals (most stages required 
more than double the TTC normally reported) perhaps due to the presence of the 
guide cannulas (lesions).  
Thus, while the role of dopamine in set-shifting is clear from two (Fletcher 
et al., 2005; Papaleo et al., 2008) of the four studies, the results of the remaining 
two studies are harder to interpret as either species/task (Roberts et al., 1994) or 
manipulation differences (Tunbridge et al., 2004) make a direct comparison 
between these studies less valid. An additional concern is that while both studies 
that report no shift-cost were specifically targeted to the dlPFC/mPFC (Roberts et 
al.; Tunbridge et al.), the two reporting an ED deficit were more global 
manipulations (i.e. transgene expression (Papaleo et al.) or i.p. amphetamine 
treatment (Fletcher et al.)). 
3.5.3 Implications for theories of attention and associative learning 
These findings (as well as those of: Sharpe and Killcross, 2014; Fallon et al., 
2016)  support Mackintosh’s theory of attention (Mackintosh, 1975), which posits 
that the ability to selectively attend and choose based on one stimulus dimension 
does not prohibit the additional learning of stimuli which may be irrelevant but 
still present. In this context, controls rats appear to behave optimally, and not only 
selectively attend to the relevant dimension stimuli, but also greatly reduce their 
attention to the irrelevant dimension to the extent that providing redundant 
Table 3.1. Studies with dopamine manipulation during the ASST. 




information during the simple-probe does not benefit them in the EDPC. However, 
in mPFCin rats, an inability to reduce attention to the irrelevant dimension, does 
not noticeably guide behaviour, until the irrelevant dimension contains 
information that is reward predictive. Thus while, the higher-order attentional set-
shifting is impaired in mPFCin rats, the lower-order inability to block redundant 
stimuli, is sufficient to alter behaviour at a stage (the EDPC) where mPFCin rats 
would otherwise show a deficit to controls.  
Further support for Mackintosh’s theory, arises from the comparison of 
our simple-probe to EDPC manipulation, to that of McGaughy et al. (2008). Pearce 
et al. (2012) found that a redundant stimulus in a blocking paradigm (A+→ AX+ → 
X+), compared to a redundant stimulus in a simple discrimination (AY+, BY-), 
elicited greater responding when presented alone. The simple-probe to EDPC 
manipulations presented here reflects the blocking phenomenon as the irrelevant 
dimension stimulus is reward-contingent (e.g. the X in the A+→ AX+ → X+ 
paradigm). In McGaughy et al. (2008) the irrelevant dimension stimulus (e.g. 
texture as “Y” in the AY+, BY- paradigm) is no more predictive of reward than the 
relevant stimuli dimension, thus even if the rats were attending to that dimension, 
it would be a poor behavioural pattern for obtaining reward, compared to 
choosing based on stimuli which were previously rewarded. 
A caveat of Mackintosh’s theory is that prediction error signals must 
represent multiple stimuli. That is to stay, individual error terms govern the 
associative strengths of stimuli. In this scenario, the intermittent rewarding of the 
irrelevant dimension stimuli would result in lower associative strength compared 
to the correct stimulus. Critically, this also predicts that the redundant stimulus 
paired with the correct stimulus during the simple-probe would also develop 
greater associative strength than either of the novel (non-reward contingent) 
previously relevant dimension stimuli presented during the EDPC. While seemingly 
contradictory, there is considerable evidence for both global and individual error 
terms. As a result, a number of hybrid models have been developed to account for 
the accumulating evidence (Haselgrove et al., 2010; Barrot et al., 2012). 




In conclusion, these behavioural data have shown that DREADDs-mediated 
mPFCin induces a set-shifting deficit consistent with previous methodologies. 
Furthermore, the data show that this deficit is likely linked to a deficit in the 
sensory gating (and working memory functions) of mPFC, consistent with findings 
in sensory gating paradigms (i.e. PPI or blocking) following mPFC- or dlPFC-
disruption. Perhaps somewhat controversially, the fact that mPFCin-rats were able 
to ‘shift’ faster during the EDPC, counters the concept that the mPFC is the 
universal shifter. Indeed, the data here support a deconstruction of the mPFC as a 
‘homunculus’ with mysterious executive functioning capacities, and instead 
supports its functions of ‘working memory’ as an emergent property of sensory 
(primarily multisensory) processing, where the inputs into the mPFC (i.e. the 
dopamine reward prediction signals), decide the output of the mPFC (biasing 
sensory processing based on the information stabilised by reward signals). Thus, 
working memory (dopamine-stabilised representations) and executive function 
(which can be reduced to sensory biasing) are essentially, the same set of 
processes. Indeed, this theory has been proposed by Hazy et al. (2006). In their 
biologically constrained mathematical model, ‘executive functions’ can be 
accomplished by simple reinforcement learning, thus demystifying the 
mechanisms underlying mPFC processes in abstract representation processing, 
such as attentional set. Applying this theory to the data presented here, although 
the shift-cost suggests that mPFCin-rats formed an attentional set, the irrelevant 
dimension responding suggests that this set was ‘weak’. It is possible that while 
mPFC-function helps in the formation of attentional set (through working memory 
and biasing of attention), it is actually the OFC which maintains the ‘representation’ 
of the attentional-set. This is congruent with the findings that lesions of the OFC 
impairs set-formation, as OFC-lesioned animals require more TTC for IDs than 
controls (Dias et al., 1996a; McAlonan and Brown, 2003; Chase et al., 2012). 
  




3.6 Histological Analysis of mPFC DREADDs  
Rationale 
 The behavioural experiments in Chapter 3 suggested effective and robust 
inhibition of the mPFC in the tested rats. We validate those results by providing 
evidence for DREADDs expression within the target region as well as a measure of 
neuronal activity (c-Fos) following administration of CNO. Additionally, the 
trafficking of DREADDs receptors through the axons of infected neurons allowed 
for investigation of where, outside of the mPFC, CNO activation of DREADDs may 
induce changes in behaviour.  
3.7 Methods and materials 
 Tissue was collected as described in the General Methods section (Chapter 
2). For mCherry and c-Fos immunoreactivity detection every 4th section of the 
frontal cortex was collected. Sections were placed in 9-hole netwells and petri 
dishes and washed four times for 5 min each in phosphate buffered saline (PBS: 
158 M NaCl in 50% distilled H2O and 50% 0.2 M phosphate buffer) on an 
automated rotator. Next the netwells were placed in blocking solution (1:5 normal 
goat serum, 1:100 10% Triton, in PBS) and rotated for an hour at room 
temperature. Sections were then washed in PBS 3 times for 5 min each. Sections 
were placed in histology pots before being incubated with 5 ml of anti-mCherry 
(rabbit anti-mCherry 1:2000, Abcam) or anti- c-Fos (rabbit c-fos 1:10000), 
suspended in antibody diluting solution (ADS; 1:100 normal goat serum, 1:100 10% 
triton, in PBS) overnight at room temperature. The following day sections were 
washed in PBS 3 times for 5 min each. Sections were then switched into histology 
pots and incubated in 5 ml biotinylated anti-rabbit antibodies (goat anti-rabbit, 
1:500, Vectorlabs, in ADS) for one hour at room temperature. After incubation, 
sections were washed 3 times for 5 min in PBS, then placed in histology pots 
containing 5 ml of the biotinylation solution (Vectastain ABC KIT, Vectorlabs) and 




incubated for one hour. Sections were than washed 3 times for 5 min in PBS and 
parvalbumin was immunoreactivity was detected by staining with 3,3’-
Diaminobenzidine (DAB; one tablet per 20 ml, Sigma, in distilled H20). The sections 
were determined to be stained when landmark anatomical structures were clearly 
identifiable or until they had been incubated for 20 min. Following DAB staining 
sections were washed 3 times for 5 min in PBS, and stored in 9-hole netwells at 
4oC until (up to 72 hours) they were mounted to treated glass slides and 
coverslipped with DPX. 
 Fluorescent mCherry detection was performed on a subset of the brains to 
examine nuclear vs axonal mCherry expression. The procedure was the same as 
for DAB immunoreactivity up until the sections were removed from the primary 
(rabbit anti-mCherry 1:2000, Abcam) incubation. Sections were removed from the 
primary and washed 5 times for 5 min each, then incubated for one hour in foil-
covered histology pots containing the secondary (goat anti-rabbit IgG H&L, Alexa 
Flour 594, Abcam). After secondary incubation, sections were washed 3 times for 
5 min in PBS, then mounted to slides. Vectashield anti-fade mounting medium 
with 4',6-diamidino-2-phenylindole (DAPI; Vectorlabs), was applied then slides 
were cover-slipped and sealed. 
3.8 Results 
3.8.1 All rats exhibited clear DREADDs expression within the mPFC 
 Figure 3.9 shows a representation image of DAB-stained mPFC neurons 
infected with AAV5-CamKII-hM4Di-mCherry. All rats (n = 12) showed mCherry 
tagged DREADDs expression within the mPFC target region (approximate distance 
from Bregma 4.2 - 2.2 mm). Additional DREADDs expression was evident in parts 
of the medial OFC ventral to the target area. However, in all cases the most 
prominent staining was within the pre- and infralimbic cortex, and the anterior 
cingulate cortex (ACC). It is possible that this spread into the medial OFC or the 
ACC could underlie the transient reversal impairment. 




3.8.2 DREADDs are trafficked throughout the projections of the infected mPFC 
neurons. 
 Fluorescent images were collected to determine axonal compared to 
cellular DREADDs expression as well as the extent of DREADDs expression through 
mPFC projections (Figure 3.10). Fluorescent detection of mCherry indicated 
reduced infection compared to the DAB-staining with less lateral extent. However, 
only a sample (n = 3) of the brains were analysed with this method. As can be seen 
in Figure 3.10, the DREADD receptors were trafficked within axons from mPFC cell 
bodies through the striatum. Implications for the expression of the receptor 
outwith mPFC cell bodies is considered further in the discussion section. 
  







Figure 3.10) Representative images of mPFC-glutamatergic neurons infected 
by microinjection of AAV5-CamKII-hM4Di-mCherry as detected by anti-
mCherry immunohistochemistry. Inset shows non-cellular (DAPI-stained; blue) 
mcherry expression. PrL = prelimbic, IL = infralimbic, Cg1 = cingulate, MO = 
medial orbital, LO = lateral orbital, M1 = primary motor cortex. 




3.8.3 No difference in c-Fos immunoreactivity following clozapine-N-oxide 
administration. 
 We sought to validate our CNO administration protocol with measurement 
of the neuronal activity marker c-Fos. Figure 3.11 is a representative grayscale 
image of sections stained for c-Fos immunoreactivity. No significant difference 
was found in the expression of c-Fos positive cells (mm2) between rats treated 
with 10 mg/kg CNO orally or vehicle (t(10) = 0.38, p = 0.71). This finding is explored 
further in the discussion section. 
  









Figure 3.11.  Gray-scale images showing representative c-Fos 
immunoreactivity throughout the PFC (estimated distance from Bregma: 2.2 - 
4.2 mm). PrL = prelimbic, IL = infralimbic, Cg1 = cingulate, MO = medial orbital, 
LO = lateral orbital, M1 = primary motor cortex. 






Figure 3.11. cont. Top. Image showing method for automated cell counting 
and size of region analysis. Bottom. Bar graph showing mean c-Fos expression 
per square mm (+ SEM) throughout the mPFC (estimated distance from 
Bregma: 2.2 - 4.2 mm). No significant differences were found between rats 
treated orally with 10 mg/kg or vehicle.  





3.9.1 Analysis of DREADDs expression. 
 The level of DREADDs expression I report supports our observed behaviour 
effects and is in line with our previous findings with ibotenic acid lesions (Birrell 
and Brown, 2000; Tait et al., 2009). Whilst the target area is the prelimbic cortex 
(PL), unfortunately the ability to limit the infection solely to that area eluded me. 
However, despite the clear infection of collateral areas, no evidence of 
confounding occurred as the only deficit to manifest was the ED shift deficit. Given 
the proximity of the medial OFC and ACC to the target areas and the clear 
infection, it is not possible to rule out inhibition of these areas in the observed 
effects.  
3.9.2 Infected projections are consistent with the pattern of mPFC neuronal 
projections 
 The immunohistochemistry results suggest that infection of mPFC neurons 
results in DREADDs expression at terminal synapses within the medial striatum, 
nucleus accumbens, and other areas  consistent with anterograde tracer 
(Phaseolus vulgaris leucoagglutinin) injections into the PL and infralimbic cortices 
(IL; Vertes, 2004). This expression within the medial striatum suggests that all rats 
had infection of the target area (PL). Again however, the spread into the ACC and 
medial OFC, and their corresponding target projections cannot be ruled out (and 
may underlie the increase in trials at REV 1). Additional experiments can further 
separate infection in the targeted PL compared to the IL by examining downstream 
areas where the innervation varies by region such as the nucleus accumbens or 
the sub-nuclei of the amygdala (Vertes, 2004). Given that the behaviour was 
consistent with ibotenic acid lesions into the same PL- targeted coordinates (Birrell 
and Brown, 2000; Tait et al., 2009), it is most likely that the effect was primarily 
mediated by the same population of neurons (within PL) as opposed to offsite 
effects. Previous lesion studies using the same coordinates have shown that the 
size of the lesion (either localised to the PL or spread into medial OFC or ACC), 




does not obscure or confound the PL-mediated ED deficit (Birrell and Brown; Tait 
et al.). 
3.9.3 Inhibitory DREADDs can be effective without reduction in activity at the cell 
body 
 Despite no physiological or anatomical evidence of the CNO-induced 
DREADDs inhibition of mPFC neurons, the behavioural data suggest the binding of 
CNO to DREADDs receptors was potent and effective at disrupting the target 
neuron population. CNO is orally bioavailable and has been shown to have 
physiological effects when administered orally such as through the drinking water 
(Jain et al., 2013; Cassataro et al., 2014). However, the oral bioavailability is 
reduced (Bryan Roth, personal communication, 2016). Furthermore, the extent to 
which the DREADDs receptors expression continued for the duration of 
experiments (approximately 4 months) could cause substantial increases in the 
receptor-ligand ratio. While most studies are done within one month of DREADDs 
infection, significant DREADDs expression throughout axons and into synapses can 
occur throughout at eight weeks or more (Stachniak et al., 2014; Kerstetter et al., 
2016). In this instance, the effective dose to induce neuronal inactivation in the 
presence of more receptors spread along the axon may be greater.  
As c-Fos is merely a measure of activity at the cell body, it does not inform, 
the number of action potentials generated following CNO administration, or on 
the propagation of generated action potentials along the axon, nor the 
subsequent induction of neurotransmitter release from the post-synaptic 
terminal. Given that these experiments employed a non-localised delivery of CNO 
it is highly likely that DREADDs receptors in the terminals were also activated by 
the ligand. Indeed, it has been shown that behavioural effects can be instigated in 
DREADDs infected animals following CNO administration directly onto the post-
synaptic terminals of a target region. Stachniak et al. (2014), reported robust 
effects on feeding behaviour following selective silencing of hypothalamic 
projections into midbrain. This effect on behaviour came with no reduction in the 




action potential generation of the cell body of the afferent neurons, evidence that 
inhibition occurs at multiple sites following CNO administration.  
One last point is the fact that I did not attempt to raise the activity of mPFC 
neurons prior to CNO administration. Low baseline c-Fos activation can mask CNO-
mediated inhibition (Sasaki et al., 2011; Koch et al., 2015; Koike et al., 2016). Koike, 
et al., reported no difference in c-Fos in ACC DREADDs infected neurons following 
10 mg /kg (i.p.) CNO despite a clear behavioural effect in a task dependent on ACC 
function. However, when c-Fos expression was pharmacologically increased via 
treatment of a GABAA receptor antagonist, a significant reduction in c-Fos positive 
cells was found in mice treated with CNO. 
 
  
Chapter 4. Effects of Neonatal-Phencyclidine (PCP) Treatment on Attentional Regulation in 
Set-Shifting and Novel Object Recognition 
83 
 
Chapter 4. Effects of Neonatal-Phencyclidine 
(PCP) Treatment on Attentional Regulation in 
Set-Shifting and Novel Object Recognition 
 
The experiments in this chapter utilised developmental disruptions targeting 
(primarily medial prefrontal cortex; mPFC) glutamatergic synapse maturation in 
neonatal rats. Findings from testing in adulthood revealed that whereas neonatal-
PCP-treatment only caused subtle non-significant deficits in the standard ASST, 
which appeared to worsen with age, significant deficits in extradimensional set-
shifting were revealed through repeat testing in a modified ASST with maximal 
separation of stimuli. Behavioural pattern analyses revealed elevated spatial and 
irrelevant dimension-based responding in neonatal-PCP-treated rats across all 
tests. Additional age-dependent effects were found for novel object recognition 
(NOR) such that, young neonatal-PCP-treated rats had deficits in the 3-min delay 
NOR, but they did not have those deficits in adulthood. However, additional 
testing in a 24-hour delay NOR found a deficit in neonatal-PCP-treated rats 
consistent with dysfunction of the mPFC.  
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4.1 Introduction to neonatal-NMDAR antagonism rats 
Due to a short gestational period in rats, the first two weeks of postnatal 
development, also known as the neonatal stage of development, roughly 
corresponds to the second trimester of pregnancy in human foetuses (Bayer et al., 
1993; Clancy et al., 2001). In both species, this is a critical timepoint for 
development of glutamatergic synapses. Experiments in rodents have shown that 
particularly during postnatal days (PND) 1 - 14, NMDARs are hypersensitive to 
glutamate signalling to strengthen key synaptic connections (Ikonomidou et al., 
1989). Blockade of NMDARs during this two-week period induces apoptosis in key 
areas for cognition, such as the hippocampal formation (CA1 and dentate gyrus), 
the caudate nucleus, and the cingulate and frontal cortices (Ikonomidou et al., 
1999). Although the apoptosis induced by NMDAR blockade is greatest during PND 
0 - 7, the phenotype of animals treated with an NMDAR antagonist during that 
time point is overly severe and not consistent behaviourally with schizophrenia 
patients. Instead, selective NMDAR blockade during PND 7 - 14, despite inducing 
less apoptosis, generates a phenotype more consistent with the neural and 
behavioural perturbations reported in patients with schizophrenia.  
While the immediate effect of NMDAR blockade during the first two weeks 
of development is apoptosis in multiple brain regions (Ikonomidou et al., 1999; 
Wang et al., 2001; Wang et al., 2003), the surviving glutamatergic neurons 
undergo additional disruptions, with long-lasting effects. Throughout the lifespan, 
calcium (Ca2+) signalling through NMDAR activation alters the NMDAR subunit 
composition of the activated cells (Scheetz and Constantine-Paton, 1994).  
Blockade of Ca2+ signalling by NMDAR antagonist phencyclidine (PCP) during PND 
5 - 10, induces select reductions in cortical NR2B subunit mRNA expression (Sircar 
et al., 1996; Anastasio and Johnson, 2008a) as well as overall reductions in NMDAR 
expression (Sircar et al., 1996). The actions of NMDAR antagonism on NR2B levels 
are the proposed mechanism for many of the subsequent cognitive and 
behavioural phenotypes of neonatal-PCP-treated rats. Reductions in NR2B subunit 
expression reduces excitatory long-term potentiation (LTP), the mechanism by 
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which cells strengthen their connections, allowing for efficient communication 
and information processing (Luscher and Malenka, 2012). Either genetically or 
pharmacologically induced acute reduction of NR2B expression in frontal cortex 
can not only reduce LTP within the region, but also impair contextual fear memory, 
a behaviour known to be regulated by frontal cortex activity (Zhao et al., 2005). All 
together the data indicate direct dysregulation of NMDAR signalling, throughout 
the time period that roughly corresponds to adolescence in rats following NMDAR 
antagonism two-weeks postnatal. 
In the next section the long-term effects of neonatal-PCP administration 
on brain function and behaviour in adolescent and adult rats are reviewed in 
relation to symptoms present in human schizophrenia patients. 
4.1.1 Neurochemistry 
 As described in the general introduction (Chapter 1), the neurochemical 
basis of schizophrenia remains a key target for studies and many rodent 
manipulations with relevance for schizophrenia are validated based on the 
presence of neurochemistry that mirrors the alterations seen in patients with 
schizophrenia.  
To begin with, the neonatal-NMDAR antagonism manipulation 
recapitulates several of the dopamine-related findings. Neonatal-NMDAR 
antagonism induces decreases in the density of tyrosine hydroxylase (an enzyme 
involved in the biosynthesis of dopamine) within the axons of mPFC-neurons 
(Wedzony et al., 2005a). Perturbation of dopaminergic signalling can be further 
demonstrated following treatment with compounds which increase dopamine at 
the synapse such as amphetamines and methamphetamines. Semba et al. (2001) 
found that neonatal-PCP treatment reduced methamphetamine-induced c-Fos 
expression in the nucleus accumbens and VTA compared to control rats, 
suggesting abnormal dopaminergic signalling in neonatal-PCP rats.  
Schizophrenia-related abnormalities are also found in the glutamatergic 
system. Although direct evidence of reduced NR2B expression past PND 21 in rats 
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or mice has not yet been reported, there is neurochemical evidence of 
dysregulated glutamate signalling through NMDARs. From PND 21 to PND 56, 
neonatal-PCP-treated rats, exhibit increased seizure activity in response to NMDA 
administration (Brooks et al., 1997b,) suggesting that the neonatal treatment 
induces hypersensitivity in the glutamatergic system. This increased sensitivity to 
NMDA may be due to continued overexpression of NR1 and NR2A (Anastasio and 
Johnson, 2008a, b) and reduced expression of NR2B (Sircar et al., 1996; Anastasio 
and Johnson, 2008a). There is evidence that increased expression of the NR1 
subunit persists up to PND 180 (Baier et al., 2009). Indeed, increased overall 
binding of NMDAR within the mPFC (suggestive of upregulation of receptor 
expression, likely due to reduced glutamate at the synapses) has been found in 
adult neonatal-NMDAR blockade rats compared to controls (Sircar, 2003; 
Anastasio and Johnson, 2008b; du Bois et al., 2009).  This overactive glutamatergic 
signalling in neonatal-PCP-treated rats is also evidenced following acute 
administration of PCP. Measurement of relative cerebral blood volume shows 
persistent (25 - 30 mins post injection) increase in the frontal cortex (amongst 
other regions) following intravenous administration of 0.5 mg/kg PCP in neonatal-
PCP-treated rats. Rats treated with vehicle also exhibited increased blood flow in 
response to acute PCP, albeit for a shorter duration (Broberg et al., 2013).  
GABAergic neurotransmission is also altered in neonatal-PCP-treated rats. 
Wang et al. (2008) reported that a single dose of PCP during PND 7 caused 
reductions in markers of GABAergic interneurons (parvalbumin, calretinin, and 
calbindin) in cortical tissue. Repeated neonatal-PCP treatment is reported to 
selectively reduce PV mRNA expression within the mPFC (Redrobe et al., 2012; 
Kaalund et al., 2013). Consistent with the reduction in GABAergic neuronal 
markers, neonatal-PCP administration diminishes inhibitory signalling within the 
mPFC, specifically in layer 2/3 (Kjaerby et al., 2014). In direct relation to known 
dysfunction of the GABA transporter in humans, neonatal-PCP administration also 
compromises sensitivity of the transporter. Also, in direct reference to the human 
condition, disruptions in neureglin-1 and its primary receptor ERB4 have recently 
Chapter 4. Effects of Neonatal-Phencyclidine (PCP) Treatment on Attentional Regulation in 
Set-Shifting and Novel Object Recognition 
87 
 
been evidenced in neonatal-PCP-treated rats (du Bois et al., 2012; Radonjic et al., 
2013).  
4.1.2 Brain structural abnormalities 
Neonatal-NMDAR blockade in rats also results in brain structural 
abnormalities reminiscent of schizophrenia. At the neuronal level, expression of 
myelin basic protein, a marker of myelination, is reduced for more than two weeks 
following exposure to PCP (Zhang et al., 2012). Additional reduction in a marker of 
oligodendrocytes (the cell type primarily responsible for myelination) is also 
evident. Both of these changes were reported to be specific to the frontal cortex. 
These changes in myelination are likely associated with the select reduction in the 
length of layer 2/3 mPFC pyramidal neuron basilar dendrites, evidenced through 
PND 60 (Wedzony et al., 2005b). Post-mortem analysis of (occipital) cortical tissue 
from neonatal-PCP-treated rats at PND 20 shows reduced number of synapses and 
increased synaptic length, while at PND 30 - 40, the neonatal-PCP-treated rats 
exhibit an increased number of synapses, and synaptic length no longer differs 
from controls (Brooks et al., 1997). However, by PND 60 no differences are present 
between groups. Given the vast loss of inhibitory interneurons and microglia, in 
combination with the effects on mPFC dendrites, it is unsurprising that many 
reports on neonatal-NMDAR blockade find lower adult brain weight in treated 
animals compared to controls (Mouri et al., 2007; Boctor and Ferguson, 2010; Lim 
et al., 2012). 
4.1.3 Schizophrenia-related innate behaviour in neonatal-NMDAR blockaded rats  
Observation of locomotor activity is a low-level measurement of 
behaviour, however distance travelled while freely exploring an open chamber is 
known to be sensitive to dysregulation of neural systems, in particular the 
dopaminergic and glutamatergic systems. Manipulation of the dopaminergic 
system via methamphetamine or amphetamine induces hyperlocomotion in 
neonatal-NMDAR blockade rats (Uehara et al., 2010; Ingallinesi et al., 2015). Acute 
treatment with PCP also causes hyperlocomotion in these rats (Wang et al., 2001; 
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Anastasio and Johnson, 2008b; Boctor and Ferguson), suggesting increased 
sensitivity in both glutamatergic and dopaminergic systems. While one study 
reports increased basal locomotor activity (Wedzony et al., 2008), baseline activity 
generally appears to be unaffected (Kawabe et al., 2007; Anastasio and Johnson, 
2008b; Boctor and Ferguson, 2010; Uehara et al., 2010; Gaskin et al., 2014), and 
differences between neonatal-NMDAR blockade rats and controls only 
consistently appear following a challenge to homeostasis (such as acute drug 
exposure). It is clear that the method induces long-lasting physiological changes 
with implications for behaviour in adult rats, in particular susceptibility of the 
glutamatergic and dopaminergic systems. 
Continuing on with innate behavioural responses, the PPI task (see Chapter 
1: Introduction for review) has also been used to assay neonatal-NMDAR blockade 
rats. The earliest report showed reduced basal PPI at PND 24 - 26 in neonatal-PCP 
rats compared to controls (Wang et al., 2001). This effect was replicated by Wang 
et al. (2003) and Anastasio and Johnson (2008b), as well as recently being shown 
in PND 32 rats (Zhang et al., 2012). However, other attempts to find PPI deficits in 
neonatal-PCP-treated rats failed at PND 25 (Boctor and Ferguson, 2009) and PND 
32 - 33 (Rasmussen et al., 2007). The apparent inconsistencies in results are not 
easily explained away by strain differences (all of the neonatal-PCP studies used 
Sprague Dawley rats), nor PPI calculations (Boctor and Ferguson), therefore it 
would appear that the effectiveness of PCP to induce PPI is, in fact, not reliable. A 
recent paper which used Lister Hooded rats reported a deficit in PPI, however 
electrophysiological recordings did not replicate the schizophrenia findings in 
these rats, suggesting that the effect was not aetiologically identical (Boctor and 
Ferguson, 2010).  
Evidence is also mixed for other neonatal-NMDAR blockade induced PPI 
deficits. In the MK801 manipulation, no PPI deficit was found following acute 
methamphetamine treatment at PND 34 - 35. However, when tested later (PND 
62 - 63), significant deficits were found across a range of pulse decibel levels 
(Uehara et al., 2010). Although baseline deficits in PPI have also been reported for 
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PND 56+, neonatal-MK801-treated rats (Harris et al., 2003), this result also failed 
to be replicated (Lyall et al., 2009). It is important to note that despite the failure 
to replicate the main PPI effect, the researchers did report a subtle but significant 
effect in the delay in prepulse-induced startle.  
Novel object recognition (NOR) primarily measures memory and relies on 
innate increases in attention to unfamiliar (novel) stimuli in the environment. 
Originally developed by Ennaceur and Delacour (1988), the test has proven to be 
highly sensitive to dysfunction in glutamatergic neurotransmission (Warburton et 
al., 2013). Interestingly, despite the numerous reports of disruptions to the 
glutamatergic system, most reports of neonatal-NMDAR blockade effects on NOR, 
during PND 50 - 60, did not find differences between treated and controls rats 
(Stefani and Moghaddam, 2005; Gaskin et al., 2014). While one study does report 
NOR deficits (5-hour delay), the analysis required pooling of data across six time 
points (PND 30 - 180) to reach significance, suggesting the effect was not robust 
at any given developmental period (Baier et al., 2009). Further studies show that, 
combined with social isolation, a deficit in NOR discrimination (2 and 24 hour delay 
periods) can manifest during PND 60 - 65 (Gaskin et al.; Watson et al., 2016), 
although this may be primarily driven by the social isolation manipulation (Gaskin 
et al.). Thus, despite the physiological effects reported earlier in the chapter, the 
effects on measures of innate adult behaviours appears to be inconsistent. 
4.1.4 Schizophrenia-related attentional set-shifting behaviour in neonatal-PCP-
treated rats 
Of most interest to this dissertation are the reported effects of neonatal-
NMDAR blockade on ASST performance. To date three reports have examined 
ASST deficits in neonatal-PCP-treated rats, all from Lundbeck research groups in 
Denmark. According to these publications, neonatal-PCP administration 
consistently induces an impairment at the ED stage (Broberg et al., 2009 2008; 
Redrobe et al., 2012), although it should be noted that the most recent report also 
includes a deficit at the reversal stage following the ED (Redrobe et al.).  
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The repeated findings of an ED impairment are entirely expected given the 
clear pattern of mPFC-specific physiological disruption. Following on these 
anatomical, sensory gating, and ASST findings, this chapter sought to replicate the 
ED impairment in neonatal-PCP-treated rats and further explore the effects of the 
treatment on attentional regulation and behavioural flexibility. 
4.3 Methods and materials 
4.3.1 Animals 
Adult male (n = 3) and female (n = 6) Lister Hooded rats were purchased 
from Charles River UK for breeding. Once the females had reached a body weight 
of 250 g (approximately 4 weeks after arrival), they were separated into pairs and 
placed with a single male in the cage. Approximately 3 weeks after pairing, 5 of 
the 6 paired dams gave birth to litters. Day of birth was counted as PND 0. Each 
dam was housed separately with her litter until weaning at PND 21. On PND 7, 9, 
and 11, male rat pups were injected subcutaneously with either 20 mg/kg/ml PCP 
(Sigma; Lot No 113M4924V) in saline or saline as a control. The first two litters (1 
and 2) received saline injections, while litters 3 & 4, were born a day later, and 
received PCP injections. Of the 15 pups that received the PCP injections, only 6 
survived. We believe this may have been due to a combined effect of the PCP and 
abnormally large litter sizes (12 - 15 pups). For the later-born fifth litter, all of the 
pups were treated with PCP regardless of sex. Litter 5 was also much smaller to 
begin with (just 6 pups), and all of these pups survived to weaning without 
incident. Post-weaning, male pups (and female pups from litter 5) were housed in 
standard housing conditions. Rats were allowed ad libitum access to food except 
during ASST testing, for which they were placed on a mild food control regimen of 
15 - 20 g per day to increase their motivation in the task. Behavioural testing began 
at PND 35 with the novel object recognition task. Following completion of this 
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testing, rats continued being fed ad libitum until PND 63 at which they were placed 
on the food control regimen one week prior to the start of ASST testing. 
4.3.2 Behavioural Testing 
 Attentional set-shifting test 
As described in General Methods (Chapter 2).  
 Maximal separation of stimuli (ASST-MSS) 
In this variant of the ASST, rather than a pseudo-random probability of any 
particular set of bowls being presented, on every trial the stimulus pairs are 
orthogonal. That is to say, the pairing of the irrelevant stimuli with the correct, 
rewarded, stimulus changed on every trial. The purpose of this was (1) to 
maximally separate the stimuli to encourage faster learning and (2) to enable 
greater confidence in judging which component (exemplar) of the compound 
stimulus the animal was selecting.  
Training and testing occurred in a different type of standard ASST chamber, 
which had 2 holes, each 4-cm wide, in the floor of each test chamber (see Figure 
4.1).  The apparatus was elevated, with runners (attached to the underside of each 
test chamber) that allowed plastic panels (38 cm x 9 cm x 2 mm) to be freely pulled 
forwards via the holes in the test chamber floors. The day before testing, rats were 
trained to pull unscented velvet-covered panels forward to obtain a cereal reward 
located at the end of the panel, with one rewarded panel in each chamber. The 
pot containing the reward was located 4 cm from the end of each panel, thus each 
rat needed to pull a panel approximately 34 cm to obtain the reward. The distance 
the rat had to pull the panel forward to obtain the reward was steadily increased 
after each successful (reward obtained) response. Once the panels were extended 
to their full length the training continued until the rat regularly made complete 
responses to each side (generally 3 to each side). Next, rats were trained on a 
simple odour discrimination. One velvet panel was scented with cumin, and the 
other with coriander. The first two pulls were deemed exploratory meaning the 
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response was noted as correct/incorrect but the rat was allowed to explore the 
unchosen panel after an incorrect response. Following these exploratory trials, 
incorrect responses resulted in the lowering of the barrier to the chamber 
containing the correct panel then progression to the next trial. Odour 
discrimination training continued until the rat made six consecutive correct 
responses. Next rats were trained on a simple texture discrimination. One panel 
was covered in a cork tile, and the rewarded panel was covered in ground cork. 
Testing occurred the following day. First, the rat was presented with a simple 
discrimination (only odour or texture stimuli presented). Next the rats performed 
a compound discrimination during which the rewarded stimulus remained the 
same, however irrelevant dimension stimuli were added (both odour and medium 
stimuli presented; see Figure 4.1 for stimuli and pairs). The third stage was an 
intradimensional discrimination during which new stimuli pairs were presented 
however the rewarded stimulus remained within the same dimension as the 
previous stages. The final stage was an extradimensional shift during which new 
pairs of stimuli were presented and one of the stimuli in the previously irrelevant 
dimension was the rewarded stimulus. If a rat had formed an attentional set then 
the ED stage would take more trials than the ID, similar to the standard 7-stage 
task. All rats were tested twice in this task.  
 
Figure 4.1) Left. Table of exemplars used. Exemplars were presented in these 
pairs. Presentation order during testing was counterbalanced (e.g. 1 → 2 → 3 
or 2 → 3 → 1). Right. Image of modified testing chambers for panels based 
testing.  
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*Compared to the bowl digging task, the use of the panels apparatus 
resulted in more overall TTC for each stage. This may have been due to the 
reduced ‘effort’ required to pull the panel, compared to digging for the reward.   
 Adolescent Novel Object Recognition Test 
At PND 35, rats were assayed for novelty preference in the NOR. The rats 
were habituated to the chamber (65 x 65 x 50 cm) for 3 days (30 mins each day) 
with sample objects placed in the same locations where test objects would be 
located. Following habituation, rats were tested twice to rule out side/object 
preferences. On the test day, rats were allowed to acclimate to the chamber for 
3 mins. Then they were placed in the holding cage while a pair of identical 
objects were placed in the test chamber. After a 1 min delay, the rat was placed 
back in the test chamber to explore the familiar object pair for 3 mins 
(acquisition phase). Following acquisition the rat was placed in the holding cage 
while the test chamber was cleaned of odours, the explored familiar objects 
were removed and replaced with a third identical familiar object and a novel 
object. After a 1 min delay, the rat was placed back into the test chamber to 
explore the familiar and novel objects for 3 mins (test phase). The discrimination 
index (DI) was calculated as time spent exploring the novel object minus time 
spent exploring the familiar object, divided by the total exploration time. This 
calculation allows for sensitivity to individual differences in total exploration 
time. All objects were counterbalanced across condition, side, and presentation 
as the familiar object (during acquisition phase), or as the novel object (during 
test phase). The repeat tests were performed within 48 hours of the previous 
test, and the novel object presentation side was counterbalanced across tests. 
For all rats, all phases (habituation, acquisition, and test) of all tests were video 
recorded. Videos were scored blind and data were recorded using the Observe 
video recording software (Jackie Macpherson, University of St Andrews). Tests 
were first analysed by repeated measures ANOVA. If no main effect of test was 
found then, DIs were averaged across the tests and the conditions were 
compared using t-test. 
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Litter 5 (n = 3, male pups) was not of age for the adolescent NOR studies 
thus were not included. Video from one control was corrupted and therefore not 
scored. 
 Adult Novel Object Recognition Test 
Once the rats had matured to adulthood (PND 126) they were assayed 
again in the novel object recognition task (NOR). The rats were habituated to the 
chamber for 3 days (30 mins each day) with sample objects placed in the same 
locations where test objects would be located. Following habituation, rats were 
tested twice to rule out side/object preferences. The first pair of tests were done 
with a 1 min delay. A week later, a second pair of tests were done with a 24-hour 






4.4.1 Neonatal-PCP-treated rats show no clear deficits in the ASST 
All rats were tested three times in the standard 7-stage ASST. The first was 
performed at PND 70 - 85, while the second and third tests were performed at 
PND 154 – 175 (Figure 4.2). A main effect of Test (F(2, 36) = 4.89, p < 0.05) was found, 
suggesting performance changed with age/experience. Compared to the first test, 
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performance improved slightly for controls, while neonatal-PCP-treated rats 
performed slightly worse, as indicated by trend level significance for the 
interaction of Test x Group (F(2 ,1) = 3.1, p = 0.057). However, there was no 
interaction of Stage x Group (F(6, 1) = 1.2, ns), nor an overall interaction of Test x 
Stage x Group (F(2, 6) < 1, ns), therefore no stage specific differences could be 
determined. Both neonatal-PCP-treated rats and controls formed and shifted an 
attentional set regardless of age (Test 1: F(1, 19) = 24.63; Test 2 & 3: F(1, 19) = 40.17, 
p < 0.05). 
Bayesian analysis of the data (for details of the analysis see Chapter 2: 
General Methods), did not reveal clear differences between groups at the stage of 
interest (the ED; Figure 4.3). However, although both groups of rats completed 
each stage of the ASST with a Bayes factor greater than 3, indicating that they were 
eventually responding to the correct stimulus, neonatal-PCP-treated rats had 
more quartiles with strong evidence of non-random systematic incorrect 
behavioural patterns (i.e., spatial patterns, irrelevant dimension, or previously 
correct stimulus responding) than controls across the entirety of the task (controls 
 
Figure 4.2) Mean TTC (+ SEM) for neonatal saline- and PCP-treated rats in the 
standard ASST. Compared to their performance as young rats (PND 70 – 85: 
left), adult (PND 154 – 175: right) control rats appeared to perform better, 
while neonatal-PCP-treated rats, appear have worsening performance. 
However, there was only a trend level Test x Group interaction (p = .057; #, ID 
significantly different than ED both groups). 
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= 7; PCP = 11).  Specifically, there was evidence of perseveration in neonatal-PCP-
treated rats during REV 1 (see the heatmap in Figure 4.3), as well as more 
irrelevant dimension responding during REV 1 and REV 2 than controls (table in 
Figure 4.3). This increased irrelevant dimension-based responding was not in lieu 
of spatial-based responding, as neonatal-PCP-treated rats, actually had one more 
quartile than controls, with strong evidence for this behavioural pattern (Figure 
4.3). These data suggest that although there were no statistically significant effects 
by stage, throughout the second and third tests, there was more evidence for 
incorrect behavioural patterns, than controls.  
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Figure 4.3. Top. Heatmap of evidence for behavioural patterns during the 
standard ASST. Compared to controls neonatal-PCP-treated rats show more 
evidence for all incorrect behavioural patterns. Bottom left. Table showing 
sum number of quartiles by stage for irrelevant dimension-based responding 
by group. Neonatal-PCP-treated rats showed more irrelevant dimension-
based responding than control rats. Bottom right. Bar graph showing sum 
number of quartiles with strong evidence for spatial- or irrelevant dimension-
based responding in control and neonatal-PCP-treated rats. 
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4.4.2 Neonatal-PCP-treated rats have an ED deficit in the ASST-MSS 
At PND 140 - 150, all rats were tested twice in the ASST-MSS. As expected 
both groups of rats required more trials to complete the ED compared to the ID 
indicating that an attentional set was formed (ID/ED main effect of stage F(3, 54) = 
30.78, p < 0.05; Figure 4.4). Unlike in the standard ASST, compared to controls, 
neonatal-PCP-treated rats required more trials to complete the ID/ED shift 
(restricted comparison ED: F(1, 54) = 16.3, p < 0.05; Stage x Group interaction: F(3 , 1) 
= 2.92, p < 0.05). Analysis of the ID/ED shift-cost revealed that neonatal-PCP-
treated rats required a mean of 10 additional trials than controls to complete the 
ID/ED shift (t(18) = 2.73 , p < 0.05). In the second test, all rats completed the SD with 
more trials compared to the first test (controls: Test 1 SD: , 12.64 (± 1.61), Test 2 
SD: 23.64 (± 4.53); neonatal-PCP-treated rats: Test 1 SD: 15.22 (± 3.76), Test 2 SD: 
24.89 (± 2.91)). This was confirmed in a significant Test x Stage interaction (F(1, 3) = 
4.03, p < 0.05). However, the main effect of Test (F(1, 54) = 1.2) and all other 
interactions with Test (Fs < 1), were not significant. 
 
Figure 4.4) Mean TTC (+ SEM) for control and PCP-treated rats in the modified 
ASST-MSS. Neonatal-PCP-treated rats, required more TTC for the ED stage 
than controls. 
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Analysis of the behavioural patterns evidenced during the ASST-MSS, 
revealed that neonatal-PCP-treated rats were more likely to have patterns of 
responding to the irrelevant dimension than controls across all stages (controls = 
3; PCP = 8; Figure 4.5). In this modified task, the evidence for irrelevant dimension 
based responding from neonatal-PCP-treated rats diminished from the CD to the 
ID in both groups (controls: from 2 to zero; neonatal-PCP-treated from 3 to 1), as 
would be expected with the formation of an attentional set. At the ED, there was 
strong evidence for neonatal-PCP-treated rats responding to stimuli within the 
previously relevant dimension for all quartiles, and there was only weak evidence 
of them responding to the correct stimulus by completion of the stage. Again, this 
was not in lieu of spatial based-responding and neonatal-PCP-treated rats also had 
more quartiles with strong evidence for spatial-based responding than controls 
(controls = 1; PCP = 3). Interestingly, three quartiles with strong evidence for 
spatial-based responding were evident in neonatal-PCP-treated rats during the SD, 
whereas this was not found for controls. 
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Figure 4.5) Top. Heatmap of behavioural patterns evidenced during the 
modified ASST-MSS. There was substantial evidence for neonatal-PCP-treated 
responding to irrelevant dimension stimuli during the CD, ID, and ED 
compared to controls. Bottom left. Table of sum quartiles per stage of 
irrelevant dimension responding. Across all stages the evidence suggested 
neonatal-PCP-treated rats responding to irrelevant dimension stimuli. Bottom 
right. Bar graph showing total spatial and irrelevant dimension quartiles by 
group across all stages except for the ED. Neonatal-PCP-treated rats showed 
more evidence of incorrect behavioural patterns (irrelevant dimension or 
spatial-based responding than controls). 
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4.4.3 Young neonatal-PCP-treated rats show deficits in the short delay novel 
object discrimination, however this deficit is not present in adult neonatal-PCP 
rats  
At PND 35 - 49, all rats were tested in the NOR task following a 1 min delay. 
Compared to controls, neonatal-PCP-treated rats exhibited reduced novel object 
exploration, as measured by the DI (t(14) = 2.42, p < 0.05; Figure 4.6). This reduction 
in time spent exploring the novel object was not due to an overall decrease in 
exploration time (controls = 48.9 secs (± 3.22), PCP = 46.78 secs (± 10.29)). At PND 
126 - 140, rats were again tested in the NOR. However, at this timepoint no 
significant differences were found in the DI between controls and neonatal-PCP-
treated rats (t(17) = 0.85, ns). The loss of a difference between groups was due to a 
reduction in the DI for controls (-0.10) and an increase in the DI for neonatal-PCP-
treated rats (+0.13). No significant differences were found between groups in 
object exploration times.  
 
 
Figure 4.6) Mean discrimination index (+ SEM) for the 1 min delay NOR. 
Although adolescent neonatal-PCP-treated rats show a deficit in exploration 
of the novel object (left), this deficit is not present in adulthood (right).  
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4.4.4 Adult neonatal-PCP-treated rats show deficits in the 24-hour delay novel 
object discrimination  
The adult neonatal- PCP-treated rats were also tested in the 24-hour delay 
NOR task. Here, neonatal-PCP-treated rats again showed a deficit in discrimination 
of the novel object compared to controls (t(18) = 2.35, p < 0.05; Figure 4.7). 
Compared to control rats, neonatal-PCP-treated rats had greater overall 
exploration time (t(18) = 3.64, p < 0.05; controls = 63.14, (± 2.45); PCP = 79.11, (± 
3.83). 
4.5 Discussion  
4.5.1 Failure to replicate the ASST deficits in neonatal-PCP-treated rats 
 Several previous reports suggested a robust ED deficit in the standard ASST 
in neonatal-PCP-treated rats (Broberg et al., 2008; Broberg et al., 2009; Redrobe 
et al.), however the experiments in this chapter did not replicate these previous 
 
 
Figure 4.7) Mean discrimination index (+ SEM) for the 24-hour delay NOR. 
Compared to controls, neonatal-PCP-treated rats show a deficit in exploration 
of the novel object, following the long delay. 
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reports. In addressing potential causes of these conflicting findings, the foremost 
consideration is the differences in ASST protocol. All three previous reports used 
the same protocol as each other, but different to the protocol used here, as 
described below.  
First, in the previous reports the odour stimuli (scented oils) were placed 
around the rim of the pots containing the media and reward. As described in the 
general methods section, all ASST experiments in this thesis were performed with 
the odour discriminanda intermixed within the media. As such both the odour and 
medium within each bowl are simultaneously experienced, whereas when the 
odour is around the rim the rat may independently experience either the odour or 
the medium. Thus, placement of the odour around the rim potentially separates 
not only the ‘compound’ nature of the stimuli, but can also result in dissociation 
of the reward from the odour cue.   
Second, the shift-direction was not counterbalanced in the previously 
published studies (Broberg et al., 2008; Broberg et al., 2009; Redrobe et al., 2012). 
All rats performed medium discriminations for the first five stages and the ED shift 
was always to an odour stimulus. Given the potential for differential difficulty 
between odour-medium and medium-odour shifts, arising from the placement of 
the odours on the rim, the failure to counterbalance stimulus dimensions for the 
ED shift may artificially, increase the TTC for the stage. The TTC for control rats 
during the all stages outwith the ED are broadly similar to published data from our 
lab (e.g. Birrell and Brown, 2000; Tait et al., 2009; Chase et al., 2012). However, 
the number of TTC for the ED is markedly greater for control and neonatal-PCP-
treated rats. 
While other differences in protocol also exist (the published papers also 
report: sprinkling cheerio dust over the media in the bowls to ‘mask’ the reward, 
only one exploratory trial, and replacement of the post-CD reversal with an 
additional ID stage), as there are no apparent differences between performance 
at the other stages, the evidence points to the lack of counterbalancing between 
dimension shift-direction, and placement of the odour around the rim of the bowl, 
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as a likely cause of differences in the previously reported ED deficit, and the lack 
of a clear deficit in this report. However, as reviewed in the introduction section 
to this chapter, other behaviours (hyperlocomotion and PPI) are also reportedly 
inconsistent in neonatal-PCP-treated rats. Therefore, the ASST findings here may 
also reflect this variability in the behavioural phenotype resulting from the 
manipulation. 
Despite the lack of a clear deficit in the ASST, the behavioural patterns 
analysis suggested suboptimal performance in neonatal-PCP-treated rats 
compared to controls. In particular, neonatal-PCP-treated rats were more likely to 
show patterns of responding to the irrelevant dimension during reversal stages. 
The pattern of results from the second and third tests also suggest that while 
control rats improved, neonatal-PCP rats’ task performance deteriorated. While 
this was only a trend level interaction, I sought to further examine the possible 
set-shifting deficit in a task designed to enhance the set-formation, and also more 
consistently detect responding to irrelevant dimension stimuli.  
4.5.2 The ASST-MSS task revealed an ED deficit in neonatal-PCP-treated rats 
 In the ASST-MSS, the stimulus presentation order was changed with the 
intent of maximally separating the stimulus pairs. The task was limited to 4 stages: 
SD, CD, ID, and ED, to control for potential interference from reversal stages. In 
addition, the test was performed in a novel testing apparatus with stimuli (odour 
and haptic) presented on panels as opposed to within bowls. The results showed 
that both control and neonatal-PCP-treated rats were able to form and shift 
attentional set in this task design, supporting its use for testing of set-shifting. In 
this task-setup, there was an ED deficit in neonatal-PCP-treated rats compared to 
controls. In addition, the behavioural patterns analysis supported the hypothesis 
that neonatal-PCP-treated rats were responding based on irrelevant dimension 
stimuli, as the evidence for this pattern was consistently present across all stages. 
Indeed, the evidence for irrelevant dimension-based responding during the CD 
suggests that the task design successfully, maximised stimulus presentation to 
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detect which element of the compound stimuli rats were likely choosing based on. 
Interestingly, control rats also showed strong evidence for irrelevant dimension-
based responding during the CD, evidence that they too failed to block the novel 
stimuli within that dimension. However, control rats only showed two quartiles of 
strong evidence for irrelevant dimension-based responding, one of which co-
occurred with strong evidence for responding based on the correct stimulus, 
compared to neonatal-PCP-treated rats which showed evidence for irrelevant 
dimension-based responding from the first quartile. Furthermore, whereas there 
was strong evidence for control rats responding to the correct stimulus by the 
third quartile of the CD, this evidence was not present until the fourth quartile for 
neonatal-PCP-treated rats. At the ED, controls also showed responding to the 
previously relevant dimension early in stage performance (second quartile), 
however the evidence suggests this pattern was quickly abandoned and control 
rats completed the ED with strong evidence for responding to the correct stimulus. 
This was not the case for neonatal-PCP-treated rats, as there was strong evidence 
for irrelevant dimension-based responding throughout the ED, and they did not 
have strong evidence for responding based on the correct stimulus by the end of 
the stage. 
However, the task was not without its flaws. The ED deficit was only 
detectable following repeat testing to increase statistical power. Additionally, as 
the task did not use reversals, during the first test several stimuli were never 
rewarded. This lack of reward for those stimuli likely drove the elevated TTC for 
the SD. For example, the rat with the highest increase in trials for the SD between 
Test 1 and Test 2 (44 trials) was rewarded for odour 2 (ginger) during the ED of 
Test 1. The SD for Test 2 was odour 1 (cinnamon). This increase in TTC at the SD 
highlights an important concern in regard to repeat testing with the task. A 
potential resolution for this is exposure to all stimuli (not in compound) and to 
allow the reward to be obtained from each following each test to remove the 
potential for this bias. Chase et al. (2012), utilised this ‘re-exposure’ procedure 
with the 4ID task. In their report, while there was a main effect of test, with 
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improved performance from test one to test two, the pattern of performance for 
both groups of rats at each stage was stable across tests. 
4.5.3 Developmental period dependent effects in neonatal-PCP-treated rats in 
the novel object recognition task 
 The results from the young and adult neonatal-PCP NOR testing are both 
consistent with previous reports in neonatal-NMDAR blockaded rats (Stefani and 
Moghaddam, 2005; Baier et al., 2009; Gaskin et al., 2014). These results further 
previous findings by showing that there is also no effect of neonatal-PCP 
administration with a short (1 min) delay, whereas the previous studies all used 2 
- 5 hour inter-trial intervals. However, the presence of a deficit after a 24-hour 
delay has never been reported previously.  
 The role of the mPFC (specifically, glutamatergic signalling within the 
region) in NOR has only recently begun to be elucidated (Warburton et al., 2013). 
Traditionally, memory has been the responsibility of medial temporal lobe regions, 
such as the hippocampus, and perirhinal and entorhinal cortices. While the mPFC 
has been shown to be involved in appetitive and aversive memory processes (for 
review see Euston et al., 2012), a role in basal memory processes is less evidenced. 
Typically, some form of ‘cognitive load’ must be in place prior to the requirement 
for mPFC function. For example, Barker and Warburton (2011) compared the 
effect lesions of the hippocampus, perirhinal cortex, and mPFC on the standard 
NOR as well as three variants of the task: object location, object-in-place, and 
temporal order. The researchers also used three different delay periods: 1 min, 3 
hours, and 24 hours. In the short delay tasks (5 min or 3 hours), the mPFC-lesioned 
rats significantly differed from controls in the high load tasks (object-in-place and 
temporal order). In the published report, mPFC-lesioned rats did not differ from 
controls at short delay NOR, and showed equal exploration of the novel object, as 
controls. However, the authors noted that mPFC-lesioned rats performed 
significantly worse at the NOR following the 24-hour delay, and did not 
successfully discriminate the novel from the familiar object as they had following 
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the shorter delays. This finding suggests a role for the mPFC in either retrieval of a 
‘remote memory’ or consolidation of the memory/experience.  
The most direct evidence suggests a PCP-induced disruption in mPFC-
mediated consolidation. Akirav and Maroun (2006) found that micro-infusion of 
NMDAR antagonist, (2R)-amino-5-phosphonovaleric acid, into the mPFC 
immediately following the acquisition phase caused a deficit in the test phase 24 
hours later. The same treatment had no effect on discrimination after a 3-hour 
delay highlighting the disruption of memory consolidation as the mechanism 
underlying the deficit. Given the reported mPFC-glutamatergic signalling 
disruptions in neonatal-PCP-treated rats (Sircar, 2003; Anastasio and Johnson, 
2008a; du Bois et al., 2009; Broberg et al., 2013) this is the most parsimonious 
explanation. Specifically, the hypo-glutamatergic state within the mPFC induced 
by neonatal-PCP administration (indicated by the abnormal expression of mPFC 
NMDAR subunits) can result in reduced NMDAR signalling much like the direct 
inhibition of mPFC NMDAR by Akirav and Maroun. 
4.5.4 Reproducibility of set-shifting results 
The failure to evidence clear and robust deficits in either of the set-shifting 
tasks (i.e. statistically robust findings from one round of testing) suggests that the 
results here and elsewhere are not highly replicable. Indeed, the neonatal-NMDAR 
blockade manipulation has been criticised for reproducibility not just in high-level 
cognitive tasks, but also in the innate behaviours such as PPI and locomotor 
activity (Boctor and Ferguson, 2009; Lim et al., 2012). Sircar (2003) suggested that 
the irreproducibility of the hyperlocomotor activity, may be due to differences in 
the cohorts’ environments, such as handling, housing, cage size/population, and 
maternal care. In this case, ameliorating the reduction in body weight commonly 
found following neonatal-PCP administration can prevent the deficits in locomotor 
behaviour in adulthood. Supporting this hypothesis, comparison of the two 
reports suggests this is the case. When PCP-treated pups are underweight 
compared to controls, a deficit in dopaminergic-related locomotor activity can be 
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found (Semba et al., 2001). However, when the environment is sufficient to 
eliminate the body weight differences, the underlying dopaminergic system is no 
longer as affected (Sircar).  
It would seem that while neonatal-PCP may predispose the system to 
disruptions in glutamatergic and dopaminergic signalling, with relevance to 
schizophrenia, the most effective and reliable manipulations rely not only on the 
drug treatment but also on additional environmental disruptions. For example, 
Gaskin et al. (2014) compared neonatal-PCP vs post-weaning social isolation, and 
a combination of the two. The “dual-hit” manipulations which employs both 
neonatal-PCP and social isolation resulted in a more robust behavioural 
phenotype than either manipulation alone. For both the NOR and PPI tests, the 
“dual hit” manipulation generated a greater deficit compared to controls, than 
neonatal-PCP alone. It should be noted that this study also failed to find any effect 
of neonatal-PCP (either alone or in combination with social isolation) on 
locomotor behaviour (either basal or in response to acute PCP treatment (3 
mg/kg)). Future experiments will likely continue to use this dual approach, as it 
has proven effective and the behavioural deficits appear responsive to 
antipsychotics (Watson et al., 2016).  
Last, it seems that many of the reported “cognitive” deficits in neonatal-
NMDAR-blockade rats are subtle. In the delayed spatial alternation task 
(performed during PND 34 -70), deficits compared to controls are present for the 
initial acquisition phases, however equivalent performance is found between 
groups by the end of testing (Wang et al., 2001; Wiley et al., 2003). Once the 
criterion accuracy was reached by both groups, no differences between groups 
were found with increasing delay periods, or acute treatment with PCP, ketamine, 
or amphetamine (Wiley et al.). Similarly, in the Morris water maze, neonatal-PCP-
treated rats show increased escape latencies during the initial acquisition trials, 
however perform equivalent to controls for the remaining trials. This finding was 
replicated by Andersen and Pouzet (2004), who furthered the finding by showing 
that neonatal-PCP-treated rats also had deficits in spatial reversal learning. The 
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authors concluded that while spatial reference memory was an inconsistent and 
slightly measured impairment, the impairment in spatial reversal learning was 
consistent and robust.  
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4.6 Histological analysis of neonatal-PCP-treated rats 
Rationale 
 Given the failure to find a robust ED deficit in the standard ASST, and only 
finding an ED deficit in the ASST-MSS task following repeat testing, this chapter 
sought to verify PCP-induced neural and anatomical disruptions. The extant 
literature (reviewed in the introduction Chapter 4.1) indicates body and brain 
weight reductions, in addition to alterations to the neuronal composition of the 
mPFC (primarily reduced PV-expressing interneurons). Additionally, given the 
apparent ‘time point sensitivity’, this section sought to highlight the ‘state’ of the 
neonatal-PCP-treated rats. 
4.7 Methods and materials 
All procedures in this section were performed as described in Chapter 2: 
General Methods. 
4.8 Results 
4.8.1 Neonatal-PCP-treated rats exhibit a deficit in weight gain and post-mortem 
brain weight 
Compared to controls, neonatal-PCP-treated rats showed reduced weight 
gain throughout development (Week x Group F(14, 1) = 5.89, p < 0.05). Specifically, 
during weeks 3 - 10, neonatal-PCP-treated rats weighed less than controls (Figure 
4.8). This difference between groups was no longer present after week 10, and 
both control and neonatal-PCP-treated rats continue to gain weight at a normal 
rate. Despite no difference in body weight at the end of testing, the brain weight 
of neonatal-PCP-treated rats was significantly less than controls (t(17) = 2.13, p < 
0.05; Figure 4.8), suggesting that neonatal-PCP-induced neuronal development 
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Figure 4.8) Top. Mean weight gain (+ SEM) throughout the duration of 
experiments. Early in development neonatal-PCP-treated rats show reduced 
weight gain, however, this remediates by early adulthood. Bottom. Mean 
brain weight (+ SEM). A post-mortem reduction in brain weight was found for 
neonatal-PCP-treated rats.  
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4.8.2 Neonatal-PCP-treated rats have less parvalbumin-expression within the 
mPFC 
 Quantification of PV-expressing cells revealed significantly fewer PV-
expressing cells within the mPFC of neonatal-PCP-treated rats compared to 
controls (t(17) = 2.11, p < 0.05; Figure 4.9).  
 
Figure 4.9) Representative images of staining for PV-expressing neurons 
within the mPFC (PL and IL) of a vehicle-treated rat.  
Control
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Figure 4.9 continued) Top. representative image of staining for PV-expressing 
neurons within the mPFC (PL and IL) of a PCP-treated rat. Bottom Image-J 
based quantification of PV-expressing neurons within the mPFC. A significant 
reduction in PV+ cells was found in neonatal-PCP-treated rats. PrL = prelimbic, 
IL = infralimbic, Cg = cingulate, MO = medial orbital, LO = lateral orbital, M1 = 
primary motor cortex. 
PCP
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4.9.1 Successful replication of neonatal-PCP induced anatomical disruption 
 The cohort of neonatal-PCP-treated rats used in these experiments, 
replicated many of the anatomical changes reported previously including 
reductions in: body weight (Boctor and Ferguson, 2009), brain weight (Boctor and 
Ferguson, 2009 2008), and PV-expressing neurons in the mPFC (Wang et al., 2008; 
Redrobe et al., 2012; Kaalund et al., 2013). The brain anatomy changes are 
hallmarks of ‘schizophrenia-related’ alterations and likely underlie the behavioural 
deficits reported in the previous section (Chapter 4.1).  
4.9.2 Role of the mPFC disruption in the novel object recognition deficits 
While the effects of neonatal-PCP induced disruptions of the mPFC are 
easily linked to the performance in the set-shifting task, the NOR (24-hour delay) 
may also be temporal lobe-dependent (Barker and Warburton, 2011; Warburton 
et al., 2013). This analysis did not explore potential alterations to the temporal 
lobe (specifically the perirhinal cortex), as the PND 7, 9, and 11 neonatal-PCP 
literature largely indicates that the effects of neonatal-PCP treatment (primarily 
the induction of apoptosis), do not extend to this region immediately following the 
last treatment with PCP (Wang et al., 2001; Wang et al., 2003 2004; Anastasio and 
Johnson, 2008b; Liu et al., 2011). Specifically, in adult neonatal-PCP-treated rats, 
acute PCP-induced MRI-measured brain activity (Broberg et al., 2013) changes in 
PV-expressing neurons (Kaalund et al., 2013), as well as dysregulated GABAergic 
inhibitory activity (Kjaerby et al., 2014), have only been evidenced for the mPFC.  
Again, however, the alterations (cellular and molecular) to the brains of 
neonatal-PCP-treated rats appears to be transient and more complicated then 
measurements at a single time point can ascertain. The first evidence for less 
obvious disruptions was presented by du Bois et al. (2009), who showed 
downregulation of muscarinic receptor 1 (M1/4) in CA1 and CA3 on PND 12 (24 
hour after last PCP-treatment). Downregulation of M1/4 was also present in the 
mPFC on PND 12, but the receptor was subsequently over-expressed at juvenile 
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and adult time-points. The upregulation was greatest at PND 32 (47% compared 
to controls) until control expression of M1/4 increased to a similar (but still 
significantly less) level at PND 96 (10% compared to controls). Examination at 
different time-points also revealed changes in expression of proteins implicated in 
schizophrenia, NMDAR, Nrg1/erb4, and PSD 95 (see Chapter 1: Introduction, for 
descriptions of these proteins) within the hippocampus. The researchers found 
increased levels of PSD 95 and NMDAR at PND 12 and PND 35 compared to 
controls. However, at PND 140 the expression of these proteins (and Nrg1/erb4) 
was reduced compared to controls. While long-term (over 4 months old rats) 
examination of GABAR expression has yet to be done in neonatal-PCP-treated rats, 
at PND, 18, 32, and 96, GABAR expression within the hippocampus is higher than 
in controls (du Bois et al., 2009). 
Thus, although the data collected here strongly support the mPFC-
mediated behavioural dysfunctions, without further analysis, a role for the 
temporal lobe cannot be eliminated. Indeed, it is possible that an interaction 
between the regions allow for the clear NOR deficit, whereas the primarily mPFC-
dependent ED deficit was not as robust due to neural compensation during 
development. 
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Chapter 5. Effects of Gestational 
Methylazoxymethanol Acetate (MAM)-treatment 
on Attentional Set-Shifting Task Performance  
 
The experiments in this chapter utilised a developmental disruption targeting 
hippocampal and cortical maturation in rats during their gestational period 
(corresponding to first trimester in humans). Testing in the standard ASST during 
adulthood revealed a dearth of dysfunction as MAM-treated rats only displayed a 
deficit at REV 1. Histological analysis indicated robust disruption of brain 
development with MAM-treated rats displaying several ‘schizophrenia-related’ 
anatomical markers such as enlargement of the lateral ventricles. The medial 
prefrontal cortex, although smaller than that of controls, was not found to exhibit 
other schizophrenia-related disruptions.  
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5.1 Introduction to the MAM manipulation 
Maternal infection during pregnancy is a potent risk factor for the 
development of schizophrenia in offspring (Boksa, 2008). Many animal 
manipulations have been developed to examine the sensitive nature of the foetus 
during the first trimester, which corresponds to the gestational days 15 - 18 in rats 
(Bayer et al., 1993; Clancy et al., 2001). Of the manipulations designed to test the 
increased risk for development of schizophrenia following an insult during this 
period, prenatal methylazoxymethanol acetate (MAM) is one of, if not the, most 
reported, with 66 PubMed indexed publications dating from 1998 - 2016. The 
MAM toxin targets DNA and was originally implicated as the cause of Guam 
neurodegenerative disease (Escalire, 1999; Kisby and Spencer, 2011). Following 
injection, MAM breaks down into reactive molecules and methylates guanine 
residues, essentially lesioning the DNA, with a strong preference for neurons 
(Matsumoto, 1966; Spencer et al., 2012). MAM manipulations in rodents have 
identified multiple clinically relevant phenotypes resulting from MAM 
administration, including cancer, susceptibility to epileptic seizures, and 
‘schizophrenia-related’ abnormalities (Lodge and Grace; Colciaghi et al., 2011; 
Spencer et al.). Interestingly, the resultant phenotype is largely dependent on the 
timing of MAM exposure such that the schizophrenia-related rats are best 
generated via exposure at gestational day 17 (MAM), a time point that coincides 
with cortical development.  
5.1.1 MAM-treated rats anatomical and histological abnormalities 
 MAM-treated rats have been reported to have brain structural and 
anatomical abnormalities which parallel findings in human schizophrenia patients. 
Whole brain weight in MAM-treated rats is significantly reduced with reports 
ranging from 7 - 11% compared to saline exposed age-matched controls (Flagstad 
et al., 2004; Moore et al., 2006), as well as reduced brain surface area and 
circumference (Matricon et al., 2010). Most astonishingly, specific regional 
‘schizophrenia-related’ alterations are also paralleled in MAM-treated rats, with 
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reductions in hippocampal volume (Matricon et al.; Chin et al., 2011), thickness 
(Moore et al.), and area (Moore et al.); and reductions in size of medial dorsal and 
medial geniculate thalamus (Moore et al.; Matricon et al.), and mPFC (PL, IL, and 
ACC; Moore et al.). In line with these reductions in regional sizes, the commonly 
found ventricular enlargement in schizophrenia patients, is also evident in MRI 
images of MAM-treated rats (Chin et al.), and ventricular enlargement has been 
observed in post mortem MAM-treated brains (Le Pen et al., 2006; Moore et al.; 
Matricon et al.). 
Also, consistent with schizophrenia patients, in addition to the gross size 
reduction, MAM-treated rats show increased cell expression per square mm 
(Moore et al., 2006; Matricon et al., 2010). These neurons are often reported as 
abnormal morphologically, with reduced spine density (Singh, 1980; Xing et al., 
2016), reduced soma size (Matricon et al.), and disrupted organisation in 
hippocampal cell layers (Matricon et al.). The latter is likely induced by the 
increased methylation (silencing activation) of the reelin glycoprotein promoter 
region in MAM-treated rats (Matricon et al.). Reelin is linked to neuron 
organisation and commonly reported as functioning abnormally in schizophrenia 
patients (see Chapter 1: Introduction). Specific alterations to interneurons are also 
reported, as MAM-treated rats display reductions in PV-expressing interneuron 
density (Penschuck et al., 2006; Lodge et al., 2009; Gastambide et al., 2012). PV-
expressing GABAergic interneurons are known to be selectively dysregulated in 
patients with schizophrenia, and are key targets for ‘schizophrenia-related’ 
behavioural deficits (Lewis et al., 2004; Lewis, 2013). In MAM-treated rats, PV-
expressing neurons are reduced in the hippocampus (Penschuck et al.; 
Gastambide et al.), mPFC (Lodge et al.; Gastambide et al.), and OFC (Gastambide 
et al.), all regions with major implications for behaviour.  
 Overall, MAM-treated rats exhibit structural and anatomical abnormalities 
which parallel the biomarkers found in patients with schizophrenia. These 
biomarkers are a large benefit of the MAM manipulation, over acute drug-induced 
manipulations, in particular since schizophrenia is believed to largely be a 
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developmental disorder arising from progressive changes in neural networks 
(Lewis and Levitt, 2002). Taking these structural and anatomical abnormalities into 
consideration, the next section will explore neurochemical deficits in MAM-
treated rats. 
5.1.2 Neurotransmitter & electrophysiological abnormalities in MAM-treated 
rats 
 Concurrent with structural abnormalities, schizophrenia is associated with 
dysregulation in basal dopaminergic, glutamatergic, and GABAergic 
neurotransmission (Guidotti et al., 2005; Laruelle, 2014; for review see Chapter 1: 
Introduction). Animal manipulations allow further investigation of these biological 
phenotypes and MAM-treated rats have been proven as useful tools, as they 
exhibit many of the same neurotransmitter dysregulations as patients with 
schizophrenia. 
Dopaminergic system aberrations found in MAM-treated rats include basal 
hyperactivity of dopamine neurons (Flagstad et al., 2004; Lodge and Grace, 2007; 
Gill et al., 2011). Specifically, Lodge and Grace, reported an increase in the number 
of spontaneously firing dopamine neurons in the VTA of MAM-treated rats 
compared to control rats. The hyperactive VTA dopamine neuron activity is 
exacerbated by administration of amphetamine, leading to increased dopamine 
release in the nucleus accumbens (Flagstad et al.). Additionally, stimulation of the 
VTA results in increased spike firing in the mPFC of MAM-treated rats, while 
controls display reduced firing in response to the same stimulation (Goto and 
Grace, 2006). These alterations in the dopaminergic system are not limited to the 
activity of VTA projections alone as local infusion of amphetamine into the mPFC 
of MAM-treated rats also results in increased extracellular dopamine in the 
nucleus accumbens (Flagstad et al.). This increased extracellular dopamine may be 
interpreted as MAM dopaminergic synapses containing excess dopamine 
packaged into the readily releasable pool of vesicles, and it is this dopamine that 
is displaced by amphetamine; or that the enzyme which breaks down extracellular 
dopamine (monoamine oxidase) is not maximally functional. This latter hypothesis 
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might better explain why the significant difference in extracellular dopamine is not 
evidenced until 30 min later; however evidence for monoamine oxidase 
dysregulation in schizophrenia is inconsistent (Li and He, 2008). At any rate, 
application of dopamine to superficial layer (1-2) mPFC neurons in MAM-treated 
rats, does not alter layer 5 mPFC cell activity, while the same treatment in control 
rats causes a reduction in firing in deep layer mPFC neurons (Lavin et al., 2005). 
Reports also indicate alterations in glutamatergic and GABAergic 
neurotransmission in adult MAM-treated rats. The ventral hippocampus projects 
heavily to the VTA and inactivation of the region (via tetrodotoxin) blunts the 
spontaneous activity of VTA dopaminergic neurons in MAM-treated rats (Lodge 
and Grace, 2007). This finding has led researchers to propose that the elevated 
dopamine neuron activity is secondary to elevated glutamatergic activity in the 
ventral hippocampus (Lodge and Grace, 2007, 2009). Further changes in the 
glutamatergic signalling pathway can be evidenced earlier in development. PND 
11 - 45 MAM-treated rats display reduced expression of NMDAR subunits within 
the dorsal hippocampus (Snyder et al., 2013). The abnormal expression of NMDAR 
subunits in MAM-treated rats may lead to the reduced LTP evidenced in CA1 
(Snyder et al.), as well as the attenuated extracellular glutamate and dopamine 
release in the mPFC following MK-801 treatment (Lena et al., 2007). 
As mentioned earlier, GABAergic PV-expressing interneurons are also 
dysregulated in schizophrenic patients (see Chapter 1: Introduction). In MAM-
treated rats the reduction in PV-expressing interneurons (Penschuck et al., 2006; 
Lodge et al., 2009; Gastambide et al., 2012) has been proposed as the driver of the 
hyperactive hippocampus (Gill et al., 2011) and subsequent hyperactive 
dopaminergic tone. Either of these hypotheses are consistent with the 
hippocampal anatomical disruptions reported in both humans with schizophrenia 
(Jaaro-Peled et al., 2010; Takayanagi et al., 2010) and MAM-treated rats 
(Gourevitch et al., 2004; Moore et al., 2006). The combination of these 
developmental biological neurochemical abnormalities underlies the behavioural 
deficits described in the next section. 
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5.1.3 Innate and behavioural flexibility deficits in MAM-treated rats 
Locomotor activity (LMA) is a highly sensitive to neurochemical 
phenotypes (reviewed in Chapter 4). Basal LMA in MAM-treated rats is elevated 
compared to controls consistent with a hyperactive dopamine system (Le Pen et 
al., 2006; Lodge and Grace, 2007; Ratajczak et al., 2015). Hyper-sensitivity of both 
the dopaminergic and glutamatergic systems is also found in MAM-treated rats as 
they show greater increases in LMA following treatment with either amphetamine 
(Flagstad et al., 2004; Perez et al., 2013; Chen et al., 2014), the D2/3R agonist 
quinpirole (Perez and Lodge, 2012), or NMDAR antagonists PCP (Moore et al., 
2006; Penschuck et al., 2006), ketamine (Phillips et al., 2012), and MK-801 (Lena 
et al., 2007). Although one publication failed to find MK-801-induced 
hyperlocomotion in MAM-treated rats, that may be due to strain differences as 
the experiment used Wistar rats (Goda et al., 2015) compared to the more 
commonly used Sprague-Dawley MAM-treated rats (Lena et al.). 
 MAM-treated rats also exhibit ‘schizophrenia-related’ symptoms in other 
tests of innate behaviour. Of these, the most regularly reported is a deficit in the 
PPI response, where MAM-treated rats are found to have a greater startle 
response to the auditory stimulus than controls (Le Pen et al., 2006; Moore et al., 
2006; Mackowiak et al., 2014). A deficit in latent inhibition (measured by 
conditioned stimulus-induced LMA changes) has also been reported for MAM-
treated rats (Lodge et al., 2009).   
 Schizophrenia symptoms normally emerge post-puberty, with few 
significant differences between adolescents who develop the disorder and 
adolescents who do not. The MAM manipulation also replicates this delayed 
emergence of symptoms in that certain behavioural deficits appear pre-puberty, 
for example, reduced social interaction time and increased LMA (Le Pen et al., 
2006), and reduced spontaneous alternation (Hazane et al., 2009). Additional 
behavioural deficits are evident in adult MAM-treated rats, such as the PPI deficit 
(Le Pen et al.; Hazane et al.; Mackowiak et al., 2014). Furthermore, the deficits are 
not limited to male MAM-treated rats. Despite a male bias for development of 
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schizophrenia (Tandon et al., 2008) either sex can develop the disorder. Hazane et 
al., reported that female MAM-treated rats also display select ‘schizophrenia-
related’ phenotypes pre-puberty and with the full array of behavioural deficits 
emerging in adulthood, suggesting that the MAM-manipulation may also serve for 
translation of schizophrenia in female patients. 
Of the available ‘animal manipulations with relevance to schizophrenia’, 
the MAM-manipulation is consistently reported to have the most ‘schizophrenia-
related’ deficits in the ASST. The first report by Featherstone et al. (2007), showed 
that MAM-treated rats had deficits at both reversal stages (REV 1 and REV 3) and 
the ED stage. These findings were mostly replicated by (Gastambide et al., 2012) 
and Perez et al. (2013), who both report deficits at REV 1, REV 2, and the ED. Most 
recently however, Gomes et al. (2015) found deficits at all reversal stages but no 
difference between MAM-treated and control rats at the ED stage.  
5.1.4 MAM-based translational evidence for schizophrenia treatments 
Many pharmacotherapies, already in use for human patients with 
psychosis, are also effective at treating ‘schizophrenia-related’ phenotypes in 
MAM-treated rats. Specifically, D2R antagonists such as haloperidol and sertindole 
can acutely reduce dopaminergic neuron activity in the VTA of MAM-treated rats 
but not controls, reflective of the fast actions of antipsychotics in schizophrenia 
patients (Valenti et al., 2011). Behaviourally, acute treatment with haloperidol, 
risperidone, and clozapine, have been shown to attenuate spontaneous, and MK-
801-induced, hyperactivity in MAM-treated rats (Le Pen et al., 2011).  
A primary purpose of a preclinical animal manipulation is to test potential 
treatments for the disorder the manipulation recapitulates, many studies have 
been done with MAM-treated rats to explore putative therapies. To this end, the 
MAM-manipulation has generated some interesting discoveries. Diazepam, a 
GABAA receptor PAM,  has been found to enhance GABAergic neurotransmission 
in MAM-treated rats after sub-chronic administration during the puberty stage of 
development (PND 31 - 40), resulting in normal VTA dopamine neuron activity, 
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and amphetamine induced hyperlocomotion, when assayed in adulthood (PND 60 
- 80; Du and Grace, 2013)). Recently, this approach was extended to MAM-treated 
rat amygdala hyperactivity with a similarly positive result of attenuated neuronal 
activity and reduced measures of anxiety in the elevated plus maze (Du and Grace, 
2016). A common adjunct treatment for schizophrenia, valproic acid, has also 
been shown to be effective at reducing ‘schizophrenia-related’ phenotypes (PPI 
and histone deacetylase 2 expression) in MAM-treated rats when administered in 
early adolescence (PND 23 – 29) or in adulthood (Bator et al., 2015). Interestingly, 
a study utilizing a combination of forward and reverse translation, found that a 
history of chronic D2R antagonists treatment in MAM-treated rats resulted in a 
blunted response to selective enhancement of GABAAα5 receptors (Gill et al., 
2014), a finding with powerful implications for treatment approaches in 
schizophrenia patients.  
MAM-based studies on enhancement of GABAergic signalling have also 
found that acute treatment with an α5-GABAR PAM also reduces the hyperactivity 
of dopaminergic neurons and amphetamine induced hyperlocomotion (Gill et al., 
2011). The authors of the study were also able to show that increasing inhibitory 
activity within the ventral hippocampus via local administration of the PAM had 
the same effect, indicating ventral hippocampus hyperactivity as a primary target 
for therapeutics. Additional studies with local administration of tetrodotoxin 
(Lodge and Grace, 2007), GABAergic interneuron cell grafts (Perez and Lodge, 
2013), and deep brain stimulation (Perez et al., 2013), targeted to the ventral 
hippocampus, also proved therapeutic for hyperdopaminergic activity in MAM-
treated rats.  
5.2 Rationale 
The empirical evidence supporting the MAM-manipulation is compelling. 
While, D2R antagonists have proven effective at treating the positive symptoms 
associated with the disorder, novel pharmacotherapies are required to reduce the 
cognitive deficits (Conn et al., 2009). A 2007 clinical trial found that patients with 
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schizophrenia had reduced positive and negative symptoms in response to a 
glutamatergic pharmacotherapy (Patil et al., 2007). Indeed, Gastambide et al. 
(2012) found that enhancement of glutamatergic signalling via an mGluR5 PAM 
normalised the ASST reversal learning performance in MAM-treated rats. 
Unfortunately, the compound used in the study was unfit for long-term human 
consumption. However, the potential for glutamatergic enhancement of ASST 
performance in MAM-treated rats (and hopefully eventually patients) drove the 
studies in this experimental chapter.  
The NMDAR PAM ORG49209 is a synthetic steroid which our lab has 
preliminary evidence supporting it as putative cognitive normaliser (Chase 
dissertation 2013). With the discovery of novel steroid binding sites and steroid-
mediated regulation of NMDARs (Park-Chung et al., 1997; Paul et al., 2013), 
interest has emerged in directly targeting NMDARs via synthetic derivatives of 
these compounds. The cholesterol metabolite 24 (S)-hydroxycholesterol is an 
endogenous neuroactive steroid which has its own allosteric NMDAR binding site. 
24 (S)-hydroxycholesterol can potently enhance NMDAR-mediated Ca2+ influx as 
measured by increased NMDA-stimulated excitatory postsynaptic currents 
(EPSCs) in cultured mouse hippocampal neurons (Paul et al.). Derived from 24 (S)-
hydroxycholesterol, the synthetic neurosteroid ORG49209 (SGE201) also 
enhances NMDAR activity as measured by increased EPSCs, in addition to 
enhanced high frequency stimulation-induced long-term potentiation in rat 
hippocampal slices (Paul et al.). Experiments from our lab found that 15 days of 
treatment with 10 mg/kg ORG49209 improved reversal learning performance in 
aged rats (12 - 18 months old; Chase, 2013). Since ORG49209 directly targets the 
NMDAR, it is of interest to discover if the compound may be effective at 
ameliorating ‘schizophrenia-related’ behaviours. The aims of this chapter were to: 
1) replicate previous findings of reversal learning and set-shifting deficits in MAM-
treated rats, and 2) to explore the potential for ORG49209 to normalise any 
deficits found.  
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5.3 Methods and materials 
5.3.1 Animals 
Male Sprague Dawley rats exposed to MAM (22 mg/kg/ml) or saline vehicle 
on gestational day 17 were obtained from (Lilly, Wokingham, UK). A total of 28 
male rats were obtained (control = 14, MAM = 14). Rats were housed in standard 
housing conditions (two to three per cage, 0700 - 1900 hr light phase, controlled 
temperature and humidity, and ad libitum water). Animals were at least 5 months 
old at the beginning of behavioural testing. One month prior to behavioural testing 
rats were placed on a food control regimen of 15 - 20 g per day, to increase their 
motivation to work for food reward. All animals continued to gain weight at a 
normal rate and were handled during weighing and general husbandry 
procedures.  
5.3.2 Baseline 7-Stage ASST testing 
 Training and testing were performed as described in Chapter 2: General 
Methods however, following acquisition of the digging for reward response, the 
rats were ‘pre-exposed’ to stimuli that would be used in the task. All odours that 
were to be tested were presented mixed in with sawdust. Medium exemplars to 
be tested were presented without any additional odour. Rats were allowed to 
retrieve rewards from both to-be-tested exemplars on all trials (i.e. no 
discriminations were made). Pre-exposure continued until rats were reliably 
digging in both exemplars (typically two trials). Presentation order of exemplars 
was counterbalanced pseudorandomly. This pre-exposure was performed 
following attempted testing of two rats which exhibited abnormally long latencies 
to dig following presentation of novel exemplars (neophobia), which significantly 
disrupted testing. Following pre-exposure, all testing proceeded as normal. All rats 
completed the pre-exposure and training stage however, three control and five 
MAM-treated rats were unable to complete the entire battery of tests as they did 
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not reliably dig and thus were excluded from further experiments. All rats were 
tested twice to increase statistical power. 
5.3.3 ORG49209 ASST testing 
 Each rat was tested a total of three times in the standard ASST to assess 
the effects of ORG49209 on ASST performance. A Latin square design was used to 
analyse vehicle (10% hydroxypropyl beta-cyclodextrin; HPBCD, Sigma, UK) and two 
doses (3 & 10 mg/kg/ml in solution in 10% HPBCD) of the NMDA receptor PAM 
ORG49209. Prior to injection, ORG49209 was sonicated in vehicle for 30 min. All 
injections were administered i.p. 30 min prior to behavioural testing.  
5.3.4 4-ID testing 
 The 4-ID task (Chase et al., 2012) allows investigation of set-
formation/shifting in the absence of reversal stage. The first stage is an SD with 
the correct stimulus being either an odour or medium exemplar; next is a CD in 
which the correct stimulus from the SD is now paired with stimuli from an 
irrelevant dimension; then ID 1 in which the correct stimulus remains within the 
same dimension as the correct stimulus from the CD, however all new stimulus 
pairs are presented. Each of the next three stages (ID 2, ID 3, ID 4), repeat this 
process of presenting new stimulus pairs but maintaining the correct stimulus 
within the same dimension. Next, the rat performs an ED in which the correct 
stimulus is now switched to an exemplar from the previously irrelevant dimension. 
Last, the rats are presented with the SD again to control for effects at the ED stage 
being caused by fatigue and/or satiety. This testing was performed, blind to 
condition, by lab member Rudi Stanislaus-Carter. 
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5.4 Results  
5.4.1 MAM-treated rats have a deficit at REV 1 of the standard ASST 
 Analysis of TTC in the first and second tests, revealed a significant 
Condition x Stage interaction (F(1, 6) = 3.65,  p < 0.05; Figure 5.1). Restricted analysis 
revealed a REV 1 impairment in MAM-treated rats compared to controls (F(1,108) = 
 
Figure 5.1) Left. Bar graph showing mean TTC (+ SEM) for the standard ASST. 
Compared to control rats, MAM-treated rats required more TTC for REV 1. 
Right. Analysis of the errors committed during the ASST revealed that MAM-
treated rats committed more errors during REV 1. 
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28.83, p < 0.05). No other significant differences were found at any other stage. 
Although there was a significant effect of Test (F(1, 18) = 12.32, p < 0.05) evidenced 
by more overall TTC in the second test compared to the first, it did not significantly 
interact with any other factor indicating the effect of test was the same across all 
stages and conditions (Test x Condition x Stage, Test x Stage interaction, and Test 
x Condition interactions, Fs < 1).  
 To compare these results to a previously published report (Gastambide et 
al., 2012), errors to criterion were also analysed. Consistent with the TTC 
measurement, a significant Condition x Stage interaction was found (F(1,6) = 2.43, 
p < 0.05). Restricted analysis revealed that MAM-treated rats committed more 
errors at REV 1 compared to controls (F(1, 108) = 15, p < 0.05; Figure 5.1). No other 
stage significant differences were found. Further analysis qualifying the errors 
committed at this stage as perseverative or regressive (Gastambide et al., 2012), 
did not yield any significant differences between the types of errors committed by 
MAM-treated rats and controls.  
5.4.2 MAM-treated have increased evidence for irrelevant dimension-based 
responding 
 Compared to control rats, there was more evidence for MAM-treated rats 
responding to the irrelevant dimension across all stages (heatmap in Figure 5.2; 
for Bayesian analysis description see Chapter 2: General Methods). The bar graph 
in Figure 5.2 shows the overall difference in evidence for spatial- vs irrelevant 
dimension based responding between groups. Whereas control rats more 
quartiles with strong evidence for spatial-based responding (total quartiles = 5) 
compared to irrelevant dimension responding (total quartiles = 3), MAM-treated 
rats showed the opposite behavioural pattern with less evidence of spatial based 
responding (total quartiles = 3), in favour of more irrelevant dimension responding 
(total quartiles = 7). This increased evidence for irrelevant dimension responding 
(compared to controls) occurred at stages of interest including: REV 1, REV 2, and 
the ED.  
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Figure 5.2. Top. Heatmap of evidence for behavioural patterns during the 
standard ASST. Compared to controls, MAM-treated rats show more evidence 
for irrelevant dimension responding (REV 1, REV 2, and the ED), as well as 
perseveration during REV 3.  Bottom left. Table showing sum number of 
quartiles by stage for irrelevant dimension-based responding by group. MAM-
treated rats showed more irrelevant dimension-based responding than 
control rats. Bottom right. Bar graph showing sum number of quartiles with 
strong evidence for spatial- or irrelevant dimension-based responding in 
control and neonatal-PCP-treated rats. 
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5.4.3 No evidence of a MAM-induced ED deficit in the 4 ID task 
To further examine the lack of increased TTC at the ED shift in MAM-
treated rats, the rats were tested in the 4-ID version of the ASST. The 4-ID task 
removes a potential confound caused by the effect of reversal impairments on set-
formation (Chase et al 2012). There are no reversal stages and the original set 
dimension (odour or medium) is maintained for the first 6 of 8 stages. Even in this 
test however, MAM-treated rats still did not have an ED shift deficit compared to 
controls (Condition x Stage interaction: F(1,7) < 1; Figure 5.3). Both control and 
MAM-treated rats formed an attentional set as indicated by increased TTC to 
complete the ED stage compared to the previous ID (main effect of Stage: F(7, 119) 




Figure 5.3. Bar graph showing mean TTC (+ SEM) for the 4-ID ASST. No 
significant differences were found between groups. Both control and MAM-
treated rats, required more trials for the ED than the previous ID. 
Chapter 5. Effects of Gestational Methylazoxymethanol Acetate (MAM)-treatment on 
Attentional Set-Shifting Task Performance 
131 
 
5.4.4 ORG49209 effect on REV 1 performance in controls and MAM-treated rats 
The effect of ORG49209 at REV 1 was of most interest, as this was the stage 
that was impaired in the MAM-treated rats in the baseline tests. An effect of 
ORG49209 was to abolish the difference between the conditions at REV 1. 
However, the effect of the drug was apparent in both conditions: a slight decrease 
in TTC for the MAM-treated rats and an increase in TTC for control rats which 
 
 
Figure 5.4. Top. Bar graph showing mean TTC (+ SEM) following treatment 
with 0, 3, or 10 mg/kg ORG49209. Treatment with ORG49209 did not produce 
any clear overall between group effects on ASST performance across stages. 
ANOVA restricted to REV1 confirmed that when vehicle treated, controls still 
required fewer TTC than MAM-treated rats. Bottom. Line graphs showing the 
effects of ORG49209 on mean (± SEM) for TTC (left) and errors (right). A 
pattern of disrupting performance in controls and improving performance in 
MAM-treated rats during REV 1 was only trend level (p = .07).  
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approached but did not reach significance (REV 1: restricted ANOVA, Dose x 
Condition interaction: F(1, 2) = 3.53, p = 0.07; Figure 5.4). ORG49209 appeared drive 
an increase in TTC for controls, reflected by a slight increase in response to 3 mg/kg 
(mean TTC increase: + 4 (± 3)); and a large increase following treatment with 10 
mg/kg (mean TTC increase: + 7.5 (± 2.5)). Whereas the effect in MAM-treated rats 
was ~ 3 TTC less regardless of dose and did not reach control vehicle performance 
(line graphs in Figure 5.4).  
5.5 Discussion 
5.5.1 Reversal learning impairment in MAM-treated rats 
Consistent with all previous reports (Featherstone et al., 2007; Gastambide 
et al., 2012; Perez et al., 2013; Gomes et al., 2015), MAM-treated rats displayed 
marked impairments in REV 1 (Figure 5.1). The REV 1 MAM deficit was the largest 
in magnitude in that report, while the REV 2 and ED deficits were reduced (albeit 
significantly worse than controls). Another recent report also found the largest 
magnitude deficit at REV 1 (Gomes et al., 2015). Therefore, replicating the REV 1 
deficit here is unsurprising, and suggests that any other deficits may be less robust. 
However, the earliest ASST MAM report had the largest magnitude differences at 
the ED and REV 3, and not REV 1 (Featherstone et al.). It should be noted that 
Featherstone et al., used a texture/fabric around the rim of the bowl which can 
dissociate the reward (located in the bowl) from the discriminanda (texture). A 
more through critique of a similar design (odours placed around the rim), has been 
discussed in Chapter 4 in regards to neonatal-PCP-treated rats.  
5.5.2 Irrelevant dimension responding and perseveration in MAM-treated rats 
 Gastambide et al. (2012) reported perseveration in MAM-treated rats, as 
measured by “digging in the incorrect bowl for 3 or more trials in consecutive 
blocks of 4 trials each”.  An attempt to replicate these findings with REV 1 and REV 
3 errors here, did not reveal any significant differences between the conditions. 
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Overall, the rats made few errors and so there were possibly floor effects that 
would compromise further analysis of this measure. The behavioural pattern 
analysis did however indicate strong evidence of perseveration (as responding to 
the previously correct stimulus) in MAM-treated rats during the first quartile of 
REV 3. Furthermore, the analysis found increased irrelevant dimension responding 
(and reduced spatial-based responding) in MAM-treated rats compared to 
controls, suggesting abnormal decision making behaviour in MAM-treated rats. As 
perseveration and dysfunctional regulation of attention are two hallmark 
schizophrenia symptoms, these behavioural findings support the ‘schizophrenia-
related’ behaviour of the MAM-treated rats, despite the TTC and errors analysis 
not being as robust as previous reports.  
5.5.3 Protocol based explanations for failures to replicate  
We hypothesise the small number of errors, particularly as compared to 
Gastambide, et al., (2012) may be due to differences in the testing protocols (e.g. 
the Brown lab protocol allows 10 min for exploration per trial, while the previous 
report allowed 3 min). Our statistical analysis of TTC revealed MAM-induced 
impairments at REV 1 with no significant differences in other stages. This varies 
slightly from the impairments in REV 1 & REV 2, as well as at the ED stage, reported 
previously by Gastambide et al. Additionally, our results differ slightly from the 
REV 1, REV 3, and ED impairments reported by Featherstone, et al. (2007). 
Addressing the ED impairments in Featherstone et al., one may hypothesise that 
the use of ‘texture’ as opposed to medium (i.e. sand paper wrapped around the 
bowl, as opposed to our use of sand as the digging medium), is an explanation for 
these differences. However, Gastambide et al., reported ED impairments in MAM-
treated rats using, digging medium as a dimension. Thus, it would appear that the 
texture vs medium argument does not explain the lack of an ED impairment in our 
MAM-treated rats. It is also possible that the ED impairment is only evident 
following a history of stress. Both of the previous attentional set-shifting reports 
in MAM-treated rats (Featherstone et al.; Gastambide et al.) utilised much stricter 
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food control regimens than those employed by our lab; our rats were fed 15 - 20 
g per day, a diet which allows steady weight gain, whilst in the previous two studies 
rats were food restricted up to 85% of their original body weight. It is possible that 
MAM-treated rats which are known to have abnormal weight gain through PND 
90 (Flagstad et al., 2004), a deficit which has also been evidenced in our rats (PND 
74 MAM-treated rats had reduced body mass at the start of food restriction; a 
consistent 4-5% reduction was recorded), may have an exacerbated response to 
the food restriction employed by the previous reports, and that this response 
manifested as the ED. Chronic psychological stress has been shown to selectively 
impair ED performance in rats (Bondi et al., 2008; Naegeli et al., 2013). However, 
Gomes et al. (2015) also food restricted to 85% body weight and did not find an 
ED deficit in MAM-treated rats. Last, it also possible that there is batch-to-batch 
variability in MAM-treated rats underlies the lack of an ED impairment in our 
report. Additional concerns regarding variability in developmental manipulations 
are discussed in the general conclusions section. 
5.5.4 ORG49209 failed to improve REV 1 performance in MAM-treated rats 
 Treatment with ORG49209 yielded interesting, albeit confusing, results. 
While the treatment abolished the REV 1 difference between control and MAM-
treated rats, this was accomplished by raising the TTC in control rats and slightly 
lowering TTC in MAM-treated rats suggesting that the drug may be detrimental to 
control rats as well as therapeutic for MAM-treated rats. However, the findings 
were not statistically robust enough to support either of these hypotheses. 
Outside of REV 1 the drug had no obvious effect in control rats suggesting that 
there is something inherently unique and (perhaps demanding) about REV 1 that 
makes this stage sensitive to interventions. Other reports have also shown select 
deficits at only REV 1 (Lapiz-Bluhm et al., 2009; Donegan et al., 2014), and when 
deficits arise across different stages in multiple reports, the REV 1 impairment is 
often the most consistent (Featherstone et al., 2007; Gastambide et al., 2012; 
Perez et al., 2013; Gomes et al., 2015).  
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5.6 Histological analysis of MAM-treated rats 
Rationale 
MAM-treated rats are reported to have numerous anatomical and 
histological abnormalities. To verify these differences within our cohort, I decided 
to examine post-mortem brain tissue for size and dimensions, and to stain brain 
sections for cresyl violet and PV. Cresyl violet stains acidic parts of cells such as 
ribosomes and rough endoplasmic reticulum, allowing for visualisation of cell layer 
structure, which is commonly reported as abnormal in schizophrenia. Additionally, 
PV-expression is commonly reported as abnormal, thus these two stains were 
used to visual the mPFC, OFC, and hippocampus of MAM-treated rats and controls. 
5.7 Methods and materials 
PV immunostaining was performed as described in General Methods 
(Chapter 2). For cresyl violet staining every 4th section of the frontal cortex was 
collected, and every 8th section of the striatum through to the hippocampus. 
Sections (50 μm thick) were mounted onto treated glass slides, and left for 48 hrs 
in a formaldehyde desiccator. Once sections were fixed to the slides they were 
dipped in a xylene bath for 2 min, followed by a 100% ethanol (EtOH) bath for 2 
min, a 50% EtOH bath (diluted in H20) for 1 min, and then an H2O bath for 2 min, 
before being placed in a cresyl violet bath for 2 min. Next slides were washed in a 
running water bath for 5 min. Then differentiated through ascending 
concentration EtOH baths (50% - 100% - 100%), before being placed in a xylene 
bath and coverslipped with DPX (Sigma). One brain was excluded from analysis 
due to a faulty dissection. For both cresyl and parvalbumin Image J analyses 7-10 
sections per brain were used for the PFC and 3-4 for the hippocampus, see Chapter 
2 General Methods. 
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5.8.1 MAM-treated rats exhibit abnormal brain and body weights 
Body weights prior to the start of food control were 7% lower in MAM-
treated rats compared to controls (t(18) = 2.11, p < 0.05; Figure 5.5). For the first 
month of food control, MAM-treated rats showed reduced weight gain compared 
to controls (Condition x Week interaction: F(1, 3) = 2.81, p < 0.05). However, over 
the full course of the experiments (42 weeks), MAM-treated rats eventually 
reached and maintained equivalent weights as controls (Figure 5.5). Following 
behavioural experiments, rats were anaesthetised and perfused for anatomy and 
histology. Brains were dissected out and the brain stem and cerebellum were 
removed to eliminate the variability generated through differences in dissection. 
Compared to controls, MAM-treated rats displayed a consistent and robust 
reduction in brain weight of ~181 mg (mean MAM (n = 9) = 949 mg, ± 14.31, 
controls (n = 11) = 1143 mg, ± 25.45; t(18) = 6.27, p < 0.05; Figure 5.5). 
 
Figure 5.5) Left. Line graph showing mean body weight through weeks of 
experiments. MAM-treated rats showed an initial reduction in body weight 
compared to controls, however this difference was abolished over the course 
of experiments and both groups gained weight as normal. Right. Despite no 
difference in body weight, post-mortem brain weight was significantly 
reduced in MAM-treated rats.  
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5.8.2 Gross observation reveals schizophrenia-related anatomy in MAM-treated 
rats  
 Given the reduction in brain weight in MAM-treated rats, the areas of 
regions of interest were calculated using cresyl violet stained sections. Gross 
observation also revealed enlargement of the lateral ventral ventricles in all MAM-
treated rats compared to controls (Figure 5.6). Furthermore, the areas of all  
 
 
Figure 5.6) Representative cresyl violet stained mPFC and OFC sections in 
controls. Bottom. Mean (+ SEM) total area (approximate distance from 
Bregma: 4.7 mm – 2.7 mm). MAM-treatment induced robust reductions in 
the size of both the mPFC and the OFC  
Control
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Figure 5.6 continued) Top. Representative cresyl violet stained mPFC and OFC 
sections from MAM-treated rats. Bottom. Mean (+ SEM) total area 
(approximate distance from Bregma: 4.7 mm – 2.7 mm). MAM-treatment 



















Control (n = 11)
MAM (n = 8)
*
*
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regions of interest were significantly smaller in MAM-treated rats compared to 
controls PFC (bar graph in Figure 5.6; mPFC, F(1,17) = 4.49, p < 0.05; OFC, F(1,17) = 
4.83, p < 0.05), and the hippocampus (CA1, F(1,17) = 14.87, p < 0.05; CA2/3, F(1,17) = 
84.97, p < 0.05; DG, F(1,17) = 34.45, p < 0.05). Additional disruption of cell layering 




Figure 5.7) Representative cresyl violet stained striatal sections in controls 
(top) and MAM-treated rats (bottom). Lateral ventricle enlargement (red 
arrows) was evident at the level of the striatum in all MAM-treated rats. 
Control
MAM-treated
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Figure 5.7 continued) Representative cresyl violet stained hippocampal; 
sections in controls (top) and MAM-treated rats (bottom). Lateral ventricle 
(red arrows) enlargement was evident in all MAM-treated rats. 
Control
MAM-treated
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5.8.3 Parvalbumin expression is altered in the hippocampus but not mPFC of 
MAM-treated rats 
 PFC analysis 
 Analysis of PV-expressing interneurons in the mPFC  revealed no significant 
differences in either total number of PV-expressing cells (F(1,17) = 2.03, ns), or 
density of PV-expressing cells (F(1,17) = 1.3, ns). Analysis of the OFC also revealed 
no significant differences in total number of PV-expressing cells (F(1,17) < 1), or 
density of PV-expressing cells (F(1,17) < 1). 
 Hippocampus analysis 
 As no significant differences were found in the mPFC or OFC, I next 
analysed the PV-immunoreactivity in the hippocampus. The total number of PV-
expressing cells was significantly less in the dentate gyrus (DG; F(1,17)  = 10.89, p < 
0.05), but not within CA1 (F(1,17)  < 1) or CA2/3 (F(1,17)  < 1, ns). The density of PV-
expressing neurons was significantly higher in CA2/3 (F(1,17)  = 9.32, p < 0.05), and 
the DG (F(1,17)  = 6.5, p < 0.05), but not within CA1 (F(1,17)  = 1.17, ns). 
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Figure 5.8) Representative PV stained PFC sections. Top right. Mean (+ SEM) 
PV-expressing cells (approximate distance from Bregma: 4.7 mm – 2.7 mm). 
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Figure 5.8) Representative PV-stained hippocampal sections. MAM-treatment 
increased the density of PV-expressing neurons in the CA2/3 region, while 
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5.9.1 Failure to replicate reduced parvalbumin expression within the PFC 
The lack of robust attentional set-shifting deficits in MAM-treated rats 
suggest that the cohort tested in this thesis lacked the biological phenotype to 
induce the previously reported ID/ED deficits. The anatomy and histology analysis 
is consistent with this rationale. Gross observation of brain sections suggested that 
the largest anatomical abnormalities were manifested in the striatum (abnormally 
rostral localisation of the lateral ventricles) and the hippocampus (microcephaly 
and disarray of hippocampal cell layers). Specific observation of the mPFC 
suggested that this region was intact and spared from the effects of the toxin. 
Despite the overall reduction in the size of the mPFC and OFC no significant 
differences were found in PV-expressing neurons. However, in the hippocampus 
formation both significant reductions in size, and PV-expressing neurons were 
discovered suggesting that this region was most affected by the MAM-treatment. 
We cannot rule out alternative histology methodology as a cause for our 
findings differing from previous studies. While Gastambide et al. (2012), reported 
a reduction in PV-expressing cells in the mPFC and OFC, Penschuck et al. (2006), 
reported no significant difference in PV-expressing cell counts in the mPFC but 
significant differences in hippocampus cell counts. Lodge et al. (2009), also reports 
PV reduction in mPFC and in the ventral subiculum. Gastambide et al., used 
paraffin embedded 6 µm sections, an antigen retrieval step with 100o C citrate 
buffer, a different brand of anti-PV primary antibody (Swant), and cells were 
counted with the ImageScope software, which allowed for the determination of 
density through all three dimensions (volumetric density analysis). Lodge et al. 
used the same thickness for brain sections, however they also used a different 
anti-PV primary antibody (Swant), and method for cell counting (z-stack collapsed 
sampling). Penschuck et al., did not find significant differences in the mPFC, 
although the authors reported using the same anti-PV primary antibody, and 
similar tissue thickness (40 µm). However, despite these differences in 
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methodology it is still possible that batch-to-batch variability accounts for the 
differences in findings.  
5.9.2 MAM treatment primarily affects the hippocampus 
Despite the few behavioural differences between control and MAM-
treated rats, anatomical and histological experiments revealed severe 
abnormalities in the brains of MAM-treated rats.  The brains of MAM-treated rats 
consistently displayed neuroanatomical pathologies that mirror those found in 
patients with schizophrenia. We confirmed previous reports of reductions in gross 
brain weight, hippocampal, prefrontal microcephaly, enlargement of the lateral 
ventricles, CA 2/3 cell layer disarray, and reduction PV-expressing interneurons 
within the DG. However, the failure to replicate the PV-expressing interneuron 
reduction within the mPFC or OFC, suggest that our assessment of cognitive 
flexibility in the ASST may have failed to replicate previous reports due to an 
incomplete replication of the MAM biology. 
From the data presented here, it would appear that the ability of the MAM 
treatment to induce ‘schizophrenia-related’ biological abnormalities may be 
limited to only reliably affecting the hippocampal formation. Proteomic and 
metabonomic analysis of MAM-treated rats found that the primarily affected area 
was the hippocampus glutamatergic signalling, and not the mPFC (Hradetzky et 
al., 2012). If the mPFC abnormalities and subsequent mPFC-dependent 
behavioural deficits are downstream of the MAM treatment altering the 
hippocampus then it is probable that not all cohorts of MAM-treated rats have the 
same second-order mPFC effects, perhaps due to biological compensation during 
development. Recently, it has been reported that variation in the pregnant dams’ 
response (indicated by weight gain or weight loss) to the toxin polyinosinic: 
polycytidylic acid (Poly I:C) can differentially determine the behavioural deficits in 
the offspring (Missault et al., 2014). Behavioural deficits are reflective of 
alterations in the underlying neurocircuitry, such that performance in the ASST 
reversal stages reflects OFC functionality (Chase et al., 2012; although there is also 
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a role for the oFC in set-formation), and performance in the ID/ED shift reflects 
mPFC functionality (Birrell and Brown, 2000). Thus, if the desired behavioural 
deficits do not manifest following the manipulation the assumption can be made 
that the targeted area was not sufficiently disrupted. This appears to the case with 
our MAM-treated rats. Furthermore, MAM-treated rats rarely present with the 
full range of cognitive deficits, despite almost each cohort having the 
‘schizophrenia-related’ biological phenotype (Hugh Marston, SFN Symposium, 
2014). The reports in the literature regarding the deficits in the ASST may likely be 
a reflection of selective reporting, rather than a statement of a consistent and 
robust behavioural phenotype resulting from MAM treatment.  
Consistent with the hypothesis that MAM treatment affects hippocampal 
development more consistently and robustly than it does mPFC development, 
other schizophrenia-related manipulations which target gestational day 15 - 17 
also largely report hippocampal disruptions (Dickerson et al., 2014; Zhang and van 
Praag, 2014) and to a lesser extent mPFC disruptions (Wischhof et al., 2015). 
Indeed, it may be possible that the hippocampal alterations reported contributed 
to the REV 1 impairment reported here. PV-expressing neurons within the DG have 
been reported to be involved in an odour discrimination digging task. Morellini et 
al. (2010) reported that mice with increased inhibitory signalling (by ablation of 
tenascin-R glycoprotein) within the DG performed better in an odour-based 
digging reversal task as indicated by reduced latency to choose the correct stimuli 
and increased numbers of correct approaches to the relevant and rewarded 
stimuli. Lesions to the DG are known to disrupt spatial working memory. Jeltsch et 
al. (2001) reported that bilateral colchicine-induced lesions of the DG resulted in 
impairments in the radial arm maze task as measured by increased visits to 
previously visited correct arms and previously visited incorrect arms. Hernandez-
Rabaza et al. (2007) found that similar lesions impaired performance in a spatial-
tactile T-maze working memory task. Tying in both the wide reports of 
hippocampal dysregulation in rats with relevance for schizophrenia, and the role 
of the DG in reversal learning, Savanthrapadian et al. (2013) reported that Poly I:C 
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rats had increased LTP within the DG as well as impaired reversal learning 
measured as increased time spent in the previously rewarded arm during a plus 
maze task. Performance of the rats however improved as the task progressed and 
was identical to that of controls. Given the reduction in evidence for spatial 
pattern based responding in MAM-treated rats it is possible that impaired 
hippocampus-dependent spatial processing leads to their increased irrelevant 
dimension based behavioural pattern. 
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Attentional regulation is integral in navigating a changing environment. 
Unfortunately, persons with schizophrenia suffer from deficits in attentional 
regulation which impairs their cognition and subsequent quality of life. The three 
empirical chapters in this thesis were designed to explore attentional regulation 
in three rat manipulations with relevance to schizophrenia. The findings 
indicated that during goal-directed behaviour, a primary cause of deficits in 
extradimensional set-shifting and reversal learning is a deficit in sensory gating 
resulting in abnormal learning of irrelevant stimuli. I posit that these data 
support theories which implicate dl/mPFC working memory biasing of attention 
as the core of the cognitive deficits in schizophrenia. Furthermore, the data here 
indicate that normal mPFC function mediates prediction error signals such that 
only relevant stimuli gain associative strength, whereas mPFC dysfunction causes 
loss of sensory gating, and non-selective prediction errors to guide learning and 
behaviour.  
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6.1 Experimental summary 
 The experiments in this thesis focused on attentional regulation in rats 
following manipulations with relevance for schizophrenia. The manipulations 
involved targeted disruption at three distinct developmental periods (gestational, 
neonatal, or adulthood). The primary measures of attentional regulation were 
performance at the reversal and ED stages of the ASST, stages where patients with 
schizophrenia perform poorly. As described in Chapter 1: Introduction, patients 
with schizophrenia have remained wanting for treatment of the cognitive deficits 
induced by the disorder. The aims of the thesis were two-fold: 1) validate ASST 
deficits in neurodevelopmental manipulations with relevance to schizophrenia 
(neonatal-PCP and MAM), and subsequently explore putative pharmacotherapies 
for those deficits; and 2) across all three manipulations (mPFCin-, neonatal-PCP-
treated, and MAM-treated rats) determine the underlying neurobiological and 
psychological mechanisms for any deficits evidenced, thus increasing knowledge 
on the potential nature of deficits in patients and provide new target mechanisms 
for treatments. 
 In Chapter 3, findings from acute mPFCin revealed that an apparent deficit 
in set-shifting may arise from enhanced learned irrelevance (due to deficient 
sensory gating), rather than perseveration alone. While it had previously be shown 
that acute manipulations resulting in mPFC-hypofunction induced a robust deficit 
at the ED stage, the experiments here replicated that finding and expanded it to 
explore the nature of the ED deficit through the use of two modified ASSTs. The 
modifications allowed comparisons to be made to findings on the role of the mPFC 
in sensory gating, primarily the role of the mPFC in the attenuation of attention to 
irrelevant stimuli within the environment. From the results, the conclusion can be 
drawn that rather than ‘cognitive flexibility’ in general being impaired in mPFCin 
rats, there is an inability to regulate attention through mPFC processes (likely 
dopamine mediated), which induces a state where mPFCin rats learn equally about 
relevant and irrelevant dimension stimuli, producing what appears under different 
conditions as both behavioural flexibility and inflexibility. Furthermore, the results 
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suggest that the apparent contradictory evidence that mPFC-hypofunction 
induces a deficit in sensory gating, although the same manipulations do not impair 
formation of attentional set, may be due to the double dissociation between the 
mPFC and OFC, with the latter being more responsible for set-formation, and the 
former being more involved in the regulation of attention. 
 The experiments in Chapter 4, with neonatal-PCP-treated rats also 
supported findings that mPFC-hypofunction induces a deficit in attentional 
regulation that manifests as an ED deficit. While the standard ASST results failed 
to meet statistical significance, this conclusion can be drawn from the results 
generated from the ASST-MSS. Additional validation for the mPFC-hypofunction 
aetiology of the ED deficit was provided by deficits in the 24-hour delay NOR task, 
as well as histological confirmation of reduced PV-expression within the mPFC of 
neonatal-PCP-treated rats.  
 The last experiments presented in Chapter 5, explored ASST performance 
in MAM-treated rats, and while evidence was found for a reversal learning 
impairment, at the first reversal stage (REV 1), the data failed to replicate previous 
reports of deficits across several reversal learning stages and, critically, the ED. The 
failure to find an ED deficit was not limited to the standard task alone, as MAM-
treated rats were also tested in a multiple ID ASST which measures set-formation 
and set-shifting without potential interference from reversal stages. In this task, 
MAM-treated rats appeared to both form, and shift attentional set, parallel to 
control performance.  
6.2 Reliability of acute versus developmental manipulations 
and the relevance to schizophrenia 
 Comparing the experiments among the three manipulations in rats, the 
results from the experiments with neonatal-PCP-treated rats (Chapter 3) and 
MAM-treated rats (Chapter 4), suggests that overall, developmental 
manipulations may not reliably generate the deficits in ASST performance 
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previously reported, whereas the acute manipulations and perhaps manipulations 
in adult rats in general, are more reliable and consistent within the published 
literature. While both developmental manipulations induced deficits in task 
performance, with neonatal-PCP-treated rats having poor performance at the ED 
stage of the ASST-MSS, and MAM-treated rats having a deficit at REV 1 of the 
standard ASST, both of these results were only due to repeat testing to increase 
statistical power. The DREADDs-mediated mPFCin however, produced a reliable 
and robust deficit that was present without repeat testing, aside from the AB 
design.  
 This difficulty in reproducing results with the developmental manipulations 
may lie in the considerable methodological differences between labs regarding, 
housing and food restrictions regimes, in combination with the brain’s inherent 
plasticity and compensation mechanisms. The literature is rife with reports of 
discordant results from both developmental manipulations (neonatal-PCP and 
MAM) suggesting that the failure to replicate the findings within these 
experiments are not uncommon. The issues surrounding a failure to replicate are 
plentiful, however the methodological differences (e.g. the medium to odour only 
shift in the neonatal-PCP ASST reports; see Chapter 4) should be well noted as the 
robustness of the findings are then drastically reduced (Steward, 2016). Therefore, 
while the developmental manipulations may induce a degree of mPFC-
hypofunction, the extent to which that disruption affects behaviour may be 
overestimated by less rigorous testing procedures. 
 In relation to the face validity and how well each model recapitulated 
schizophrenia-related biology and behaviour, while the MAM-model generated 
the most consistent anatomical pathology, the behavioural deficits were not 
consistent with schizophrenia. Indeed, it is possible that additional manipulations 
in conjunction with the MAM-treatment (such as an environmental stressor), may 
be needed to generate the behavioural deficits, similar to the gene x environment 
interaction findings described in Chapter 1: Introduction. The remaining two 
manipulations (neonatal-PCP treatment and DREADDs mPFC inhibition) both 
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generated clear behavioural phenotypes but did not induce robust anatomical 
disruption consistent with schizophrenia. Rather these manipulations better 
captured the behavioural deficits that can arise from specific disruptions of the 
mPFC rather than the gross anatomical disruptions induced by schizophrenia. 
Indeed, while the MAM-model may be best in studies of schizophrenia-related 
biology such as disrupted dopaminergic signalling and hippocampal pathology, the 
manipulations later in development may be better utilised for behavioural studies. 
6.3 Utility of the Bayesian analysis for characterisation of 
behavioural pattern 
 The narrative at the beginning of this thesis referred to my experience of 
the ‘cocktail party effect’ (Cherry, 1953). Ironically, the experience of this 
phenomenon is more likely in healthy persons with ‘low’ working memory capacity 
than those with ‘high’ working memory capacity.  Conway et al. (2001), reported 
that while the majority (65%) of participants who classified as having a low 
working memory capacity, reported hearing their name in an unattended 
irrelevant message during a selective listening procedure; only a minority (20%: of 
which I assume I would have been one of) of the high working memory capacity 
participants had the same experience. The Bayesian analysis consistently 
implicated abnormal behavioural patterns in the form of irrelevant dimension-
based responding during performance of the ASST in all three schizophrenia-
related rat manipulations. This common finding suggests that while performance 
in the ASST may not have been consistently impaired across all three groups, an 
underlying deficit in sensory gating, perhaps due to impaired working memory, 
may have manifested in all three. In direct contrast, the pattern for control rats 
was consistently the opposite with more spatial-based responding during 
challenging stages, such as reversals. Without the additional behavioural pattern 
analysis, this common finding would have eluded basic ASST TTC and errors 
measurements, and may have only been uncovered by additional testing such as 
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PPI or blocking experiments. Indeed, this is the first thesis from this lab to 
document a methodological analysis that performs consistently across set-shifting 
tests, can empirically differentiate between behavioural patterns, and can 
provides unifying results across behavioural phenotypes.  
 As described in Chapter 2: General Methods, the Bayesian analysis is 
constrained by only two parameters, the likelihood ratio, ‘c’, and the experimenter 
defined number of hypotheses tested by the analysis. There was consistent 
corroboration of 6-in-a-row criterion based stage completion, with the Bayesian 
analysis also indicating strong evidence for responding based on the correct 
stimulus. Indeed, this was evident across all stages for control rats. This finding 
supports the validity of the analysis with the parameters used, and if anything 
suggests that the frequentist based criterion may inadvertently be overtraining 
control rats, as during several stages, the Bayesian-derived evidence suggested 
responding based on the correct stimulus during the third quartile of that stage. 
On the other hand, the behavioural pattern analysis suggests that the frequentist 
criterion may be too lenient for experimental manipulations as the Bayes factor 
was not substantial for neonatal-PCP-treated, and mPFCin rats at the completion 
of several stages. Indeed, if a Bayesian criterion had been used, it is likely that 
deficits which did not manifest in the TTC data by measurement with the 6-in-a-
row criterion, may have been detected. 
 The Bayesian analysis was pivotal in the development of the modified tasks 
in this thesis as the simple-4 stage, and 6-stage simple-probe ASSTs developed for 
the mPFCin experiments (Chapter 3), as well as the ASST-MSS task employed with 
the neonatal-PCP-treated rats (Chapter 4), were generated to address the 
Bayesian-derived hypothesis that the rats were responding to stimuli within the 
irrelevant dimension. These tasks successfully confirmed this hypothesis, further 
validating use of the analysis with the current parameters. 
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6.4 Modifications to the standard ASST allow exploration of 
additional phenomenon 
In addition to experiments utilising the standard ASST, this thesis describes 
three new additional tasks to investigate responding based on irrelevant 
dimension stimuli. The adaptability and direct translatability of the rodent and 
human versions of the ASST to such modifications, is a primary strength it 
possesses over other assays, such as the WCST which are less amenable to stage 
substitutions and insertions. For example, the early modifications to the human 
ASST by Owen et al. (1993), which aimed to separate ED deficits arising from 
perseveration versus learned irrelevance, were directly translated into the rodent 
task by McGaughy et al. (2008). Within this thesis, the stimulus presentation of 
the Houses and Faces task designed for human testing (Hampshire and Owen, 
2006), was partially back translated for use in rats, with the critical maximal 
separation between relevant and irrelevant stimuli across trials preserved, as well 
as the use of a novel panels-based ASST apparatus for testing. Additionally, the 
standard ASST, was amenable to the insertion of a blocking stage (Kamin, 1968; 
but see: Sharpe and Killcross, 2014), in the 6-stage simple-probe task. Both of 
these manipulations were implemented without requiring lengthy additional 
training of the rats overall, and did not hinder performance in control rats, while 
providing critical information on task performance in both mPFCin and neonatal-
PCP-treated rats. 
Despite the obvious benefits of the rodent ASST, it remains critically flawed 
due to the reliance on an observer’s subjective scoring of the rat’s choice (digging), 
as well as the labour involved in the observer also preparing and presenting the 
stimuli for each trial. The potential for human error and bias is considerable, and 
there is variability amongst labs not only in the non-organic components of testing 
(apparatus, stimuli used, testing procedure), but also in the training of observers. 
While the panels modification presents some advancement in testing, in that the 
scoring of a ‘pull’ is based on a specific length marked on the panel itself, the 
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panels modification still remains susceptible to human error in stimulus 
preparations (such as too little or too much odour on the panels), and ultimately, 
the task needs to be automated. Unfortunately, thus far automation attempts 
have failed to generate a viable alternative. Implementation of a visual 
discrimination ASST, using an automated touchscreen, has been explored in mice. 
However, the task required several days (median of 13) for a single mouse to 
complete all stages of a single test (Brigman et al., 2005). Thus, to address the 
questions of set-formation and set-shifting, the researchers split the mice into two 
groups, one which performed an additional ID on the final day of testing, and one 
which performed an ED. Brigman et al., found no difference in performance for 
mice which were required to perform an ED shift compared to those performing 
an additional ID, thus there was no indication of set-formation. Similar results have 
been found with rats within the same visual discrimination touchscreen apparatus 
(Johan Alsiö personal communication) and thus far no studies have been published 
with either species showing viability of the method. 
This ‘rock and a hard place’ scenario with subjectivity concerns regarding 
the bowl digging methods, and lack of evidence for attentional set-formation in 
the objective automated procedure, remains a primary concern for the future of 
the ASST paradigm. Ideally, an automated procedure utilising stimuli rats readily 
discriminate (i.e. odours and media), will be developed as a middle ground, 
however, this has yet to be successfully accomplished, and the Birrell and Brown 
(2000) ASST remains the most common measure of attentional set-shifting in 
rodents (Gilmour et al., 2012). 
6.5 Relevance of findings for theories of attention  
 In Chapter 3, I introduced the conclusion that rather than performing 
ambiguous ‘higher order cognitive processes’, the role of the mPFC was to 
maintain a representation of the relevant information (e.g. the correct stimulus), 
and bias sensory processing (attention) and dopamine signalling, in favour of that 
information while ‘ignoring’ the irrelevant information. The consistent Bayesian 
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derived evidence for irrelevant dimension-based responding, concurrent with the 
deficit in sensory gating reported for all three manipulations, supports the recent 
findings that individual error terms(Mackintosh, 1975) exist for stimuli presented 
in associative learning assays, rather than a single global error term (Rescorla and 
Wagner, 1972; Pearce and Hall, 1980). Indeed, the mPFC is likely the site of 
multisensory integration and abstract rule representation that reduces processing 
of the less predictive prediction errors, resulting in phenomena such as ‘Kamin 
blocking’. 
 One of the earliest descriptions of schizophrenia, described that at its core 
was “loosening of associations” (Bleuler, 1911). All three schizophrenia-related 
manipulations support this as a core deficit arising from ‘schizophrenia-related’ 
biology. Furthermore, the findings of this thesis and the recent evidence from 
animal behaviour experiments supporting individual prediction error terms 
(Haselgrove et al., 2010; Pearce et al., 2012; Sharpe and Killcross, 2014), indicates 
that earlier ASST manipulations designed to disentangle perseveration to the 
previously relevant dimension, compared to learned irrelevance in patients with 
frontal lobe damage (Owen et al., 1993), schizophrenia (Elliott et al., 1995), or in 
rats with deficient mPFC-noradrenergic signalling (McGaughy et al., 2008), may 
have failed to detect learned irrelevance contributions due to the lack of 
associative strength between the tested irrelevant dimension and reward 
feedback. In both the primate (where a novel dimension is introduced), and the 
rodent (which uses a never discriminable dimension), learned irrelevance 
modifications, the tested dimension would not have elicited individual prediction 
error signals, to the extent of the irrelevant dimension stimuli in the 4-stage, and 
6-stage simple probe ASSTs. In the modifications in this thesis, the irrelevant 
dimension stimuli were either 50% predictive of reward during the standard 
discriminations, or 100% predictive or reward during the probe stages. Thus, 
further investigation into the nature of the ED deficit in patients with dlPFC 
damage, or schizophrenia, is warranted. Ideally, by taking advantage of the 
associative learning theories posits of individual prediction error terms. 
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 A recent implementation of a design which allowed individual prediction 
error to influence a learned irrelevance manipulation, re-examined perseveration 
versus learned irrelevance in Parkinson’s patients (Fallon et al., 2016). Using visual 
compound discriminations with two superimposed stimuli from three possible 
dimensions (e.g. fruit, houses, faces), the researchers found that Parkinson’s 
patients were impaired at stages that required responding to stimuli in a novel 
dimension presented in compound with stimuli from the previously relevant 
dimension, in addition to being impaired in responding to stimuli in previously 
irrelevant dimension compounded with a novel dimension. This was in contrast to 
a previous finding not using a design with an individual prediction error 
component (Owen et al., 1993). Thus, patients had both perseveration to the 
previously relevant dimension, in addition to enhanced learned irrelevance. Both 
schizophrenia and Parkinson’s disease induce dysfunctional dopamine signalling, 
and it is possible that if indeed individual prediction error signals contribute to the 
aberrant processing of irrelevant dimension stimuli, resulting in enhanced learned 
irrelevance, then similar findings may be found in patients with chronic 
schizophrenia. Indeed recent studies have returned to the dopaminergic 
dysfunction in schizophrenia as a target for remediation of the cognitive 
symptoms, with researchers focusing on agonism  of D1Rs, as enhancement of this 
signalling pathway has been evidenced to improve working memory in monkeys 
(recently reviewed by: Arnsten et al., 2016). However, there is also potential for 
enhancement of D2Rs to enhance dlPFC function (Ott and Nieder, 2016). Given 
this yet mysterious relationship between D1/2Rs and working memory, and the 
extant efficacy of D2R antagonists for treatment of schizophrenia’s positive 
symptoms, it is possibly more pragmatic to pursue glutamatergic, GABAergic or 
other transmitter signalling pathways to improve cognition in patients already 
treated with atypical antipsychotics.  
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6.6 General Conclusion 
 The major conclusion of this thesis is that dysfunctional sensory gating, 
arising from mPFC-hypofunction, is the mechanism by which ASST performance 
measures, primarily ED set-shifting, and potentially, reversal learning are derived. 
The ‘working memory’ function of the mPFC (and dlPFC in primates), is critically 
important in the regulation of attention through biasing of sensory processing to 
task relevant stimuli, and inhibiting processing of irrelevant stimuli. Indeed, this 
function of mPFC is likely an emergent property of its multisensory processing. The 
role of dopamine and individual prediction errors, in the irrelevant dimension-
based responding evidenced in this thesis warrants further investigation. Future 
experiments can target dopamine projections to the mPFC and determine if 
inhibition of those synapses disrupts working memory, and sensory gating, 
resulting in irrelevant dimension-based responding in the ASST. Experiments in the 
mechanistic basis of ASST deficits provide additional neural circuit targets for 
remediation of the debilitating cognitive symptoms of neuropsychiatric disorders 
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